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Understanding of the viral and host factors that determine time for progression to acquired 
immunodeficiency syndrome (AIDS) in individuals infected with human immunodeficiency 
virus type 1 (HIV-1) could aid in the design of an effective HIV-1 vaccine.  Human 
leukocyte antigen (HLA) class I profile is strongly and consistently associated with 
differential rates of HIV-1 disease progression, however the mechanisms explaining this are 
not well understood.  It has been hypothesised that “protective” HLA alleles select escape 
mutations in functionally important epitopes in the conserved group specific antigen (Gag) 
protein resulting in HIV-1 attenuation, which may result in slower disease progression.  
Many of the studies investigating the fitness cost of Gag escape mutations have concentrated 
on a few pre-selected mutations and have not assessed fitness consequences in the natural 
sequence background.  Furthermore, the majority of studies have focussed on HIV-1 subtype 
B, while HIV-1 subtype C is the most prevalent subtype worldwide.  Therefore, in the 
present study, a large population-based approach and clinically-derived Gag-protease 
sequences were used to comprehensively investigate the relationship between immune-
driven sequence variation in Gag, viral replication capacity and markers of disease 
progression in HIV-1 subtype C chronic infection.  The influence of Gag function on HIV-1 
disease progression was further investigated in early HIV-1 subtype C infection.  It was also 
hypothesised that Gag may contribute significantly to overall HIV-1 fitness and towards 
fitness differences between HIV-1 subtypes. 
 
Materials and Methods 
Recombinant viruses encoding Gag-protease, derived from antiretroviral naïve HIV-1 
subtype C chronically (n=406) and recently (n=60) infected patients as well as a small subset 
of HIV-1 subtype B chronically infected patients (n=25), were generated by electroporation 
 viii 
of an HIV-inducible green fluorescent protein (GFP)-reporter T cell line with plasma-
derived gag-protease PCR products and linearised gag-protease-deleted NL4-3 plasmid.  
The replication capacities of recombinant viruses, as well as intact HIV-1 isolates from 
peripheral blood mononuclear cells of patients chronically infected with HIV-1 subtype C 
(n=16), were assayed in the GFP-reporter T cell line by flow cytometry.  Replication 
capacity was defined as the slope of increase in percentage infected cells from days 3-6 
following infection, normalised to the growth of a wild-type NL4-3 control.  Replication 
capacities were related to patient HLA alleles and markers of disease progression (viral load, 
CD4+ T cell count, and rate of CD4+ T cell decline in chronically infected patients, and viral 
set point and rate of CD4+ T cell decline in recently infected patients).  Replication 
capacities were compared between isolates and recombinant viruses encoding Gag-protease 
from the same isolates, as well as between HIV-1 subtype B and C recombinant viruses 
matched for viral load and CD4+ T cell count.  Bulk sequencing of patient-derived gag-
protease amplicons was performed and mutations were identified that were significantly 
associated with altered viral replication capacity.  The fitness effect of some of these 




In HIV-1 subtype C chronic infection, protective HLA-B alleles, most notably HLA-B*81 
(p<0.0001), were associated with lower replication capacities.  HLA-associated mutations at 
low entropy sites (i.e. conserved sites) in or adjacent to Gag epitopes were associated with 
lower replication capacities (p=0.02), especially the HLA-B*81-associated 186S mutation in 
the TL9 epitope (p=0.0001).  The fitness cost of this mutation was confirmed in site-directed 
mutagenesis experiments (p<0.001), and the co-varying mutations tested did not 
significantly compensate for this fitness cost.  Replication capacity also correlated positively 
 ix 
with baseline viral load (p<0.0001) and negatively with baseline CD4+ T cell count 
(p=0.0004), but not with subsequent rate of CD4+ T cell decline (p=0.73). 
 
In HIV-1 subtype C recent infection, replication capacities of the early viruses did not 
correlate with subsequent viral set points (p=0.37) but were significantly lower in individuals 
with below median viral set points (p=0.03), and there was a trend of correlation between 
lower replication capacities and slower rates of CD4+ T cell decline (p=0.09).  Overall, the 
proportion of host HLA-specific Gag polymorphisms in or adjacent to epitopes was 
negatively associated with replication capacities (p=0.04) but host HLA-B-specific 
polymorphisms were associated with higher viral set points (p=0.01), suggesting a balance 
between effective Gag CD8+ T cell responses and viral replication capacity in influencing 
viral set point. 
 
A moderate statistically significant correlation was found between the replication capacities 
of whole isolates and their corresponding Gag-protease recombinant viruses (p=0.04) and 
the replication capacities of the subtype C recombinant viruses were significantly lower than 
that of the subtype B recombinant viruses (p<0.0001).  The subtype-specific difference in the 
consensus amino acids at Gag codons 483 and 484 was found in site-directed mutagenesis 
experiments to largely contribute to the fitness difference between subtypes, possibly by 
influencing budding efficiency. 
 
Discussion 
The data support that protective HLA alleles, in particular HLA-B*81, attenuate HIV-1 
through HLA-restricted CD8+ T cell-mediated selection pressure on Gag.  Results suggest 
that viral replication capacity determined by sequence variability in Gag-protease has an 
impact on HIV-1 disease progression, but also indicate that a balance between HLA-driven 
fitness costs and maintenance of effective CD8+ T cell responses is important in determining 
 x 
clinical outcome.  Gag-protease was observed to significantly contribute to overall HIV-1 
replication capacity and variability in this region between HIV-1 subtypes B and C is 
suggested to partly explain the difference in viral fitness between these subtypes.  Specific 
mutations in Gag-protease associated with viral attenuation were identified and it was also 
observed that mutations in conserved Gag regions carried the greatest cost to HIV-1 
replication capacity.  Overall, the data support the concept of, and may assist in the rational 
design of, an HIV-1 vaccine in which immune responses are directed towards several 
conserved epitopes, particularly in Gag, with the aim to constrain immune escape (thereby 
maintaining effective CD8+ T cell responses) and attenuate HIV-1 (in the event of partial 
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CHAPTER 1 - INTRODUCTION 
1.1 History and epidemiology of human immunodeficiency virus (HIV) type 1 infection 
HIV is a retrovirus belonging to the Retroviridae family and Lentivirus genus [1].  It infects 
human immune cells that express the cluster of differentiation (CD)4 protein, causing 
progressive immune dysfunction and deficiency that results in a syndrome of opportunistic 
infections and cancers, known as acquired immunodeficiency syndrome (AIDS) [1].  HIV 
infection is a modern disease that was first recognised in 1981 [2, 3].  Homosexual men, 
blood transfusion recipients, intravenous drug users, as well as children and sexual partners 
of these individuals, were first described as affected by this new immunodeficiency 
syndrome, suggesting that the etiologic agent was transmitted in body fluids [2].  By 1984, 
HIV was established as the causative agent [1, 2, 4-7], and was later renamed HIV type 1 
(HIV-1) to distinguish it from a related, but considerably less prevalent, AIDS-causing 
retrovirus, HIV-2, isolated in 1986 [2].   
 
HIV-1 is closely related to simian immunodeficiency viruses (SIVs) that infect chimpanzees 
in west-central Africa [3].  The origin of the three major strains of HIV-1, namely groups M, 
N and O, can be traced to three independent transmissions of SIV from chimpanzees (and 
possibly gorillas in the case of group O) to humans in the region of the Cameroon where 
these apes were butchered for bush meat [3, 8].  Recently (in 2009), another HIV-1 strain, 
thought to be transmitted from gorillas to humans, was identified with the proposed 
designation of group P [9].  Using some early HIV-1 group M sequences (1959 and 1960), 
which already indicated significant diversification of the common ancestor, and statistical 
models estimating the rate of evolution, the date of origin of the HIV-1 group M strain was 
estimated to be 1908 [3, 8].   Since then, especially with the growth of cities in Africa and 
increasing ease of global travel from about the mid-twentieth century onward [3], the 
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epidemic has grown exponentially, resulting in 33 million people living with HIV at the end 
of 2009, with 1.8 million deaths in 2009 alone [10], and approximately 2.6 million new 
infections diagnosed per year [11].     
 
The HIV-1 group M strain accounts for greater than 95% of HIV infections [3, 8].  It is 
considerably diverse, consisting of 9 different subtypes (A-D, F-H, J-K) and at least 48 
circulating recombinant forms (CRFs) [8].  Subtypes and CRFs are unevenly distributed 
globally (probably due to founder effects), with the greatest diversity found in west-central 
Africa.  Subtype B predominates in Europe, the Americas and Australia; subtypes B, C and 
CRF-01 (a recombinant of subtypes A and E) are found in Asia; while subtype C 
predominates in sub-Saharan Africa [1, 2, 8].  Since approximately 68% of the global burden 
of HIV-1 disease is carried by sub-Saharan Africa [10], HIV-1 subtype C, which is the focus 
of the present study, is the most prevalent subtype worldwide [8]. 
 
A discussion on the structure and function of HIV-1 and its interaction with the human host 
to cause disease follows. 
 
1.2 Structure of HIV-1 
1.2.1 Genome organisation 
The 9719 base pair (bp) HIV-1 genome (reference strain HXB2) is made up of nine 
overlapping genes flanked by two identical 634 bp long terminal repeat (LTR) regions: 
group specific antigen (gag, 1,503 bp in HXB2 reference strain), polymerase (pol, 3,012 bp), 
envelope glycoprotein (env, 2,571 bp), transactivator of transcription factor (tat, 306 bp), 
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regulator of virion protein (rev, 351 bp), viral infectivity factor (vif, 579 bp), viral protein R 
(vpr, 292 bp), viral protein U (vpu, 249 bp), and negative regulation factor (nef, 621 bp) [12].  
Tat and Rev, also known as the regulatory proteins, control viral gene expression and nuclear 
export, respectively, while the accessory proteins Vif, Vpr, Vpu, and Nef antagonise host 
defences and enhance pathogenicity [13].  The three major proteins shared by all 
Retroviridae, Gag, Pol, and Env, are synthesised as polyproteins, namely precursor of 55 
kDa (Pr55
gag
; Gag polyprotein), Pr160
gagpol
 (Gag-Pol polyprotein minus Gag p6), and 
glycoprotein of 160 kDa (gp160; Env polyprotein) [13].  Viral protease cleaves the Gag 
polyprotein into protein of 17 kDa (p17) matrix (132 amino acids [aa]), p24 capsid (231 aa), 
p7 nucleocapsid (55 aa), and p6 (52 aa), as well as the spacer peptides, p2 (14 aa) and p1 (16 
aa) [12, 13].  Protease also cleaves the enzymatic Pol proteins from the Gag-Pol precursor, 
namely protease (99 aa), reverse transcriptase (560 aa), and integrase (288 aa) [12, 13].  The 
Env polyprotein is cleaved by a host cellular enzyme into surface envelope gp120 (511 aa) 
and transmembrane envelope gp41 (345 aa) [12, 13].        
 
1.2.2 HIV-1 structure 
The outermost layer of the HIV particle is the envelope, which consists of the viral envelope 
glycoproteins inserted into lipid membrane derived from the host cell plasma membrane [2].  
The outer shell immediately underneath and bound to the lipid bilayer of the envelope is 
composed of up to 5,000 Gag p17 matrix molecules [14, 15] that are assembled as hexamers 
of trimers [16].  The matrix molecule is folded into five alpha (α)-helices and a three-
stranded beta (β)-sheet [14].  Immediately beneath the matrix is the conical structure formed 
by approximately 1,500 Gag p24 capsid molecules arranged in hexamers [15].  The capsid 
units are composed of an amino (N)-terminal domain (seven α-helices, two β-hairpins, and a 
cyclophilin A [CypA] binding loop) [17, 18] connected by a short linker to a carboxy (C)-
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terminal domain that is mostly helical [19].  Enclosed within the capsid structure are 
approximately 1,500 Gag p7 nucleocapsid molecules that are in tight association with the 
two copies of plus single-stranded viral genomic ribonucleic acid (RNA) through their two 
zinc (Zn) finger domains, which are themselves connected by a highly basic linker domain 
[20, 21].  Incorporated into the nucleocapsid are also about 50 copies of reverse 
transcriptase, protease, and integrase in dimeric forms as well as approximately 100-200 
molecules of Vpr [21].       
 
The genome organisation and the major components of the virus structure are shown in 
Figure 1.1. 
 
1.3 HIV-1 replication cycle: role of Gag 
The replication cycle of HIV-1 may be categorised into several steps (depicted in Figure 
1.1):  (i) virus entry, (ii) reverse transcription of genomic RNA to double stranded 
deoxyribonucleic acid (DNA), (iii) uncoating of the capsid particle to release the viral pre-
integration complex, (iv) nuclear import of the pre-integration complex, (v) integration of 
viral DNA into the host cell genome, (vi) transcription and nuclear export of RNA, (vii) viral 
protein synthesis and virus assembly, (viii) budding and cell exit, and (ix) maturation.  Each 
of these events in the replication cycle will be briefly outlined below with a focus on the 
important role of Gag, the major viral structural protein that is of particular interest in the 
present study (summarised in Table 1.1, presented at the end of Section 1.3, page 15).  Note 
that Gag residues referred to in the text are numbered sequentially from the start codon 
(residue 1) according to the HXB2 reference strain.   
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Figure 1.1 Genome organisation, structure, and replication cycle of HIV-1 
(i) The organisation of the 9 overlapping genes, encoding HIV-1 proteins, flanked by the 
LTRs is shown, with the regions coding for the major proteins (Gag, Pol, and Env) 
highlighted in colour (adapted from http://www.hiv.lanl.gov/content/sequence/ [267]).   
(ii) The main elements of the mature virion are depicted with colours corresponding to 
coding regions of the HIV-1 genome as shown in (i) (modified from Freed (2001) [13]).   
(iii) The various steps of the HIV-1 replication cycle are illustrated from cell entry of the 
virus to virion maturation (modified from Freed (1998) [18]).  The direct or indirect role of 
the HIV-1 proteins in mediating various steps of the replication cycle is indicated by 
numbering in (i). 
HIV-1 – human immunodeficiency virus type 1; LTR – long terminal repeat region; Gag – group specific antigen; M – 
matrix; Cap – capsid; p2 – protein of 2 kDa; Nu – nucleocapsid; p1 – protein of 1 kDa; p6 – protein of 6 kDa; Pol – 
polymerase; PR – protease; RT – reverse transcriptase; hd – heterodimer; RN – RNase H; IN – integrase; Vif – viral 
infectivity factor; Vpr – viral protein R;  Tat – transactivator of transcription factor; Rev – regulator of virion protein; Vpu – 
viral protein U; Env – envelope glycoprotein; gp120 – glycoprotein of 120 kDa; gp41 – glycoprotein of 41 kDa; Nef – 
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1.3.1 Virus entry 
Gp120 binds to the CD4 receptor protein, which is present on the surface of T helper cells, T 
regulatory cells, monocytes, macrophages, dendritic cells, and Langerhans cells [1].  This 
causes a conformational change in gp120, allowing a secondary co-receptor binding site to 
engage either the C-C chemokine receptor 5 (CCR5) protein (found on T cells, monocytes, 
macrophages, dendritic cells, and Langerhans cells) or the CXC chemokine receptor 4 
(CXCR4) protein (found on T cells) [13, 22].  HIV-1 may use other co-receptor proteins to a 
much lesser extent [1].  Co-receptor binding triggers fusion pore formation and a 
conformational change in gp41 that results in the formation of a helical bundle structure, 
which completes fusion of the viral and cellular membranes [22, 23].  Viral fusion is 
dependent on virion maturation, and Gag interaction with Env gp41 is thought to couple 
fusion to maturation [24, 25].     
 
1.3.2 Reverse transcription 
Following virus entry, the virus shell alternately binds to actin filaments and a microtubule 
network that mediates its transit to the nuclear membrane [26].  Reverse transcription is 
thought to predominantly take place at the nuclear pore and occurs within an intact capsid 
shell prior to uncoating [26].   
 
Reverse transcription is initiated by the binding of host cell transfer (t)RNA
lys
 to the 5’ end 
primer binding site (PBS) of the plus single-stranded HIV-1 RNA [2], which is chaperoned 
by the Gag nucleocapsid [18].  The packaging of tRNA
lys
 into virions is mediated through 
the binding of Gag (at Gag residues 308-362) to lysyl-tRNA synthetase which then interacts 
with tRNA
lys 
[27].  Following the synthesis of a segment of minus strand DNA from the PBS 
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to the 5’ end by viral reverse transcriptase, viral RNase H (cleaved from reverse 
transcriptase) degrades the RNA portion of the DNA/RNA hybrid [2].  The synthesised 
DNA segment then binds to the 3’ end of the RNA and acts as a primer for minus strand  
DNA synthesis (known as the first strand transfer).  RNase H simultaneously degrades RNA, 
leaving two RNA segments which act as primers for complementary plus strand DNA 
synthesis.  Following displacement of tRNA
lys
 from the PBS by RNase H, the 
complementary PBS on both strands can hybridise and both strands of DNA are synthesised 
to completion (known as the second strand transfer).  These strand transfer reactions are 
chaperoned by the Gag nucleocapsid and mutations at Gag residues 400 and 421 in the Zn 
fingers (residues 392-405 and 413-426) of the nucleocapsid cause defects in reverse 
transcription [28].   
 
These nucleocapsid mutations [28], as well as mutations at Gag residues 384, 387, 388, and 
391 in the nucleocapsid [29], also cause decreased stability of the newly synthesised DNA 
indicating a role for Gag nucleocapsid in protection of newly synthesised DNA.  The Gag 
matrix protein may also be involved in stabilising newly synthesised DNA or in facilitating 
reverse transcription as a mutation at residue 21 reduced viral DNA synthesis [30].  The 
mechanism underlying the effects of this mutation may be due to increased membrane 
binding of the matrix protein.  In addition, Vif protects the newly synthesised DNA from 
hypermutation by the host restriction factor apolipoprotein B messenger RNA editing 
catalytic subunit-like protein 3G (APOBEC3G) though targeting it for degradation [2].              
 
The final step of reverse transcription is the formation of a DNA flap upon the termination of 
plus strand synthesis [26].  This is thought to trigger uncoating of the capsid [26], which still 
remains an ill-defined process [31].  
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1.3.3 Uncoating 
The regulation of uncoating is important for the success of reverse transcription as evidenced 
by the impaired reverse transcription in virions with unstable capsid cores [32].  The Gag 
capsid and its interaction with host factors, such as CypA, tripartite motif-containing 5α 
protein (TRIM5α), and possibly other restriction factors, regulates uncoating [31].  The Gag 
capsid binds CypA through the CypA binding loop region (Gag residues 217-225 [33]) 
which results in conformational changes to the C-terminal domain of the capsid and may 
therefore play a role in destabilisation of the capsid during uncoating [17, 27].  CypA is also 
thought to protect the capsid from host restriction factors that promote premature uncoating 
[31, 34].  Rhesus and human TRIM5α were shown to restrict HIV-1 [35] through accelerated 
uncoating [36] and human CypA was suggested to block restriction factor 1 (Ref1; a human 
TRIM5α variant) activity in human cells [37].  However, human TRIM5α has only a modest 
effect on HIV-1 and this was later found to be independent of capsid-CypA interaction [38].  
Therefore, CypA through interaction with the Gag capsid may protect HIV-1 from an 
unknown host restriction factor [31, 34, 39].      
 
1.3.4 Nuclear import 
Uncoating of the capsid is required prior to nuclear entry of newly synthesised DNA [26].  
The pre-integration complex is composed of Gag matrix, Gag nucleocapsid, reverse 
transcriptase, integrase, Vpr, double-stranded DNA, and several host proteins, including lens 
epithelium-derived growth factor (LEDGF) [14, 26, 40].  Vpr, integrase, the DNA flap, and 
the matrix protein have nuclear localisation signals (NLSs) [14], which may be recognised 
by importins in the nuclear pore complex, resulting in transport through the complex [40].  
However, whether NLS of viral components are required for nuclear import remains 
controversial [40].  The NLS in matrix are at residues 25-32 and 110-114 [14, 41].  
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However, mutation of residues 26 and 27 did not change nuclear transport but impaired 
infectivity and integration, suggesting a role for matrix in integration [42].       
 
1.3.5 Integration 
The HIV-1 integrase protein catalyses the integration of viral DNA with host cell DNA.  The 
3’ ends of viral DNA are cleaved and the cellular target DNA is cleaved in a staggered 
manner, followed by the joining of these [2].  The nucleocapsid is involved in 3’ end 
processing since mutation of Gag residues 400 and 421 results in defective processing and 
impaired integration [28].  Cellular repair enzymes then fill in the gaps between integrated 
viral DNA and host DNA [2].  Intact pre-integration complexes including the host cellular 
factors that are part of the complex are required for efficient integration [40].      
 
1.3.6 Transcription and nuclear export 
HIV-1 Tat recruits a complex of host cellular factors to the integrated viral LTR, resulting in 
the phosphorylation of RNA polymerase II and stimulation of transcription [40].  Vpr may 
also activate transcription and regulate viral gene expression [43].  Singly and multiply 
spliced RNAs encoding viral proteins are transcribed, and unspliced RNA which constitutes 
the HIV-1 genome is also produced [40].  Rev interacts with the cellular machinery to export 
these viral RNAs into the cytoplasm where they are translated into viral proteins and 
polyprotein precursors [2].  The Gag matrix protein possesses a nuclear export signal at the 
N-terminus, which when disrupted by mutation at residues 18 and 22 results in the 




The Env glycoproteins are synthesised on ribosomes attached to the endoplasmic reticulum 
membrane, while Gag and Gag-Pol precursors are synthesised on free ribosomes in the 
cytoplasm [21].  The trafficking of Env glycoproteins to the plasma membrane occurs via the 
secretory pathway during which time the cellular enzyme, furin, cleaves Env into the gp41 
and gp120 subunits [21].  The gp120/gp41 complex segregates to lipid rafts where virion 
assembly is targeted [45], and are actively recruited into virions via interaction of Gag 
matrix with the gp41 cytoplasmic tail [46].  The N-terminal 100 amino acids of the matrix 
protein are required for the incorporation of envelope glycoproteins into virion particles [46], 
including specific interacting residues at Gag codons 8, 9, 13, 16, 17, 18, 31, 35, and 63 [47-
50].  More recently, this interaction was found to be mediated by host tail-interacting protein 
of 47 kDa (TIP47), and the binding of this factor by matrix residues 6-17 was shown to be 
essential for envelope glycoprotein incorporation into virions [50].   
 
The nucleocapsid domain of the Gag polyprotein binds to full-length viral genomic RNA 
and this complex trafficks to the lipid rafts of the plasma membrane via an endosomal 
pathway [51, 52].  Gag-RNA complexes may also be trafficked to sites of cell-cell contact 
by the endosomal pathway, thereby facilitating cell-to-cell transmission [52].  Gag 
trafficking is largely dependent on the matrix protein [14, 18, 53].  The first N-terminal α-
helical matrix domain (residues 11-19 [54]) and Gag residues 132 and 135 interact with host 
proteins of the endosomal pathway clathrin adaptor protein (AP)-3 and AP-2, respectively 
[55, 56].  Domains in the matrix protein may also interact with other cellular factors of the 
endosomal pathway [21].  Residues 85-89 of the matrix protein are involved in directing 
assembly to the plasma membrane, rather than to intracellular membranes [57].  The matrix 
protein is also responsible for binding to and therefore targeting assembly to the plasma 
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membrane.  The highly basic domain at the N-terminus of matrix (residues 15-31 [58]) is 
positively charged and specifically interacts electrostatically with a negatively charged acidic 
phospholipid found in the plasma membrane [59].  This binding, as well as Gag 
nucleocapsid binding to viral genomic RNA and Gag multimerisation, increases the 
exposure of the previously sequestered myristate moiety bound to the N-terminus of matrix 
(the first 7 amino acids are required for myristate recognition [57]) to promote anchoring of 
myristate into the inner leaflet of the plasma membrane [59].  A salt bridge formed between 
residues 12 and 89 is important for this myristate exposure and pH, which may vary in 
subcellular locations, may regulate this [60].  A hydrophobic domain (residues 7-9 [61]) 
synergising with the basic domain and myristate also plays a role in membrane binding.  
Importantly, membrane binding can also be regulated by phosphorylation:  upon viral entry 
phosphorylation of serine residues 9, 67, 72, and 77 may promote membrane dissociation, 
facilitating early steps of the life cycle [62, 63].               
 
The binding of the Gag nucleocapsid to RNA occurs through the hydrophobic plateau [53], 
which is located between residues 390 and 423 and encompasses Zn finger domains and 
basic residues that flank the first Zn finger [21].  This binding is important for the initiation 
of Gag multimerisation, through the localising and concentrating of Gag monomers as well 
as providing an RNA scaffold for assembly [2, 53].  Some multimerisation may initiate 
before the complex reaches the plasma membrane, but extensive multimerisation occurs at 
the plasma membrane with the accumulation of Gag-RNA complexes in the lipid raft 
domains [59].  Multimerisation is mediated largely by interactions between the capsid 
domains to form hexamers (that are joined mainly through the capsid C-terminal domains) 
[15].  Approximately 5,000 Gag subunits interact to form a spherical capsid that encloses 2 
copies of the viral RNA genome as well as other viral and cellular proteins [15]. 
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The role of the Gag p6 protein during virus assembly is the incorporation of Vpr via residues 
463-466, 482-484, and 489-493 [64].  It also plays an important role in the budding of virus 
particles and their release from the cell [65]. 
 
1.3.8 Budding 
Budding of the new virion particle is thought to be mediated primarily by the interaction of 
Gag p6 late (L)-domain PTAP (residues 455-458) with the host tumour susceptibility gene 
101 (Tsg101) protein [66].  Another L-domain which binds the host apoptosis-linked gene 2-
interacting protein X (Alix) was identified in Gag p6, namely LYPLASLRSL (residues 483-
492; essential residues in bold) [64, 67].  Tsg101 and Alix recruit the endosomal sorting 
complexes required for transport (ESCRT) to direct viral budding [65].  Mutations in the 
Alix binding region of p6 impact negatively on virus replication, and more severely so when 
Tsg101 (part of the ESCRT-I complex) binding is simultaneously inactivated [68].  Recently 
it was also shown that the basic residues of the Gag nucleocapsid (380, 384, 387, 388, 391, 
397, 403, 406, 409-411, 415, 418, 424, 429) are required for budding, probably through 
allowing interaction with host ESCRT machinery downstream of Tsg101 [65].   
 
1.3.9 Maturation 
Upon budding, the viral protease enzyme cleaves the Gag and Gag-Pol precursors, resulting 
in virion maturation.  The Gag matrix remains associated with the envelope and 1,000-1,500 
subunits of the Gag capsid re-assemble into a cone-shaped structure [15].  In the mature 
capsid, interfaces between N-terminal domains and between N-terminal domains and C-
terminal domains form the hexamers; while interfaces between C-terminal domains connect 
the hexamers [15].  In general, mutations in the capsid C-terminal domain (residues 283-
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363) impair virus assembly, but mutations in the capsid N-terminal domain (residues 133-
277) impair maturation [69].  Virus maturation is essential for virus infectivity [70] (Section 
1.3.1).  Recently, mutation of a conserved Gag residue in p6, 488, was demonstrated to 
reduce Gag cleavage between the capsid and spacer peptide resulting in irregular core 
structure and consequently reduced viral infectivity [64].  Refer to Table 1.1 for a summary 
of the role of Gag in the HIV-1 replication cycle.         
 
Virion maturation completes the viral replication cycle, which requires approximately 2 days 





 virions per day, each with a cell-free half-life of 30 to 60 
minutes [1].  Productively infected CD4+ T cells have a half-life of 1 day and are therefore 
rapidly eliminated [1, 72].  However, the pathogenesis of HIV-1 is complex and the disease 
is likely the result of both direct cytopathic and indirect effects [73]. 
 
1.4 HIV-1 Pathogenesis 
1.4.1 Acute infection 
HIV-1 is most commonly transmitted across a mucosal surface, although other important 
modes of transmission include parenteral (e.g. intravenous drug use, blood transfusion) and 
mother-to-child transmission (intrapartum, perinatally or via breast milk) [1, 74].  HIV-1 
may gain access to the genital or rectal submucosa through minor breaches of the epithelium 
induced by sexual intercourse [75].  Alternative possibilities include transcytosis through the 
epithelium, contact with intraepithelial dendritic cells, or movement through intercellular 
spaces in the epithelium [72].  Studies conducted on rhesus macaques infected with SIV and  
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Table 1.1 Role of Gag proteins in the HIV-1 replication cycle 
Gag 
protein 





9, 67, 72, 77 Serine residues phosphorylated on viral entry, which 
may promote membrane dissociation. 
Early post-entry 
steps 
21 Mutation increased membrane binding, reducing 
viral DNA synthesis. 
Early post-entry 
steps 
25-32, 110-114  NLSs which may be involved in nuclear import. Nuclear import 
26, 27 Impaired integration when mutated. Integration 
18, 22  Impaired nuclear export when mutated. Nuclear export 
1-100: 6-17, 18, 
31, 35, 63 
Envelope glycoprotein incorporation.  Residues 6-17 
bind TIP47, which mediates the incorporation.  This 
interaction couples Gag maturation to fusion. 
Assembly/Entry 
11-19, 132 Trafficking of Gag proteins. Assembly 
85-89 Targeting virus assembly to plasma membrane. Assembly 
15-31 Basic domain mediating membrane binding. Assembly 
7-9 Hydrophobic domain synergising with basic domain 
and myristate to promote membrane binding. 
Assembly 
1-7 Binding of myristate required for membrane binding. Assembly 






308-362 Binds to lysyl-tRNA synthetase that mediates 
packaging of tRNA
lys
 which is required for initiation 
of reverse transcription. 
Reverse 
transcription 
217-225 Binds cyclophilin A which protects HIV-1 from an 
unknown restriction factor and facilitates proper 
uncoating of the capsid. 
Uncoating 
135 Trafficking of Gag proteins. Assembly 
283-363 Mutations in this domain mainly impair virus 
assembly. 
Assembly 







400, 421 Impaired reverse transcription when mutated.  Zn 




384, 387, 388, 
391, 400, 421 





400, 421 Mutations impaired 3’ end processing of viral DNA. Integration 
390-423  Hydrophobic plateau binding RNA genome to 
nucleocapsid.  This regulates myristate exposure 
promoting membrane binding and provides a 
scaffold for virus assembly.  
Assembly 
380, 384, 387, 
388, 391, 397, 
403, 406, 409-411, 
415, 418, 424, 429 
Basic residues required for budding possibly through 






Mediates incorporation of Vpr into virions. Assembly 
455-458 (PTAP) Interacts with Tsg101protein (part of ESCRT-I) to 




Interacts with Alix protein to recruit ESCRT 
machinery for budding. 
Budding 
488 Mutation disrupts Gag cleavage by protease. Maturation /Entry 
HIV-1 – human immunodeficiency virus type 1; NLS - nuclear localisation signal; TIP47 – tail-interacting protein of 47 
kDa; tRNA – transfer ribonucleic acid; Zn - zinc; DNA – deoxyribonucleic acid; ESCRT - endosomal sorting complexes 
required for transport; p6 – protein of 6 kDa; Vpr – viral protein R; Tsg101 protein – tumour susceptibility 101 protein; 
Alix – apoptosis-linked gene 2-interacting protein X. 
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sequencing of HIV-1 transmitted viruses indicate that the first cells infected are sub- 
optimally activated CD4+ CCR5+ memory T cells [72, 75, 76] and that the transmitted virus 
is dependent on CCR5 (not CXCR4) for cell entry [77].  Other cells found in the mucosa that 
could be infected in the acute phase include Langerhans cells (mucosal dendritic cells) and 
macrophages [73, 78, 79].  The initial infection is supported by signalling from the mucosal 
epithelial cells (triggered by pathogen-mediated activation of toll-like receptors [TLRs]) that 
recruits dendritic cells, which in turn secrete cytokines that attract activated CD4+ T cells 
susceptible to infection [75, 76].  Thus, the innate immune response promotes establishment 
of infection (Section 1.4.4.1).   
 
After approximately 10 days (the eclipse phase [72, 80, 81]), the expansion of infection is 
sufficient to result in dissemination of cell-free virus or infected cells to the draining lymph 
node and consequently the bloodstream and secondary lymphoid organs [72, 75].  The 
dendritic cells in the mucosa may also internalise HIV-1 through dendritic cell-specific 
intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) receptors and retain the 
infectious particles, migrate to the draining lymph node, and make contact with CD4+ T 
cells in the lymph node, resulting in efficient transfer of HIV-1 that assists in dissemination 
of the virus [1, 73, 79].  Furthermore, trapping of HIV-1 virions by dendritic cells in the 
lymph node exposes susceptible CD4+ T cells to infection as they migrate into the lymph 
node follicle to provide help to B cells [1].  Since many susceptible cells are found in close 
proximity within the lymphoid tissues, a massive burst of HIV-1 replication occurs in these 
tissues.  This is particularly true in the gut-associated lymphoid tissue which harbours a high 
concentration of activated CD4+ CCR5+ memory T cells [72].  Interestingly, it was recently 
noted that successfully transmitted viruses have a high affinity for α4β7+ CD4+ T cells, 
which are present in the vaginal/rectal mucosa and home to the gut (where the exponential 
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replication is best facilitated), suggesting this characteristic may be crucial to the successful 
establishment of infection [11].  A massive depletion of CD4+ T cells occurs during this 
early exponential phase of viral replication.  During this replication burst, at around 21-28 
days post-infection, peak plasma viremia (>1 million HIV-1 RNA copies/ml) is reached, and 
more than 50% of individuals may experience acute viral symptoms, such as fever, rash, 
and/or lymphadenopathy [72, 82].   
 
Prior to this replication burst, HIV-1 RNA is first detectable in the blood (Fiebig stage I, 10-
17 days post-infection) followed by p24 antigen (Fiebig stage II, 17-22 days post-infection) 
[80, 81].  The first HIV-specific antibodies become detectable (seroconversion) during the 
phase of peak viremia (Fiebig stage III, 22-25) [80, 81], but they are non-neutralising (i.e. 
they are unable to block virus entry into cells) (Section 1.4.4.2).  Viremia then declines 
during the following Fiebig stages (stage IV [25-31 days post-infection], stage V [31-101 
days post-infection], and stage VI [open-ended, early chronic infection phase]), which are 
characterised by the detection of different antibodies by Western blot, and a steady state 
(viral set point) is established during Fiebig stages V or VI [80, 81].  The CD8+ T cell 
responses emerge as plasma viremia approaches peak and peaking of these responses is 
coincident with decline in viremia, suggesting that the suppression of viral replication is 
largely mediated by CD8+ T cells [72] (Section 1.4.4.3.1).   
 
During the acute phase of infection a reservoir of latently infected cells is established [72, 
74].  These cells are primarily resting memory CD4+ T cells [83], but macrophages are also 
important reservoirs [73, 78].  These latently infected cells are invisible to the immune 
response, safe from antiretroviral drugs, long-lived (some persist for decades), and produce 
infectious virus only when re-activated; thereby preventing elimination of the infection [78, 
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83] (Section 1.5.1).  Productively infected macrophages are also an important reservoir as 
they can survive for several weeks and efficiently transmit HIV-1 to CD4+ T cells via cell-
to-cell synapses [84].        
 
1.4.2 Chronic infection 
The viral set point is maintained by a balance between ongoing virus replication and host 
immune responses as the host enters a chronic phase of infection [1, 72].  During this time 
there is a gradual decline in circulating CD4+ T cells and loss of immune function.  The 
decline in immune function may be due to direct manipulation of immune cells by HIV-1 
proteins as well as the depletion of CD4+ T cells, since these cells provide help to the 
humoral and cell-mediated arms of the immune system (Section 1.4.4.3.2).  The depletion of 
CD4+ T cells is not only caused by direct infection but also as a result of chronic immune 
activation and inflammation. 
 
Chronic immune activation plays a central role in HIV-1 pathogenesis, and this is 
highlighted by the lack of immune activation and symptomatic disease in SIV natural hosts 
despite uncontrolled viremia [85-87].  This state of chronic immune activation may be due to 
several factors:  immune responses to ongoing HIV-1 replication, direct activation of T cells 
and macrophages by HIV-1 Nef and gp120, microbial translocation across the gut mucosa 
(due to depletion of CD4+ T cells in the gut) resulting in production of pro-inflammatory 
cytokines by innate immune cells, reactivation of viral infections such as cytomegalovirus 
and Epstein Barr virus, and molecular mimicry of human leukocyte antigen (HLA) molecule 
domains resulting in allogeneic non-specific T cell activation [85-87].  The pro-
inflammatory cytokines released during chronic immune activation lead to activation of 
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latently infected cells resulting in virus replication, and activation of uninfected CD4+ T 
cells, which leads to rapid apoptosis in most cases and is perhaps the greatest contributor of 
CD4+ T cell loss [85].  As the immune system becomes progressively exhausted, there is a 
decline in its ability to regenerate depleted CD4+ T cells.  The persistence of HIV-1 
replication stimulates the proliferation and differentiation of HIV-1-specific CD8+ T cells 
and they become progressively exhausted, losing cytolytic and cytokine-secreting ability, 
which ultimately results in their deletion [82].  Thus the ability to control HIV-1 replication 
is further impaired, leading to further CD4+ T cell depletion; however, high levels of virus 
replication continue to be supported at this stage by macrophages [78].  The high level of 
pro-inflammatory cytokines may also promote a range of disorders, such as osteoporosis, 
atherosclerosis, and neuronal injury [85].                  
 
1.4.3 Advanced disease 
When CD4+ T cell counts decrease below 200 cells/mm
3
, the host becomes highly 
susceptible to opportunistic infections (e.g. oral candidiasis, pneumococcal infections, and 
tuberculosis) and certain cancers resulting mainly from viral infections (e.g. Kaposi’s 
sarcoma caused by human herpes virus-8 and lymphomas caused by Epstein-Barr virus) 
[74].  Once CD4+ T cell counts are less than 200 cells/mm
3
 and/or one or more AIDS-
defining illnesses are present, the patient is considered to have AIDS [1].  The average time 
from infection to AIDS is 8-10 years, but this may vary considerably due to host and viral 
factors (Section 1.6).  At this stage of advanced disease, the immune system is overwhelmed 
and death ensues as a result of infections.               
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1.4.4 Host immune responses and viral evasion 
Although host immune responses are mounted to HIV-1 from the earliest stage, they are 
unsuccessful in eliminating infection.  The responses of different immune cells during acute 
and chronic infection and the ability of HIV-1 to subvert, evade, or use these immune 
responses to sustain infection are next discussed.   
 
1.4.4.1 Innate immunity 
1.4.4.1.1 Dendritic cells 
In acute infection, dendritic cells are activated through cytokines secreted by mucosal 
epithelial cells or directly through TLR-mediated recognition of HIV-1 RNA [88] (Section 
1.4.1).  Activation results in the secretion of pro-inflammatory cytokines, importantly 
interferon-α (IFN-α), which activates a range of antiviral pathways [89] and upregulates 
restriction factors (Section 1.4.4.1.4).  IFN-α as well as antigen presentation by dendritic 
cells activates CD4+ T cells, which co-ordinate adaptive immune responses [79, 88, 89] 
(Section 1.4.4.3.2).   HIV-1 counteracts these antiviral effects by Vpr-mediated 
downregulation of IFN-α production and through impairing the function of dendritic cells 
[89, 90].  However, IFN-α also contributes to disease progression by recruiting susceptible 
cells to the site of infection and by promoting chronic immune activation [75, 89].          
 
1.4.4.1.2 Macrophages 
Macrophages are also involved in activating innate and adaptive immune responses through 
cytokine secretion and antigen presentation [78].  However, HIV-1 can interfere with antigen 
presentation by macrophages, shift macrophages to a pro-inflammatory phenotype to 
promote chronic immune activation, impair macrophage phagocytic function, and induce 
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(via Nef) macrophages to secrete factors that permit the infection of resting T cells, thereby 
increasing the latent reservoir [73, 78]. 
   
1.4.4.1.3 Natural killer (NK) cells 
In early infection, NK cells may be recruited and activated by cytokines secreted by 
dendritic cells and macrophages [88, 89, 91].  NK cells may produce CCR5 ligands (such as 
macrophage inflammatory protein-1α [MIP-1α]) that compete with HIV-1 for the CCR5 co-
receptor and they may also kill infected cells via release of perforin (which punches holes in 
the plasma membrane) and granzymes (which initiate cell death by apoptosis) [74, 88, 89].  
The binding of inhibitory or activating killer cell immunoglobulin-like receptors (KIRs) on 
NK cells to HLA molecules on infected cells will determine whether killing is inhibited or 
promoted [89, 91].  HIV-1 evades this recognition by Nef-mediated selective 
downregulation of the expression of HLA-A and HLA-B molecules, but not HLA-C or 
HLA-E molecules (which interact with NK cells to avoid killing) [91, 92].  NK cells may 
also recognise infected cells by binding via their fragment crystallisable (Fc) receptors to 
antibody bound to the surface of infected cells (antibody-dependent cell-mediated 
cytotoxicity [ADCC]), however production of antibody only occurs approximately 3 weeks 
following infection [1] (Section 1.4.4.2).  NK function becomes increasingly impaired in 
chronic infection, with the accumulation of a dysfunctional CD56- CD16+ NK cell 
population [88].    
 
1.4.4.1.4 Host restriction factors 
To date, three major retroviral restriction factors have been described, including 
APOBEC3G (Section 1.3.2), TRIM5α (Section 1.3.3), and tetherin (acts to tether virions to 
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the cell surface, preventing their release) [36].  These restriction factors are upregulated by 
IFN-α (and other type 1 IFNs), which is secreted during acute infection [90] (Section 
1.4.4.1.1).  However, mutations in the Gag capsid protein may result in evasion from 
TRIM5α activity [36].  Furthermore, specific viral factors antagonise the action of restriction 
factors, namely Vif targets APOBEC3G for degradation (Section 1.3.2) and Vpu sequesters 
tetherin from the site of viral budding [36].  
 
1.4.4.2 Humoral immunity 
Immune complexes consisting of viral proteins and antibody can first be detected at 
approximately 18 days post-infection, followed by free antibody to Env gp41 (23 days post-
infection) and Env gp120 (38 days post-infection) [72].  These initial antibody responses are 
non-neutralising and fail to block HIV-1 entry into cells.  However, non-neutralising 
antibodies can function to recruit (via their constant region) NK cells (via their Fc receptors) 
to lyse infected cells (ADCC) [91] (Section 1.4.4.1.3).  With the progression of disease and 
persistent viral replication, the ability of antibodies to induce ADCC is impaired [93].   
 
Neutralising antibodies that block viral entry into cells develop at approximately 12 weeks 
post-infection.  However, this response is often narrowly directed to the variable Env regions 
of the infecting viral strain [72], and HIV evades this response by the selection of viral 
variants that are not easily neutralised.  Mutations in the viral sequence arise at a high rate 
due to the low fidelity of HIV-1 reverse transcriptase (1 error per 10,000 nucleotides) and the 
high replication rate [36], leading to viral variants.  The mutations that are present in the 
viral variants selected by the immune response are known as “escape mutations”.  As novel 
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neutralising antibodies develop, the mutant virus escapes again, thus the response continues 
to lag behind viral evolution [93, 94]. 
 
Broad-specificity neutralising antibodies (that target conserved Env regions shared by 
diverse viral isolates) are rare, may only develop after 20-30 months of infection [72], and 
even then are generally not associated with control of viremia [93].  The rarity of broadly 
neutralising antibodies can be explained by the variable carbohydrates (which can shift by 
point mutations) masking the Env glycoprotein and external loops masking the more 
conserved Env domains, which are only accessible for a short time during viral entry [36, 
79].  The delay in the development of broadly neutralising antibodies could also be due to 
impaired antibody maturation (required for high affinity antibody development) resulting 
from extensive damage to germinal centres in lymphoid tissue during acute infection as well 
as impaired CD4+ T cell help [93].  Further dysregulation in humoral immunity in HIV-1 
infection includes abnormal B cell activation and the development of autoantibodies [93]. 
   
1.4.4.3 Cell-mediated immunity 
1.4.4.3.1 CD8+ T cells 
HIV-1-specifc CD8+ T cell responses have been detected as early as Fiebig stage I and II, 
however these responses appear to peak as viral load begins to decline [72] (Section 1.4.1).  
The coincident peak of CD8+ T cell responses with viral decline suggests that they are an 
important contributor to the inhibition of virus replication in early infection [95].  This is 
further supported by experiments that demonstrated a marked increase in SIV viremia 
following depletion of CD8+ T cells in rhesus macaques [96, 97], while depletion of 
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antibody-generating B cells in an animal model had little impact on viral load decline in 
primary SIV infection [74, 98].   
 
Cytotoxic CD8+ T cells recognise HIV-1 infected cells and subsequently eliminate them via 
the secretion of perforin and granzymes (reviewed in [91]).  This recognition is dependent on 
the presentation of viral epitopes (typically 8-10 amino acid sequences produced by 
processing of viral proteins within the cytoplasm) by HLA class I molecules (encoded by the 
Major Histocompatibility Complex [MHC] locus) on the surface of infected cells to the 
CD8+ T cell.  The CD8 molecule on the T cell interacts with a constant region on the HLA 
molecule, and assists binding of the T cell receptor (TCR) to the epitope-HLA complex.  
This interaction is sufficient to trigger killing if the CD8+ T cell is already a differentiated 
effector cell, however naïve CD8+ T cells also require co-stimulatory signals (and this may 
be aided by CD4+ T cells) to become activated (Section 1.4.4.3.2).  It should be noted that 
activated CD8+ T cells also produce antiviral cytokines (e.g. IFN-α) and chemokines (e.g. 
MIP-1α and MIP-1β, which are CCR5 ligands), and recent evidence suggests that these non-
cytolytic mechanisms of viral inhibition may in fact be more important than direct cell 
killing [99, 100].    
 
The HLA class I molecule is a heterodimer of β2-microglobulin, which is a constant region 
shared by all class I proteins, and an α-chain, which is the variable region that recognises and 
non-covalently binds epitope [91].  Every individual expresses 6 HLA class I alleles (two 
HLA-A, two HLA-B, and two HLA-C alleles) and 6 HLA class II alleles (two HLA-DR, 
two HLA-DP, and two HLA-DQ alleles) (Section 1.4.4.3.2), of which there are currently 
4,721 and 1,353 variant alleles, respectively, in total [101].  Each HLA molecule has a 
defined range of epitopes to which it can bind that is largely dependent on the epitope 
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residues that make direct contact with the HLA molecule (anchor residues) [91].  Thus, the 
HLA class I profile of an individual determines which viral epitopes mediate cytotoxic 
CD8+ T cell recognition and killing of infected cells, as well as other CD8+ T cell-mediated 
antiviral effects.                    
 
HIV-1 can counteract CD8+ T cell recognition through Nef-mediated selective 
downregulation of HLA class I molecules [36, 92].  Another important mechanism of 
evasion is the development of escape mutations in or adjacent to epitopes presented by the 
host HLA molecules.  These mutations may impair intracellular processing, disrupt the 
binding of the epitope to the HLA molecule, or disrupt recognition of the presented epitope 
by the TCR [102-105].  CD8+ T cell escape mutations are rapidly selected as viremia 
declines, indicating that CD8+ T cell-mediated immune pressure makes an important 
contribution to this decline, while Env mutations selected by neutralising antibodies only 
appear approximately 12 weeks following infection [72, 106].   
 
Mathematical modelling has estimated that 15-35% of HIV-infected cells are killed by a 
single CD8+ T cell response (of a few responses present) in early infection [72, 106] while 
only 4-6% of infected cells are eliminated by CD8+ T cells during chronic infection [107].  
Therefore, the CD8+ T cells present in later infection are not as efficient as those in early 
infection, despite targeting a broader array of viral sequences (approximately 10 epitopes) 
[82, 108].  There may be several reasons for this impairment.  The substantial loss of CD4+ 
T cells in acute infection results in decreased HIV-1-specific CD4+ T cell responses within 
the first few months and, therefore, a lack of CD4+ T cell help for subsequent CD8+ T cell 
responses [82].  CD4+ T cells are required for the maintenance of CD8+ T cell responses 
after acute infection [109], for their progression into long-term memory cells [72], and to 
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prevent rapid exhaustion [82].  Chronic high levels of HIV-1 antigen may also result in 
exhaustion, loss of function, and elimination of CD8+ T cells (Section 1.4.2).  The resulting 
immune activation from HIV-1 infection may also impair CD8+ T cell responses by 
upregulating expansion of Fox P3+ CD25+ regulatory T cells, which inhibit the immune 
system by undetermined mechanisms that may include interleukin (IL)-10 and transforming 
growth factor-β secretion [82].  HIV-1 Nef might also aid in the evasion of CD8+ T cell 
responses through impairment of CD4+ T helper cell responses [36]. 
 
1.4.4.3.2 CD4+ T cells 
HIV-1-specific CD4+ T cell responses are present in acute infection but decline rapidly [72, 
82].  They provide help to innate immune cells, CD8+ T cells and B cells (reviewed in [91]).  
Antigen presenting cells (APC; macrophages, dendritic cells, and B cells) engulf HIV-1 
antigen into a phagolysosome where it is processed into peptides of 13-17 amino acids.  
These peptides are then presented by HLA class II molecules on the APC surface to CD4+ T 
cells.  The CD4 molecule on the T cell interacts with the HLA class II constant region and 
enhances binding of the TCR to the epitope-HLA complex.  A co-stimulatory signal, 
principally the binding of B7 on the APC to CD28 on the CD4+ T cell, is required for 
activation of naïve CD4+ T cells.  The activated CD4+ T helper 1 cells produce IL-2 which 
is required for the proliferation and differentiation of CD8+ T cells that have encountered 
antigen and other cytokines, such as IFN-γ, which promote the activity of macrophages.  The 
CD4+ T helper 1 cells may also initiate co-stimulatory signals that are required for full 
activation of naïve CD8+ T cells encountering antigen.  The activated CD4+ T helper 2 cells 
produce cytokines (e.g. IL-4 and IL-5) which stimulate proliferation of B cells that have 
encountered antigen and the production of soluble antibodies.   
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HIV-1 impairs all arms of the immune system through the depletion of CD4+ T helper cells 
(Section 1.4.2) with preferential infection and elimination of HIV-1-specific CD4+ T cells 
[110].  The depletion of uninfected CD4+ T cells is partly mediated by Nef-mediated 
upregulation of Fas ligand on infected cells that triggers apoptosis when binding to Fas on 
uninfected cells [1].  HIV-1 Nef further impairs CD4+ T cell function by inhibiting HLA 
class II epitope presentation and downregulating CD28 [36].  The preferential infection of 
the memory subset of CD4+ T cells also impairs immunity to previously encountered 
pathogens [111]. 
 
The general impairment of immune responses contributes to the gradual decline in immune 
function, the end result of which is death.  Section 1.4 is summarised in Figure 1.2.   
 
1.5 Therapy and preventative strategies  
1.5.1 Antiretroviral therapy and prevention 
Since combination antiretroviral therapy (ART) was introduced in 1996, HIV-related 
morbidity and mortality has fallen and life-expectancy has increased significantly for those 
receiving treatment [83, 112].  Currently, there are 25 single drugs in 6 different classes, 
targeting various stages of the HIV-1 replication cycle (Section 1.3), approved for use:  
nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase 
inhibitors (NNRTIs), protease inhibitors (PIs), entry/fusion inhibitors (FIs), CCR5 
antagonists, and integrase inhibitors [112, 113].  First line therapy consists of a combination 
of 3 drugs -  2 NRTIs and a third drug from another class [112].  Multiple options are 
available for second line therapy should drug toxicity, drug-drug interactions, and/or 
resistance necessitate this [112]. 
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Figure 1.2 Pathogenesis of HIV-1 infection 
(i) The graph shows viral load and CD4+ T cell count patterns, pathogenic events, 
approximate timing of initiation of immune responses, clinical manifestations and 
approximate time frames of the different stages of HIV-1 disease (acute phase, chronic 
phase, AIDS).  Roman numerals indicate the Fiebig stages I-V of acute infection and the 
open-ended stage VI of early chronic infection.  These Fiebig stages are characterised by the 
detection of HIV-1 RNA by PCR, p24 antigen by ELISA, and antibodies by Western blot or 
ELISA (shown below the graph).  The graph is adapted from McMichael et al. (2010) [72] 
and Kuritzkes and Walker (2007) [74].   
(ii) The different host immune responses are depicted and some of the mechanisms by which 
HIV-1 evades, damages, and uses the host immune responses to its advantage are listed.  
Dotted lines in immune response diagrams indicate binding, plus signs (+) indicate 
enhancement of activity and the asterisks (*) indicate the cells influenced by CD4+ T helper 
cells.   
HIV-1 – human immunodeficiency virus type 1; AIDS – acquired immunodeficiency syndrome; RNA – ribonucleic acid; 
CD – cluster of differentiation;  PCR – polymerase chain reaction; p24 – protein of 24 kDa; Ab - antibody; p31 - protein of 
31 kDa; E – enzyme-linked immunosorbent assay (ELISA); WB – Western blot; APC – antigen presenting cell; IFN-α – 
interferon alpha; NK cell – natural killer cell; KIR – killer cell immunoglobulin-like receptor; HLA – human leukocyte 
antigen; Ag - antigen; TCR – T cell receptor; Fc – fragment crystallisable; ADCC – antibody-dependent cell-mediated 
cytotoxic activity; Vpr – viral protein R; Nef – negative regulation factor; Vif – viral infectivity factor; Vpu – viral protein 
U; Env – envelope glycoprotein.   
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There are several challenges with ART.  Even with highly potent therapy that suppresses 
viral load to undetectable levels there is low-level persistent residual HIV-1 replication from 
latently infected cells that become periodically activated, long-lived macrophages, and cells 
in anatomical sites such as the brain where penetration of drugs is limited [73, 78, 83, 112].  
It is estimated that it would take 70 years of highly effective ART to purge this reservoir 
[74].  There are intensive efforts investigating the possibility of curing HIV-1 by activating 
latent reservoirs in combination with ART [83], and there is already an example of an HIV-1 
cure in a man who received a bone marrow transplant from a CCR5 negative donor [114].  
However, in the absence of a cure, complex treatment regimens that are difficult to maintain 
for long periods must be adhered to for life [115], with the high likelihood of drug resistance 
since greater than 95% adherence is required to avoid this.  Continuous use of ART together 
with the persistent immune activation despite therapy increase the risk for cardiovascular 
disease, metabolic disorders, neurocognitive abnormalities, liver and renal disease, bone 
disorders, malignancy, and frailty [83].  Therefore, people on treatment do not reach a full 
life expectancy.  In Denmark, an HIV-1 infected individual on therapy is half as likely to 
reach age 70 [116].  Furthermore, long-term ART for every infected individual for their 
lifetime is not sustainable due to high costs, and current coverage in low- and middle-income 
countries is only 40% [83]. 
 
Some novel ideas for therapeutics are being investigated, such as therapeutic vaccines and 
gene therapy.  Two recent therapeutic vaccine trials of an adenovirus serotype 5 HIV-1 Gag 
vaccine and autologous dendritic cells pulsed with autologous heat-inactivated HIV-1 
resulted in modest reductions in viral load and are therefore promising [117].  Delivery to 
mice of hematopoietic stem cells in which CCR5 alleles were disrupted (by a Zn finger 
nuclease) at a mean frequency of 17%, resulted in preferential expansion of CCR5-negative 
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cells and HIV-1 control [118].  Thus, Zn finger nuclease treatment of patient hematopoietic 
stem cells is also a possible treatment approach.   
 
Since delivery of ART is failing to keep pace with the number of infected individuals, 
several preventative approaches are being investigated to reduce the number of new HIV-1 
transmissions.  These include male circumcision, risk reduction counselling, condom use, 
and pre-exposure or post-exposure ART prophylaxis [119].  Recently 39% efficacy of 
protection from HIV-1 acquisition was shown in women using a 1% tenovifir gel before and 
after sexual intercourse [120].  However, the ideal way to combat the spread of HIV-1 is 
with an effective preventative vaccine. [94, 119, 121-123].  Historically vaccines have 
proven to be the most successful and cost-effective way to reduce the incidence of infectious 
diseases, such as polio, measles, mumps, rubella, hepatitis B, and influenza [94, 123].  The 
development of an effective HIV-1 vaccine has been elusive thus far. 
 
1.5.2 Vaccines 
Successful vaccines to infectious agents have resulted from empirical testing of immunogens 
leading to the development of a product that induces a natural, effective immune response, 
which serves to protect recipients from disease caused by future infections [94, 123].  The 
challenges to developing an HIV-1 vaccine are numerous [1, 94, 112, 123].  A protective 
HIV-1 vaccine would have to induce effective immune responses to clear the infection 
within the narrow window of a few days before a latent reservoir is established (Section 
1.4.1).  Further, these immune responses would have to be effective against the enormous 
diversity of HIV-1 strains, which far exceeds the diversity of influenza for which a new 
vaccine is needed every year [94].  Broadly neutralising antibodies could provide complete 
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protection from infection, however there has not yet been success in inducing these 
antibodies since the conserved epitopes to which they are directed are masked (Section 
1.4.4.2) and poorly immunogenic [119].  Complete protection from HIV-1 infection may not 
be achieved, but even a vaccine that could elicit immune responses to suppress viral load to 
1,000-2,000 HIV RNA copies/ml, could substantially slow disease progression, markedly 
reduce transmission, and therefore have enormous public health benefit [94, 122].  Such a 
vaccine would pose the challenge of continued suppression of viral load despite the high 
mutation rate of HIV-1 which leads to escape of immune responses [123] (Section 1.4.4.3.1).                         
 
To date, greater than 30 candidate HIV-1 vaccines have been tested in human clinical trials, 
the most recent ones being the Step/Phambili and RV144 trials [119, 124-126].  All vaccine 
trials, with the exception of the RV144 trial, have failed to impact HIV-1 acquisition, and all 
failed to influence disease progression in vaccinees who acquired HIV-1 [119].  The Step 
(conducted in America and Australia) and Phambili (conducted in South Africa) trials 
evaluated the efficacy of a T cell only vaccine, consisting of an adenovirus serotype 5 vector 
containing the HIV-1 gag, pol, and nef genes [127].  The reasons for the failure of this T cell 
only vaccine are not fully understood, but may be related to non-optimal specificity and 
breadth of CD8+ T cell responses elicited [121, 127].  The RV144 trial, which tested a 
recombinant HIV-1 (env-gag-protease)-canarypox vector prime and a recombinant gp120  
plus alum boost, was more successful, showing a 31% efficacy in protection from HIV-1 
acquisition [126].  CD4+ T cell Env responses, ADCC, antibody binding to gp120, and low 
titre neutralising antibodies were detected [126, 127].  It has been suggested that the modest 
protective effect was likely mediated by non-neutralising antibodies, suggesting the possible 
importance of innate immunity in preventing infection [93].  The general consensus is that 
an effective vaccine will have to elicit B cell, CD4+ T cell and CD8+ T cell responses, and 
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include adjuvants that stimulate innate immune responses [119].  However, the results of the 
vaccine trials highlight the lack of understanding of what constitutes an effective immune 
response against HIV-1 and how to elicit it. 
 
There is a wide range in the time of progression to AIDS amongst HIV-1 infected 
individuals (Section 1.6.1) with a small minority spontaneously suppressing viral loads to 
low or undetectable levels indefinitely.  Understanding the mechanisms of differential 
disease progression rates and natural control of HIV-1 replication to low levels could result 
in the identification of effective immune responses and the design of an effective vaccine.  
Therefore, a review of the factors determining degree of control of viral replication and HIV-
1 disease progression follows. 
      
1.6 Factors influencing the rate of disease progression 
1.6.1 Spectrum and measurement of disease progression rate 
There is a wide range in the ability of infected individuals to control HIV-1 replication and 
therefore the rate of disease progression varies greatly between individuals.  The average 
time for progression to AIDS is 8-10 years [128].  However, approximately 5% of 
individuals progress to AIDS within 2-3 years [129, 130] while another 5-8%, termed long-
term non-progressors (LTNPs), are able to maintain low viremia (mostly defined as less than 
2,000 HIV RNA copies/ml) and stable CD4+ T cell counts for at least 5 years without ART 
[131, 132].  A subset (less than 0.2% of the total HIV-1-infected population) of LTNPs, 
termed elite controllers, suppress viral load to undetectable levels (less than 50 HIV RNA 
copies/ml) indefinitely without treatment and generally do not have clinical symptoms [131, 
132]. 
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Many studies assessing the influence of various factors on HIV-1 disease progression have 
used time to AIDS as a direct endpoint to measure disease progression rate.  Others have 
used indirect markers of disease, such as the viral set point following seroconversion or 
within the first 6-12 months, which are strong predictors of progression to AIDS [74, 133].  
Viral load and immune activation (as measured by the CD38 marker on CD8+ T cells) are 
the strongest predictors of time to AIDS (predicting 47% and 40% variability in time to 
AIDS, respectively) followed by CD4+ T cell count (predicting 29%) [130, 134-136].  Thus, 
early viral set point, viral load, and CD4+ T cell count are often used as surrogate markers of 
disease progression [137].  CD4+ T cell decline has an inverse relationship to plasma viral 
load [130] but recently was found to explain only about 3% of variability in time to AIDS 
due to the high variability in the CD4+ T cell decline measurement [135].  CD4+ T cell 
decline is also sometimes used as a marker of disease progression, although usually in 
conjunction with other markers.                
 
1.6.3 Viral and host factors 
Several host genetic and immune factors as well as viral genetic factors may influence the 
rate of HIV-1 disease progression [79, 129, 132, 138-140].  For example, individuals who 
are homozygous for a 32-bp deletion in the CCR5 co-receptor gene show almost complete 
protection against HIV-1 acquisition (since the transmitted virus is highly dependent on this 
co-receptor for cell entry), and those who are heterozygous for the deletion or have 
polymorphisms that decrease CCR5 expression have delayed progression to AIDS [129, 
141].  Polymorphisms in the CypA (Section 1.3.3) and Tsg101 (Section 1.3.8) host genes 
involved in HIV-1 replication have also been associated with differences in susceptibility to 
HIV-1 infection or in the rate of progression to AIDS [129, 142].  However, the majority of 
host genetic factors linked to altered disease progression mediate their effect through 
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influencing host immune responses to HIV-1.  Similarly most viral genetic factors associated 
with slower or faster rates of disease progression are themselves consequences of host 
immune responses and/or affect pathogenesis through altering the effectiveness of host 
immune responses.  Therefore the host and viral factors influencing HIV-1 disease 
progression will be discussed in terms of the innate, humoral and cell-mediated immune 
responses. 
 
1.6.3.1 Innate immune responses 
LTNPs maintain higher levels of dendritic cells [131], which play an important role in the 
innate immune response (Section 1.4.4.1.1).  Dendritic cells produce IFN-α (Section 
1.4.4.1.1) and two single-nucleotide polymorphisms (SNPs) in the IFN-α receptor have been 
associated with susceptibility to HIV-1 infection [143].  Polymorphisms in restriction genes 
upregulated by IFN-α and other type 1 IFNs, namely TRIM5α and APOBEC3G, have been 
linked to altered disease progression [144, 145].  However, it appears that polymorphisms in 
identified restriction factors are not the cause of viral control in the majority of elite 
controllers [131]. 
 
Increased NK cell activity has been detected in exposed but seronegative individuals [146] 
and factors influencing NK cell activity have also been linked to altered disease progression.  
A SNP in the HLA-C promoter gene has been identified as a major genetic determinant 
associated with lower viral set point, and may mediate its effect through influencing 
interactions with NK or CD8+ T cells leading to more efficient cell lysis [147].  However, 
this SNP does not explain elite control in the majority of elite controllers [131, 148].  The 
expression of the activating KIR3DS1 (on NK cells) in combination with HLA-Bw4 
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molecule ligands (including HLA-B*57 and HLA-B*27) is associated with slower 
progression to AIDS [149], and is overexpressed in LTNPs but not elite controllers [131].  
Long-term non-progression in blood transfusion recipients of a Nef-deleted virus [150, 151] 
may be partly accounted for by lack of Nef-mediated downregulation of HLA, which 
antagonises both NK cell and CD8+ T cell immune responses (Sections 1.4.4.1.3 and 
1.4.4.3.1), although viral attenuation could also be a contributing factor (Section 1.6.5).  
However, the majority of elite controllers do not harbour viruses with gross genetic defects 
such as Nef-deletions [152].      
 
1.6.3.2 Humoral immune responses 
There is not much data to suggest that antibody responses determine control of HIV-1 
replication, although there is more evidence that they may be important in preventing 
infection [93, 131, 132].  In a macaque-SIV/HIV model, passively administered antibodies 
can protect against infection and disruption of ADCC activity dramatically increases 
susceptibility to SIV/HIV chimera infection [153].  Further, the modest protection against 
HIV-1 acquisition by the RV144 vaccine may have been elicited by non-neutralising 
antibodies [93] (Section 1.5.2).  Mucosal immunoglobulin A (IgA) antibodies capable of 
neutralisation were also identified in exposed but seronegative individuals [146]. 
 
It has been shown that ADCC activity is more potent in elite controllers than in progressors 
[93].  However, since equally potent ADCC activity was shown in some acutely infected 
individuals and individuals on ART, potency may be a consequence rather than cause of 
level of viremia [93].  Broadly neutralising antibodies are less common in aviremic LTNPs 
[154] and elite controllers have lower titres of broadly neutralising antibodies and similar 
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levels of autologous neutralising antibodies when compared with progressors [155, 156].  
Collectively these data suggest that neither ADCC nor neutralising antibodies play a major 
role in maintaining viremic control in HIV-1 controllers.  
    
1.6.3.3 Cell-mediated immune responses 
1.6.3.3.1 CD4+ T cell responses 
HIV-specific CD4+ T cell responses of elite controllers and LTNPs have a higher 
proliferative potential than those of progressors, and also result in the secretion of multiple 
cytokines, including IL-2, upon stimulation, while CD4+ T cells from progressors mostly 
secrete IFN-γ [90, 131, 157].  Further, there are preserved central memory and activated 
effector memory CD4+ T cell subsets in HIV-1 controllers [158].  The preservation of a 
vigorous CD4+ T cell response in HIV-1 controllers may be important for CD8+ T cell-
mediated control of virus replication, but whether or not it is crucial is unknown [82].  
However, a recent study has shown that IL-21-secreting CD4+ T cells (preserved in elite 
controllers) may contribute to viral control through enhancing CD8+ T cell function [159].  
It is also unclear whether preserved CD4+ T cell responses in controllers are a cause or 
consequence of low viremia and there is conflicting data in this regard [82, 90, 131].  It is 
clear at least that the proliferative capacity of HIV-specific CD4+ T cells can be restored by 
ART to levels observed in LTNPs, suggesting that this characteristic is influenced by the 
level of viremia [90, 160].          
 
1.6.3.3.2 CD8+ T cell responses 
As with HIV-specific CD4+ T cell responses, there are qualitative differences in HIV-
specific CD8+ T cell responses between elite or viremic controllers and progressors.  HIV-
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specific CD8+ T cells from elite controllers and/or LTNPs are polyfunctional (secreting 
multiple cytokines) [161], have a high proliferative capacity when stimulated [162], are more 
efficient at lytic granule loading, and have a high per-cell killing capacity [163].  Some 
studies have found restoration of CD8+ T cell polyfunctionality by ART, suggesting that 
polyfunctionality is a consequence rather than cause of low viremia [164, 165].  However, 
these studies measured polyfunctionality in response to antigen stimulation and did not 
compare to LTNPs.  This may account for the different result obtained in a recent study in 
which CD8+ T cell polyfunctionality in response to autologous HIV-1-infected CD4+ T 
cells was compared in patients on ART versus LTNPs with matched suppressed viral loads, 
where polyfunctionality was greater in LTNPs [160].  However, these authors argue that 
polyfunctionality is not likely to be an important determinant of immune control as 
polyfunctional cells form a small subset of the total HIV-specific CD8+ T cell response 
[160].  Proliferative and cytotoxic capacities of CD8+ T cells were superior in LTNPs when 
compared with patients on ART and these characteristics may contribute to immune control 
of HIV-1 [131, 160].  Interestingly, HIV-1 specific CD8+ as well as CD4+ T cell responses 
have been detected in HIV-1 exposed but seronegative individuals [146, 166].       
 
The important role that the CD8+ T cells play in reducing viral load from a peak in early 
infection to a lower viral set point (Section 1.4.4.3.1) and the strong association of this set 
point with progression to AIDS (Section 1.6.1), as well as the CD8+ T cell depletion 
experiments in monkeys (Section 1.4.4.3.1), provide evidence that the CD8+ T cell 
responses are important in determining viral control and disease progression.  However, 
perhaps the strongest evidence supporting this is the consistent, strong association of 
different HLA class I alleles, which present viral epitopes to activate CD8+ T cell mediated 
killing of infected cells (Section 1.4.4.3.1), with the rate of progression to AIDS [132, 167-
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172].  A recent genome-wide association study on nearly 1,000 HIV-1 controllers revealed 
313 SNPs associated with control, all of which were within the region coding for HLA 
concentrated in and around class I genes, suggesting it is the major factor involved in 
determining viral control [169]. 
   
1.6.4 HLA class I alleles 
1.6.4.1 Genetic associations 
Although there are some associations between HLA class II alleles and rate of HIV-1 disease 
progression (e.g. DRB1*13 is associated with slower disease progression) [167, 172, 173], 
HLA class I alleles are clearly the strongest and most consistent markers of disease 
progression [132, 167].  HLA-B*57 (especially B*5701) and HLA-B*27 have been most 
robustly associated with slower progression to AIDS in European and North-American 
individuals, while HLA-B*35-Px is consistently associated with rapid progression to AIDS 
in these populations [167].  In African populations, alleles consistently and strongly 
identified with low viral loads and/or high CD4+ T cell counts and/or are overrepresented in 
LTNPs include HLA-B*57 (especially B*5703), HLA-B*5801, and HLA-B*8101 [170, 
174, 175].  In contrast, in these African populations, HLA-B*5802 and HLA-B*18 are 
significantly associated with higher viral loads [170, 174, 176].  In addition, rare HLA class I 
types have been associated with slower disease progression and HLA class I homozygotes 
have been associated with faster disease progression [132, 167].  There is also some 
evidence that HLA types may be associated with differing resistance to infection [167], for 
example HLA-B*57 expressed in combination with KIR3DL1*h/*y is more prevalent in 
exposed seronegative individuals [177].  The underlying basis for the strong association 
between HLA class I alleles and disease progression (and/or resistance to infection) is not 
fully understood.  Some possible mechanisms are outlined below.   
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1.6.4.2 HLA: mechanisms of control 
1.6.4.2.1 Interactions with NK cells 
HLA-B class I alleles may have either a Bw4 or Bw6 specificity.  Most HLA alleles 
associated with protective effects have Bw4 specificity while those associated with rapid 
disease progression more often have Bw6 specificity [167].  Since co-expression of Bw4 
alleles, like HLA-B*57, and KIR3D molecules (on NK cells) are associated with slower 
disease progression (Section 1.6.3.1) or resistance to infection (Section 1.6.4.1), this 
suggests that an underlying mechanism of HLA protection may be interaction with NK cells.  
 
1.6.4.2.2 Immune activation 
One suggested mechanism of protection of certain HLA alleles is association with lack of 
immune activation.  For example, the protective alleles HLA-B*57 and HLA-B*27 have 
been associated with lower levels of markers of immune activation and inflammation which 
may contribute to a clinical benefit in these individuals [178].  It has also been proposed that 
the sequence homology between HIV gp120 and regions of both HLA class I and II 
molecules may promote allogeneic T cell reactions and immune activation, and that this may 
differ depending on the HLA repertoire, thereby partly explaining HLA allele association 
with disease progression [87].  Consistent with this, antibodies to a conserved region of 
gp120 displaying structural homology with HLA were found in the sera of slow progressors 
[179].  Further supporting this idea, there is much evidence that immune activation plays a 
central role in determining development of AIDS:  CD38 (a marker of activation) expression 
on CD8+ T cells predicts progression to AIDS to a similar degree as HIV-1 viral load in 
early infection and is the strongest predictor in later infection [134], CD4+ and CD8+ T cell 
activation predict progression to AIDS [180], polymorphisms in the CXCR6 receptor (a 
mediator of inflammation) are strongly associated with long-term non-progression to AIDS 
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[181], polymorphisms in genes encoding pro-inflammatory (e.g. tumour necrosis factor-α) 
and anti-inflammatory cytokines (e.g. IL-10) have been associated with altered rate of 
progression to AIDS [129], elite controllers have lower levels of HIV-specific CD8+ and 
CD4+ T cell activation [182], elite controllers have immune activation restricted to the T cell 
effector compartment and not a generalised pattern of immune activation [158], and natural 
hosts of SIV (African green monkeys and sooty mangabeys) have high viremia but low 
levels of immune activation and non-progression to AIDS [85, 86].  
 
1.6.4.2.3 CD8+ T cell responses 
However, Mamu-B*08 (similar to HLA-B*27) positive macaques were less likely to achieve 
elite control when infected with a strain of SIV encoding escape mutations in Mamu-B*08-
restricted epitopes, suggesting that the protective mechanism of certain HLA alleles is likely 
CD8+ T cell-based [131].  This may be related to the quality or specificity of CD8+ T cell 
responses restricted by certain HLA alleles.   
 
1.6.4.2.3.1 Immunodominance and quality 
HLA alleles associated with slower progression to AIDS mediate strong, immunodominant 
CD8+ T cell responses (that make a major contribution to the total CD8+ T cell response) in 
early infection, which may explain their protective effect [183].  Further, individuals who 
display a larger contribution of the most immunodominant CD8+ T cell response for a given 
HLA allele to their total CD8+ T cell response in early infection generally have lower viral 
set points (even after exclusion of protective HLA alleles) [184].  Thus, strong CD8+ T cell 
responses in early infection may mediate viral control.  The protective HLA-B*57 and HLA-
B*27 alleles have a greater frequency of polyfunctional T cell responses, which may be due 
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to low avidity T cell receptors on these populations [185].  Another recent finding is that the 
nature of the HLA-B*57 peptide binding results in greater cross-reactivity and therefore 
greater potential to recognise epitopes containing point mutations at certain residues, which 
may allow more effective CD8+ T cell responses to emerging mutant viruses [186]. 
 
1.6.4.2.3.2 Gag-focussed specificity 
1.6.4.2.3.2.1 Epitope restriction specificity 
A feature of protective HLA alleles is the restriction of conserved epitopes in Gag [174, 187, 
188]; in contrast to unfavourable HLA alleles, such as HLA-B*5802, which preferentially 
present more variable Env-derived epitopes to CD8+ T cells [176].  In addition, protective 
HLA alleles have been associated with immunodominant targeting of Gag [189, 190].  It is 
also of interest to note that even after excluding protective HLA alleles, CD8+ T cell 
responses to conserved epitopes across the HIV-1 proteome have been associated with lower 
viral loads [191, 192].    
 
1.6.4.2.3.2.2 Gag T cell responses associated with viral control 
While the overall breadth and magnitude of the CD8+ T cell response does not correlate with 
rate of disease progression [108], several studies have shown an association between 
preferential Gag-specific CD8+ T cell responses and favourable clinical outcomes.  Kiepiela 
et al. (2007) showed an inverse correlation between the number of CD8+ T cell responses to 
the conserved Gag protein and viral load as well as a correlation between the number of 
responses to the highly variable Env and higher viral loads in chronic subtype C HIV-1 
infection [193].  Similarly, the magnitude and breadth of CD8+ T cell responses to Gag or 
Gag capsid (p24) correlated inversely with viral loads and directly with CD4+ T cell counts 
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[194] and broad Gag-biased epitope repertoires were associated with lower viral loads [195].  
Zuñiga and colleagues (2006) showed that the contribution of Gag p24 CD8+ T cell 
responses to the total CD8+ T cell response is positively associated with low viral loads and 
high CD4+ T cell counts [196].  Recently, Pereyra et al. (2008) showed that HIV-1 
controllers preferentially target Gag over other viral proteins [156].  Superior in vitro 
suppression of viral replication in autologous CD4+ T cells using inhibition assays is 
mediated by Gag-specific rather than Nef- or Env-specific CD8+ T cell responses [197, 
198].  However, it should also be noted that while some acute infection studies have shown 
that early CD8+ T cell responses to Gag result in lower viral set points [199], others have 
shown no correlation with viral set point [200] or no correlation between Gag-specific CD8+ 
T cell responses in early chronic infection and progression to AIDS [201].                          
 
The link between Gag-specific CD4+ T cell responses and viral control further supports the 
important role of Gag-specific CD8+ T cell responses in disease progression.  HIV-1 
controllers have a high avidity memory Gag-specific CD4+ T cell population that proliferate 
extensively in response to minimal amounts of antigen [202].  Gag-specific CD4+ T cell 
responses are maintained in LTNPs (although these responses after seroconversion had no 
prognostic value for progression to AIDS in that study) [203], and Gag p24-specific CD4+ T 
cell responses in early infection predicted lower viral set points [204].  CD4+ T helper 1 
cells (which promote CD8+ T cell mediated immunity) that are predominantly directed to 
Gag are associated with elite control while the opposite is true for those predominantly 
directed towards Env, suggesting that Gag-specific CD8+ T cell responses are important in 




1.6.4.2.3.2.3 HLA-associated mutations in Gag associated with viral control 
Protective HLA alleles are not only associated with presentation of Gag epitopes and 
preferential Gag-specific CD8+ T cell responses, but also with strong selection pressure 
resulting in the development of escape mutations in these key Gag epitopes [174, 187].  
HLA-driven mutations that were associated with lower viral loads in chronic subtype C 
HIV-1 infection were found predominantly in Gag and were restricted by protective HLA 
alleles [206].  Further, in acutely HIV-1-infected individuals, increasing numbers of 
transmitted HLA-B-associated polymorphisms [207], or more specifically the presence of 
transmitted polymorphisms associated with the protective HLA-B*57 and HLA-B*5801 
alleles [208], were associated with lower viral set points.  Protective HLA-B alleles (linked 
to lower viral loads) were also associated with a higher number of mutations in Gag that 
revert following transmission to hosts without the relevant HLA alleles to select them when 
compared with HLA-B alleles linked to higher viral loads [209].  Reversion of HLA-
associated mutations when transmitted to HLA-mismatched recipients (i.e. in the absence of 
their selection pressure) implies that these mutations carry a cost to viral fitness or 
replication capacity [209, 210].  
 
Collectively, these studies indirectly suggest an important mechanism of HLA association 
with disease progression rate:  CD8+ T cell responses restricted by favourable HLA alleles 
select for escape mutations in conserved epitopes, particularly those in Gag, resulting in a 
fitness cost to HIV-1 and this may at least in part explain slower disease progression in 
individuals with these alleles.  In the next section, direct evidence for fitness cost of HLA-
driven Gag mutations, as well as direct evidence for impact of viral fitness on HIV-1 disease 
progression, is discussed.   
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1.6.5 Viral fitness 
1.6.5.1 Fitness costs of HLA-associated Gag escape mutations 
A fitness cost for some escape mutations in Gag p24 capsid, a particularly conserved region 
of the Gag protein, that are associated with protective HLA alleles has been directly 
demonstrated through insertion of the escape mutation (by site-directed mutagenesis) into a 
laboratory-adapted strain of HIV-1 followed by in vitro measurement of viral replication.  
The HLA-B*5703/B*5801-associated T242N mutation in the TW10 epitope reduces 
recognition by CD8+ T cells [210], reverts on transmission to HLA-mismatched recipients 
[210], and decreases replication capacity in vitro [33, 187, 211].  Similarly, the A146P 
mutation alone or in combination with I147L in the HLA-B*5703/B*5801-restricted ISW9 
epitope, and the A163G mutation (which arises following escape in TW10 and ISW9 
epitopes) in the HLA-B*5703-restricted KF11 epitope, significantly reduced recognition by 
CD8+ T cells as well as viral replication in vitro [102, 104, 187, 212].  The protective allele 
HLA-B*27 is associated with selection of the escape mutation R264K, which dramatically 
reduces viral replication capacity in vitro [213].   
 
Interestingly, HLA-B*57/B*5801-associated mutations are often selected early in infection 
while the HLA-B*27-associated R264K mutation is typically selected very late in infection 
and correlates with the onset of AIDS [168, 187, 213-215].  This suggests that the 
mechanism of slower disease progression mediated by different HLA alleles may be 
different.  It has been argued that HLA-B*57 and HLA-B*5801 may mediate their protective 
effect through strong early immunodominant CD8+ T cell responses that result in rapid 
selection of Gag escape mutations and early viral attenuation, while HLA-B*27 may mediate 
its protective effect through an effective CD8+ T cell response that is maintained through a 
high genetic barrier to escape (due to the associated high viral fitness cost) [168, 187, 213]. 
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A recent study has indicated that escape mutations in more conserved regions, such as Gag 
p24, often result in viral fitness costs while escape mutations in the more variable Env region 
often carry no fitness cost or actually increase viral fitness in vitro [104].  Mutations arising 
in Gag may be more likely to result in fitness costs since it is a key structural component of 
the virion and plays important roles during several stages in the HIV-1 replication cycle 
(Sections 1.2 and 1.3), therefore requiring conservation.  Escape mutations occurring in 
conserved regions of Gag that are not restricted by the protective HLA alleles have also been 
shown to result in viral fitness costs, including:  E207D alone or in combination with V215L 
(in Gag p24) in the A*25-restricted EW10 epitope [104], E17K (a conserved p17 residue) in 
a B*4002-restricted epitope, and K26R (a conserved p17 residue) in a B*08 restricted 
epitope [216].   
 
For most of the escape mutations listed above, secondarily arising co-varying mutations that 
partially compensate for fitness costs have been described.  Brockman et al. (2007) show 
that mutations at Gag codons 219, 223, 228, and 248 cumulatively increase the replication 
capacity of T242N mutants, although fitness is not restored to wild-type levels [33].  
Interestingly, the underlying mechanism of the T242N fitness defect is disrupted interaction 
with CypA and these compensatory mutations conferred independence from CypA [33].  
Troyer et al. (2009) showed that while I147L increased the replication capacity of a A146P 
mutant, the double mutant was still significantly less fit than the wild-type [104].  Similarly, 
S165N partially compensates for the fitness cost of a subtype C A163G mutant [212].   The 
S173A mutation is strongly linked to and arises in conjunction with the R264K HLA-B*27-
associated escape mutation, and restores viral replication capacity to near wild-type levels 
[213].   
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1.6.5.2 Viral fitness and disease progression 
1.6.5.2.1 Whole isolate fitness  
Some of the first studies to suggest an impact of viral fitness on HIV-1 disease progression 
described unusually slow progression (or non-progression) to symptomatic disease in 
recipients of an attenuated strain of HIV-1 containing a deletion in the nef gene [150, 151].  
However, the long-term outcome in these individuals might also be explained by the absence 
of the many antagonistic effects of Nef (Section 1.4.4).  Some reports have shown distinct 
differences in the fitness of HIV-1 isolates from LTNPs and progressors (although isolates 
from both groups are replication competent) [217-219].  Further indicating that viral 
replicative ability influences rate of disease progression, a study showed that differences in 
viral set point after rebound following treatment interruption were driven by viral fitness 
[220]. 
 
There is also evidence that difference in fitness between HIV-1 isolates of different subtypes 
may influence disease progression.  Slower rates of CD4+ T cell decline in HIV-1 subtype C 
infection when compared with subtype A and D infection have been reported, but slower 
disease progression in HIV-1 subtype C infected individuals has not been directly shown 
[221].  In a recent report, HIV-1 subtype C isolates were shown to have equal 
transmissibility but were dramatically less fit when compared to other M group subtypes 
[221].  These authors suggest that the global prevalence of HIV-1 subtype C may be 
explained by the lower pathogenic viral fitness of this subtype, which may result in slower 




1.6.5.2.2 Gag-mediated viral fitness  
Some studies suggest that Env is the strongest determinant of HIV-1 fitness, explaining as 
much as 86% of the variability in viral fitness [222, 223], however Campbell et al. (2003) 
showed that protease-reverse transcriptase may explain 53% of the variability in HIV-1 
fitness [224].  Recently, recombinant viruses encoding Gag p24 correlated with HIV-1 
isolate replication capacity, providing direct evidence that Gag p24 is also a significant 
determinant of HIV-1 fitness [219].   
 
There is evidence that reduced Gag function as a result of HLA-driven mutations, and 
thereby lowered viral fitness, might impact on the rate of disease progression.  Recombinant 
viruses encoding Gag-protease from HIV-1 subtype B infected elite controllers were 
significantly attenuated [225].  In a small number of LTNP infants without HLA-
B*57/B*5801 alleles, whole viral isolates as well as recombinant viruses encoding Gag p24 
(from the infant’s virus) had classical Gag p24 mutations associated with these protective 
HLA alleles (and a lack of compensatory mutations) as well as significantly reduced fitness 
[219].  In contrast, in progressor infants who received a virus with these Gag p24 mutations, 
compensatory mutations were present and the viral isolates were fitter [219].  A more recent 
study demonstrated reduced viral replication capacity, attributed to B*57/B*5801-associated 
mutations in Gag as well as drug-resistance mutations in protease, in HIV-1 subtype B 
acutely infected individuals of various HLA profiles who subsequently became HIV-1 
controllers [226].  While these studies suggest long-term benefit in HLA-mismatched 
recipients of an attenuated virus encoding HLA-B*57/B*5801-associated escape mutations 
in Gag, other studies investigating HLA-mismatched recipients have observed reversion of 
these mutations within 2 years, resulting in restored fitness and loss of viral control [187, 
227].  Reversion and loss of viral control suggest that an effective CD8+ T cell response 
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mediated by possession of the protective HLA allele is thus also required for maintenance of 
less fit viral variants and long-term control.   
 
1.6.5.2.3 Gag-mediated viral fitness/CD8+ T cell response balance  
There is much evidence to suggest that viral fitness alone cannot explain disease progression 
but rather that the balance between CD8+ T cell responses to the virus and mutations that 
arise as a result of this contributes to clinical outcome.  Kawada et al. (2006) demonstrated 
loss of virus control in monkeys with the accumulation of Gag escape mutations in SIV, 
although SIV was progressively attenuated in vitro [228].  Similarly, Crawford et al. (2009) 
showed a decrease in in vitro fitness with the sequential accumulation of HLA-B*5703-
associated mutations in Gag (A146P, I147L, T242N, A163G) and a loss in viral control 
simultaneous with evasion from effective CD8+ T cell responses to all of the HLA-B*5703-
restricted Gag p24 epitopes [187].  Further, although elite controllers have viruses with 
significantly reduced Gag-protease mediated fitness [225], they may also select rare fitness-
reducing mutations in Gag and have the ability to recognise and make strong de novo CD8+ 
T cell responses to these variants [229].   
 
Contrasting the importance of the balance between CD8+ T cell responses and viral fitness 
in determining disease progression is a recent study by Schneidewind et al. (2009) 
investigating a small number of infants [227].  This study showed favourable clinical 
outcome and viral control in HLA-B*57 haplo-identical infants receiving a virus with HLA-
B*57-selected mutations in Gag p24 even when CD8+ T cell responses to these epitopes 
were undetectable.  It should however be noted that reversion of these mutations did not 
occur in these infants, suggesting their maintenance by low level CD8+ T cell responses that 
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were not detectable in the blood but may have been present in the lymph nodes or other 
compartments.  Also, CD8+ T cell responses to B*57-associated variants have previously 
been detected in HLA-B*57 positive infants [230].  Further, in contrast to the findings of 
Schneidewind et al. (2009) [227], other groups have reported that individuals with HLA-
B*57 or HLA-B*27 who received a virus with escape mutations in Gag from individuals 
with these same HLA alleles did not display a favourable clinical course [187, 231].   
 
An overview of the factors influencing HIV-1 disease progression is illustrated in Figure 1.3.   
 
1.7 Measurement of viral fitness or replication capacity 
Depending on the question addressed, the fitness consequences of a particular viral mutation, 
viral genomic region, or whole viral isolate can be measured.  The advantages and 
limitations of each of these measurements, as well as the advantages and disadvantages of 
different cell types and assays used to obtain viral fitness measurements, are discussed 
below. 
 
1.7.1 Starting material 
1.7.1.1 Mutant viruses 
To measure the fitness effect of a particular mutation, this mutation may be introduced by 
site-directed mutagenesis into a laboratory-adapted strain of HIV-1 and the consequence 
determined by comparison of the mutant versus wild-type viruses [33, 187, 211].  Since a 
standard laboratory-adapted strain is used to introduce mutations, a reporter gene can be 
engineered into the strain to allow for ease of virus detection [232].  This may be for 
example, firefly luciferase (which is a luminescent marker) [232, 233] or jellyfish green 
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Figure 1.3 Spectrum and markers of HIV-1 disease progression rate and factors 
influencing the rate of progression 
(i) Timeline indicating the wide variability in time of progression to AIDS in individuals 
infected with HIV-1. 
(ii) The graph shows early viral set point as a predictor of HIV-1 disease progression and 
other commonly used and/or significant markers of disease progression rate are listed.  The 
graph was adapted from Kuritzkes and Walker (2007) [74]. 
(iii) Overlapping and interacting host genetic, host immune and viral factors influencing the 
rate of HIV-1 disease progression are outlined.  HLA class I alleles are most strongly 
associated with disease progression rate and interactions between HLA alleles and other 
immune factors which may partly explain the association are shown.  Highlighted with red 
arrows is the interaction pathway suggesting that certain HLA alleles restrict Gag-specific 
CD8+ T cell responses which select for escape mutations in Gag that impact viral fitness and 
therefore disease progression.  This pathway is highlighted, and HLA and viral fitness 
factors are underlined, since the focus of the present study is to investigate the influence of 
HLA-driven mutations in Gag-protease on HIV-1 fitness and therefore disease progression.  
HIV-1 – human immunodeficiency virus type 1; AIDS – acquired immunodeficiency syndrome; LTNP – long-term non-
progressors; EC – elite controllers; RNA – ribonucleic acid; CD – cluster of differentiation; CCR5 – C-C chemokine 
receptor 5; Tsg101 – tumour susceptibility gene 101 protein; IFN-α - interferon alpha; APOBEC3G - apolipoprotein B 
messenger RNA editing catalytic subunit-like protein 3G; TRIM5α - tripartite motif-containing 5 alpha; KIR – killer cell 
immunoglobulin-like receptor; HLA – human leukocyte antigen; ADCC – antibody-dependent cell-mediated cytotoxic 
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fluorescent protein (GFP; which can be detected by flow cytometry) [219, 234, 235].   Other 
methods of detection include direct detection of viral gene products/activities or reporter 
genes engineered into cells [232] (Section 1.7.1.3).  Fitness differences can be directly 
attributed to the mutation and results are therefore easily interpreted.  However, a limitation 
of this approach is the consideration of the fitness consequences of a particular mutation 
outside of the context of the natural viral sequence background, where co-existing mutations 
are likely to occur [236].  Introduction of numerous secondary mutations through site-
directed mutagenesis is possible, however this process is labour-intensive and still may not 
recapitulate natural conditions. 
 
1.7.1.2 Recombinant viruses  
In contrast to point mutations, a entire genomic region may be inserted into a standard viral 
backbone (with or without a reporter gene for detection), allowing for a direct link between 
measured fitness and the viral protein or region of interest [236].   
 
The genomic region analysed may be a single clone or a pool of sequences amplified from 
clinical samples or other sources [236].  The advantage of using a single clone is that the 
precise sequence is known, while a population sequence reflects mutations present in the 
virus pool but not necessarily occurring in combination in one virus strain.  However, 
analysis of a virus pool may be more representative of the diversity in vivo.   
 
The construction of recombinant viruses may be performed using restriction enzymes, a 
yeast recombination system, or homologous recombination of the viral genomic region 
(amplified using primers complementary to the vector) and vector in mammalian cells [237, 
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238].  Due to the variability of HIV-1, there is often a lack of convenient, unique restriction 
sites [238, 239].  A yeast recombination system does not require unique restriction sites, but 
(with the exception of a very recently developed system [238]) sub-cloning is required to 
achieve full infectivity [238-240].  Homologous recombination is less labour-intensive, 
although it is time-consuming as eukaryotic recombination is of poor efficiency [238].  
Another alternative is gene complementation involving transfection of cells with a gene 
expression vector and a full length vector with the relevant gene deleted to produce 
pseudovirions [233, 241].  However, this introduces foreign genetic elements [238] and since 
pseudovirions may only complete one replication cycle, this may only be applied in single 
cycle fitness assays (Section 1.7.3.1). 
 
Although viral fitness effects measured by this approach can be attributed to a genomic 
region, it may not be clear which mutations are primarily responsible, necessitating further 
investigations [236].  Another limitation is that since the genomic region is not in the natural 
context, interactions with other genes are not taken into account [232, 236].  For example, 
Gag interactions with gp41 in Env (Section 1.3.7) may be disrupted by examining either 
protein in isolation.  A measurement of whole viral isolates is therefore likely to yield the 
most reliable fitness results [232, 236]. 
 
1.7.1.3 Whole isolates         
HIV-1 may be isolated from peripheral blood mononuclear cells (PBMCs) or plasma, with 
similar or higher rates of success from PBMCs and greater efficiency from PBMCs [242, 
243].  There are also methods to extract clones from viral isolates [244] to allow fitness of 
specific clones to be measured.  Despite accuracy of measurement, the genetic determinant 
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for the fitness effect is not known and isolation of virus requires extra costs, is time-
consuming and difficult for some strains [236].  If the fitness of whole isolates is measured 
in primary cells (e.g. PBMCs), measurement of fitness is limited to the direct detection of 
viral products (e.g. p24 antigen by enzyme-linked immunosorbent assay [ELISA]) or activity 
(e.g. reverse transcriptase activity) [232], neither of which assess particle infectivity [71].  
However, if isolates are grown in a cell line, the cell line may be manipulated to express a 
reporter gene, such as GFP, on infection, thereby allowing an easy, convenient, and 
relatively inexpensive measure of viral spread in the culture [71, 235]. 
 
1.7.2 Primary cells versus T cell lines 
Viral fitness measured in primary cells (cells cultured directly from human subjects) should 
yield results representative of the in vivo situation.  PBMCs are the primary cells most 
commonly used in HIV-1 fitness assays to investigate pathogenic fitness; however, other cell 
types may be used for specific research questions. For example, Langerhans cells may be 
used to directly assess HIV-1 transmission fitness [222].  It is important to note that fitness 
measurements obtained in PBMCs may differ from those obtained using established T cell 
lines, and may also vary between different T cell lines [232].  For example, reduced viral 
fitness due to the M184V NRTI resistance mutation was evident in PBMCs but not in T cell 
lines, due to lower nucleotide concentrations present in PBMCs [245].  Although the fitness 
defect of T242N was detected in a CEM-GXR cell line [246], this fitness cost was 
significantly more pronounced in a Jurkat cell line and in PBMCs, possibly because this 
mutation disrupts capsid-CypA interaction (Section 1.6.5.1) and CEM-GXR cells display 
higher CypA levels [33].  However, no significant influence of cell type was detected in 
studies investigating the fitness of resistance mutants to NNRTI [232] and another study 
showed similar results for fitness effects of escape and compensatory mutations in PBMCs 
54 
and cell lines [213].  Although PBMCs are the cells infected in vivo, they are highly variable 
between donors, require stimulation before use and cannot be maintained for long periods in 
vitro [71, 236].  Cell lines overcome these difficulties. 
 
1.7.3 Single and multiple cycle fitness assays 
1.7.3.1 Single cycle assays 
Single cycle assays are commonly used to measure infectivity and generally involve 
infection of cell lines with pseudovirions or recombinant viruses encoding reporter genes, 
followed by reporter gene detection in cells (luminescence/fluorescence) between 24-72 
hours post-infection [211, 219, 241].  Single cycle assays have the advantage of yielding 
results quickly.  However, they have the disadvantage of not measuring the full replication 
cycle and are often less sensitive [71].  Multiple cycle assays can amplify fitness differences 
of variants over many cycles, thus increasing sensitivity, and are able to measure spread of 
infection in a culture [71]. 
 
1.7.3.2 Multiple cycle assays 
1.7.3.2.1 Pairwise growth competition assays 
In pairwise growth competitions, two viral variants compete for the same resources under the 
same culture conditions, making this an accurate and sensitive measure of viral fitness [236].  
The fitter variant outcompetes the other and the relative proportion of the variants at 
different time points can be measured by a heteroduplex tracking assay (HTA), population 
sequencing, or real-time polymerase chain reaction (PCR) [232, 236].  HTA requires that the 
variants are sufficiently different to design unique probes allowing resolution of the two 
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probe-PCR product heteroduplexes on a gel [218, 247].  Quantitation of relative variant 
proportions by population sequencing has a limited linear range, however clonal sequence 
analysis is labour-intensive [232].  Real-time PCR is higher throughput, however this assay 
has to be optimised for each primer/probe used to appropriately differentiate the variants 
[232].  Therefore, the methods of detection are generally complex, technically demanding, 
labour-intensive, costly, require prior sequence knowledge, and results are difficult to 
quantify [71, 232].  These difficulties may be largely overcome if recombinant viruses 
instead of whole viral isolates are competed, by engineering different fluorescent genes (or 
reporter genes detected by fluorescent antibodies) into the virus backbones used, thereby 
allowing relative quantification by flow cytometry [234, 248].  However, another theoretical 
potential problem may be recombination of the variants compared since they are in a single 
culture, although this risk can be minimised by low inoculation dose and a limited culture 
period [232]. 
 
1.7.3.2.2 Parallel assays            
Parallel mono-culture replication assays are simpler and less labour-intensive than growth 
competitions [71, 232].  Cell populations in parallel cultures may grow at slightly different 
rates and could therefore influence calculated viral fitness, which may be important when 
fitness differences are very small [236].  They are therefore less sensitive than growth 
competitions, although more sensitive than single cycle assays.  Viral gene products or 
activity may be directly detected or reporter genes in the viral backbone may be detected.  
Alternatively cell reporter genes can be used to measure spread of infection. 
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1.7.4 Choice of assay for the present study 
For the present study, a flow cytometry-based, multiple cycle, parallel mono-culture 
infection assay using a GFP-reporter CEM-GXR T cell line [71] was chosen to investigate 
fitness consequences of sequence variability in the Gag-protease region, specific Gag 
mutations, as well as the fitness of whole HIV-1 isolates.  This assay was chosen because of 
its relative sensitivity (due to measuring multiple cycles), simple and inexpensive detection 
techniques (that may be applied to recombinant viruses or whole isolates), and consistency 
between experiments (due to its use of a homogenous population of cells) (Sections 1.7.2 
and 1.7.3.2.2).  The measure of viral spread overcomes the potential problem of detecting 
defective virus particles by p24 ELISA for example (Section 1.7.1.3).  
 
Homologous recombination in the CEM-GXR cell line was chosen to construct the Gag-
protease recombinant viruses [225] since the protocol is simple and not labour-intensive 
(Section 1.7.1.2).  The patient-derived virus pool was measured as opposed to clones, since 
this is likely to be more representative of in vivo conditions and is less labour-intensive than 
cloning for the large number of individuals tested (Section 1.7.1.2).  
 
1.8 The present study: rationale, aims and objectives 
A better understanding of the determinants that affect the rate of HIV-1 disease progression 
and why some individuals control HIV-1 to low viral loads is important for designing an 
effective HIV-1 vaccine, for which the need is urgent (Section 1.5.2). Variation in HLA class 
I alleles is the strongest correlate of progression to AIDS, however, the mechanisms 
underlying this association are incompletely understood (Section 1.6.4), and may differ 
between HLA alleles (Section 1.6.5.1).  One hypothesised mechanism is that certain HLA 
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alleles select for mutations in conserved, structurally/functionally important Gag epitopes 
through CD8+ T cell mediated pressure, resulting in reduced viral fitness, lower viral loads 
and slower disease progression in these individuals (Section 1.6.4.2.3.2.3).  Further, 
individuals without protective HLA alleles who control viral load tend to make CD8+ T cell 
responses to conserved regions of HIV-1, such as Gag, or may be recipients of a virus with 
reduced Gag-protease function, suggesting that viral attenuation might possibly also explain 
viral control in individuals without protective HLA alleles.   
 
These hypotheses require further investigation, since many previous studies investigating 
fitness cost of Gag escape mutations and their clinical relevance have concentrated only on a 
few pre-selected escape mutations associated with protective HLA alleles, have not assessed 
fitness consequences in the natural sequence background (in the presence of other escape 
and compensatory mutations), and/or have focused on a limited number of patients.  The 
majority of studies have also focused on HIV-1 subtype B, rather than HIV-1 subtype C 
which contributes most to the global epidemic.  Furthermore, the clinical relevance or impact 
of Gag function on HIV-1 disease progression requires further clarification (Section 1.6.5).  
It is also not known which Gag mutations carry the greatest fitness cost, whether certain 
mutations (or combinations thereof) selected by common/non-protective HLA alleles might 
impact on viral fitness and HIV-1 disease progression, whether Gag function contributes 
substantially to overall HIV-1 fitness (given its important role in replication [Section 1.3]), 
and whether Gag function might explain differences in fitness (and pathogenicity) between 
HIV-1 subtypes, all of which have important implications for design of a vaccine aiming to 
drive HIV-1 to a less fit state.  Such a vaccine will also require knowledge of compensatory 
pathways developed by HIV-1, which may be revealed by fitness studies using clinically-
derived sequences.           
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Thus, the main aim of the present study was to examine the hypothesis that HLA-driven 
variation in HIV-1 Gag significantly impacts on viral fitness and disease progression.  This 
was assessed through a comprehensive investigation using clinically-derived Gag-protease 
sequences collected from a large population of chronically HIV-1 subtype C infected 
individuals.  Protease was included in order to maintain the natural sequence interaction 
between Gag and protease, viz. site-specific cleavage of the Gag polyprotein by protease 
enzymatic activity (Section 1.3.9), the importance of which is indicated by the co-evolution 
of these proteins [249, 250].  The specific aims of the present project were to: 
 Assess to what extent HLA alleles influence HIV-1 fitness through their ability to 
drive sequence variability in Gag-protease. 
 Analyse the impact of Gag-protease-mediated fitness on HIV-1 disease progression. 
 Identify Gag-protease mutations that significantly impact HIV-1 fitness and 
mutations that may compensate for viral attenuation. 
 Determine whether Gag-protease contributes significantly to overall HIV-1 fitness. 
 Determine whether fitness differences between HIV-1 subtype B and C may be partly 
explained by Gag-protease function. 
 
To achieve these aims the following specific objectives were fulfilled: 
 Construction of recombinant viruses encoding Gag-protease sequences derived from 
HIV-1 subtype C chronically infected patients (n=406) and recently infected patients 
(n=60), as well as a small subset of HIV-1 subtype B chronically infected patients 
(n=25). 
 Analysis of in vitro replication capacity for Gag-protease recombinant viruses using a 
flow cytometry-based GFP-reporter T cell assay. 
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 Relation of Gag-protease replication capacity values to HLA class I profiles in the 
large population of HIV-1 subtype C chronically infected patients. 
 Relation of Gag-protease replication capacity values to cross-sectional viral loads, 
CD4+ T cell counts, and subsequent rate of CD4+ T cell decline in HIV-1 subtype C 
chronically infected patients, and to viral set point and rate of CD4+ T cell decline in 
recently infected patients. 
 Sequencing of Gag-protease, identification of HLA-associated mutations and relation 
of mutations to Gag-protease replication capacity values. 
 Isolation of HIV-1 from infected PBMCs followed by replication capacity 
measurement and comparison to replication capacity values of recombinant viruses 
encoding Gag-protease from the same isolates. 
 Comparison of in vitro replication capacities of HIV-1 subtype B and C Gag-protease 
recombinant viruses and identification of subtype-specific mutations linked to altered 
replication capacities. 
 Confirmation of suspected fitness cost and/or compensation of HLA-associated or 
subtype-specific mutations by site-directed mutagenesis followed by assaying the 





















CHAPTER2 – MATERIALS AND METHODS 
2.1 Ethics 
The present study forms a component of research protocols approved by the Biomedical 
Research Ethics Committee of the University of KwaZulu-Natal (E028/99 and E036/06) as 
well as collaborative projects approved independently by the Institutional Review Boards of 
Botswana (PPME-13/18/1 Vol VI [17]) and the Harvard School of Public Health (USA) 
(P10491-136).  Study materials from previously recruited patients comprised stored plasma 
and PBMCs.  Written informed consent was obtained from these individuals at the time of 
recruitment and patient identity remained confidential.  In addition, reverse transcriptase 
polymerase chain reaction (RT-PCR) products containing HIV-1 subtype B gag-protease 
sequences were obtained from collaborators at the University of British Columbia.  
Collection of these anonymised patient-derived materials was approved by the Research 
Ethics Board of the University of British Columbia/Providence Healthcare (Canada) (H07-
03006).  
 
2.2 Measurement of replication capacities of viruses encoding Gag-protease isolated 
from chronically and recently HIV-1 infected subjects   
2.2.1 Study subjects 
2.2.1.1 HIV-1 subtype C chronically infected subjects 
Study subjects chronically infected with HIV-1 subtype C comprised 406 antiretroviral naïve 
individuals from the Sinikithemba (SK) cohort in Durban, South Africa.  Plasma samples at 
study entry (baseline) that were stored at -80 °C were the study material used for 
experiments to determine Gag-protease-mediated replication capacities.  In addition, viral 
loads, CD4+ T cell counts, and HLA class I profiles of these subjects were available [170].  
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Viral load measurements were previously obtained by the Roche Amplicor version 1.5 assay 
at baseline and approximately every 6 months thereafter.  CD4+ T cell count measurements 
were obtained by flow cytometry at study baseline and at intervals of approximately 3 
months thereafter.  Baseline measurements were available for all participants and 
antiretroviral naïve follow-up was available for 339 individuals.  For each of these 339 
subjects, a rate of CD4+ T cell decline over the treatment-free follow up period was 
calculated by linear regression in collaboration with Bingxia Wang (Program in HIV 
Outcomes Research, Massachusetts General Hospital, Massachusetts).  HLA types to 4-digit 
resolution were previously determined using molecular methods.  Cohort characteristics, as 
well as demographic data, are presented in Table 2.1.   
 
2.2.1.2 HIV-1 subtype B chronically infected subjects 
For comparison of Gag-protease-mediated replication capacities with HIV-1 subtype C 
samples, gag-protease RT-PCR products from 25 HIV-1 subtype B infected individuals 
from the British Columbia HOMER cohort were donated by Dr. Zabrina Brumme (Simon 
Fraser University, Canada; formerly of the Ragon Institute of Massachusetts General 
Hospital, Massachusetts Institute of Technology and Harvard University).  The Gag-
protease-mediated replication capacities for 803 individuals from the HOMER cohort were 
previously measured [251].  The 25 samples donated were chosen as they covered the range 
of replication capacities and were a representative subset of the cohort in terms of Gag-
protease-mediated replication capacity.  Viral load and CD4+ T cell data on these 25 
subjects was also provided.  Twenty-five HIV-1 subtype C chronically infected patients 
matched for CD4+ T cell counts and viral loads with the HIV-1 subtype B chronically 
infected patients were randomly selected from the SK cohort (Table 2.2).   
 
63 
Table 2.1 Clinical and demographic characteristics of HIV-1 subtype C chronically 
infected patients 
Characteristic Median (interquartile range) or percentage (%) 
Gender 79% Female, 21% Male 
Age (at baseline) 31 (27-36) years 
Viral load (at baseline) 4.77 (4.15-5.27) log10 copies/ml 
CD4+ T cell count (at baseline) 340 (238-477) cells/mm
3
 
Rate of CD4+ T cell decline -30 (-73 to -3) cells/mm
3
 per year 
Follow-up time 2.29 (1.21-3.02) years 
 













Table 2.2 Clinical characteristics of matched HIV-1 subtype B and C chronically 
infected patients 
Characteristic 
Median (interquartile range)  
Subtype B (n=25) Subtype C (n=25) 
Viral load 5.38 (5.17-5.61) log10copies/ml 5.3 (4.9-5.7) log10copies/ml 
CD4+ T cell count 140 (60-320) cells/mm
3



















2.2.1.3 HIV-1 subtype C recently infected subjects   
Study subjects recently infected with HIV-1 subtype C comprised 32 individuals from the 
HIV Pathogenesis Programme Acute Infection Study in Durban, South Africa, and 28 
individuals from the Tshedimoso Study in Botswana (plasma samples donated by Vladimir 
Novitsky from the Department of Immunology and Infectious Diseases, Harvard School of 
Public Health, Boston, MA).   
 
At screening, 27 subjects from Durban had detectable HIV RNA but had not yet 
seroconverted (negative ELISA and negative Western blot according to Centre for Disease 
Control criteria) and were defined as acutely infected [252].  The date of infection was 
estimated to be 14 days prior to screening as previously described [253].  A further 5 
subjects from Durban had an incomplete Western blot at the time of screening that later 
became complete and these were defined as recently infected.  The date of infection was 
estimated for 2 of these subjects by Fiebig staging but was indeterminable for the other 3 
who were screened in Fiebig stage V-VI or VI [81].  For acutely infected subjects from 
Botswana, days post-seroconversion were estimated as the midpoint between the last 
seronegative and the first seropositive test, while for recently infected subjects the 
calculation was based on Fiebig staging [254].  For comparison with the Durban subjects, 
the days post-infection were estimated for the Botswana subjects by adding 22 days to the 
estimated days post-seroconversion since this is the estimated window period [81].    Plasma 
samples from the earliest time point available for use following screening of subjects (5 at 
Fiebig stage IV, 45 at Fiebig stage V, 7 at Fiebig stage VI, and 3 indeterminable; median of 
55 days post-infection, interquartile range [IQR]: 43-76 days) were the material used for 
analysis of Gag-protease-mediated replication capacities.  In addition, Gag-protease-
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mediated replication capacities were analysed at a median of 1 year [IQR, 0.92 to 1.13 years] 
later for 13 of the Durban subjects for whom plasma samples were available. 
   
Viral loads, CD4+ T cell counts, and HLA profiles were previously determined for all 
subjects, and CD8+ T cell responses to Gag optimal epitopes were also available for 13 of 
the Durban subjects for whom replication capacity was measured longitudinally [252].  For 
Durban subjects, viral loads were obtained at screening and at approximate intervals of 2 
weeks, 2 weeks, 2 weeks, 1 month, 1 month, and thereafter every 4-5 months by the Roche 
Amplicor version 1.5 assay or the Cobas Taqman HIV-1 Test.  For Botswana subjects, viral 
loads were obtained approximately every 100 days using the Cobas Ampli-Prep/Cobas 
Amplicor HIV-1 Monitor Test version 1.5 [255].  CD4+ T cell count measurements were 
performed at the same intervals by flow cytometry for both Durban and Botswana 
participants [255].  Viral set points were calculated by averaging the viral loads between 3 
and 12 months post-infection, since peak viremia occurs in Fiebig stage III and then there is 
a decline towards a steady state which is established during Fiebig stages V or VI 
(approximately 3 months post-infection) [81].  Rates of CD4+ T cell decline were calculated 
as described above (Section 2.2.1.1).  HLA class I typing was previously performed at least 
to 2-digit resolution and to 4-digit resolution for the majority of samples by molecular 
methods.  CD8+ T cell responses to Gag optimal epitopes were previously measured [252], 
at the earliest available time points and a median of 6.1 weeks (IQR: 5.9-7 weeks) later, by 
interferon gamma (IFN-γ) enzyme-linked immunospot assay (ELISPOT) using fresh or 
frozen PBMC samples.  A response was defined as positive if greater than 100 spot forming 
cells (SFCs)/10
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 PBMCs after subtraction of the negative control value plus 3 standard 
deviations.  Demographics and characteristics of recently infected patients are shown in 
Table 2.3.  
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Table 2.3 Clinical and demographic characteristics of HIV-1 subtype C recently 
infected patients 
Characteristic Median (interquartile range) or percentage (%) 
Gender 65% Female, 35% Male 
Age (at sampling) 27 (25-34) years 
Fiebig stage (at sampling) 8.3% stage IV, 75% stage V, 11.7% stage VI, 5% unknown 
Viral load (at sampling) 5.06 (4.33-5.57) log10 copies/ml 
CD4+ T cell count (at sampling) 418 (302-524) cells/mm
3
 
Viral set point 4.69 (4.11-5.15) log10 copies/ml 
Rate of CD4+ T cell decline -7 (-13-1) cells/mm
3
 per month 
Follow-up time 365 (184-457) days 
 











2.2.2 Generation of Gag-protease NL4-3 recombinant virus stocks 
Gag-protease NL4-3 recombinant viruses were generated by co-transfection of a CEM-
derived T cell line with patient-derived gag-protease amplicons and gag-protease-deleted 
NL4-3 plasmid (pNL4-3∆gag-protease) based on methods previously described [225]. 
 
2.2.2.1 Amplification and sequencing of patient-derived gag-protease 
Patient plasma samples were thawed at room temperature.  HIV-1 RNA was extracted from 
140 μl plasma using the QIAamp Viral RNA Mini Kit (Qiagen, Valencia, USA) as per 
manufacturer’s instructions.  If the plasma viral load was less than 5,000 copies/ml, virus 
was concentrated by centrifugation (Jouan MR23i, Thermo Scientific, USA) at 14,000 rpm 
for 2 hours at 4 °C prior to RNA extraction.  RT-PCR was performed using the Superscript 
III One-Step RT-PCR kit (Invitrogen, Carlsbad, USA) and the following gag-protease 
specific primers:   5’ CAC TGC TTA AGC CTC AAT AAA GCT TGC C3’ (HXB2 
nucleotides 512-539) and 5’ TTT AAC CCT GCT GGG TGT GGT ATY CCT 3’ (2851-
2825).  The RT-PCR reaction comprised 14.4 μl diethyl pyrocarbonate (DEPC) treated  
water (Invitrogen), 20 μl 2X buffer, 0.8 μl of each primer (10 μM), 0.8 μl RT/Taq enzyme 
mix, and 4 μl RNA extract.  The reaction mixture was incubated (GeneAmp PCR system 
9700, Applied Biosystems, Foster City, USA) at 30 °C for 55 minutes and 94 °C for 2 
minutes, followed by 35 cycles of 94 °C for 15 seconds, 55 °C for 30 seconds, and 68 °C for 
2 minutes, and ended with a 5-minute incubation at 68 °C.    
 
A second round of PCR was performed with 100-mer forward (5’ GAC TCG GCT TGC 
TGA AGC GCG CAC GGC AAG AGG CGA GGG GCG GCG ACT GGT GAG TAC GCC 
AAA AAT TTT GAC TAG CGG AGG CTA GAA GGA GAG AGA TGG G 3’) and 
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reverse (5’ GGC CCA ATT TTT GAA ATT TTT CCT TCC TTT TCC ATT TCT GTA 
CAA ATT TCT ACT AAT GCT TTT ATT TTT TCT TCT GTC AAT GGC CAT TGT 
TTA ACT TTT G 3’) primers that were exactly complementary to NL4-3 on either side of 
gag-protease using the TaKaRa Ex Taq HS enzyme kit (Takara, Shiga, Japan).  Two 50 μl 
PCR reactions were prepared per sample, comprising 37 μl DEPC water, 5 μl 10X Ex Taq 
buffer, 4 μl deoxyribonucleotide triphosphate (dNTP), 0.8 μl forward primer (10 μM), 0.8 μl 
reverse primer (10 μM), and 0.25 μl Ex Taq to 2 μl RT-PCR product.  Thermocycler 
conditions were as follows:  94 
o
C for 2 minutes, 40 cycles of 94 
o
C for 30 seconds, 60 
o
C 
for 30 seconds, and 72 
o
C for 2 minutes, followed by 72 
o
C for 7 minutes.    PCR products 
from two 50 μl reactions were pooled and stored at -20 °C.  Approximately 80-90 μl of PCR 
product was used in the generation of recombinant viruses.  Gag-protease amplification was 
confirmed by running 5 μl of the product on a 1% polyacrylamide gel, resulting in a band of 
 1.7 kb.  The remainder was diluted 1:15 in DEPC water and set aside for sequencing.  
 
Gag-protease PCR product was population or bulk sequenced using the Big Dye ready 
reaction termination mix V3 (Applied Biosystems) and the following sequencing primers:   
5’ CTT GTC TAG GGC TTC CTT GGT 3’(1098-1078), 5’ CTT CAG ACA GGA ACA 
GAG GA 3’(991-1010), 5’ GGT TCT CTC ATC TGG CCT GG 3’(1481-1462), 5’ CAA 
CAA GGT TTC TGT CAT CC 3’(1755-1736), 5’ CCT TGC CAC AGT TGA AAC ATT T 
3’(1981-1960),  5’ TAG AAG AAA TGA TGA CAG 3’(1817-1834), 5’ CAG CCA AGC 
TGA GTC AA 3’(2536-2520) and  5’ GGA GCA GAT GAT ACA GTA TT 3’ (2331-2350).  
Each sequencing reaction per primer prepared in a 96-well plate (Applied Biosystems) 
comprised 0.4 μl big dye mix, 2.6 μl sequencing primer, 2 μl sequencing buffer, 4 μl DEPC 
water, and 1 μl diluted template.  The reaction was incubated at 96 °C for 1 minute, followed 
by 25 cycles of 96 °C for 10 seconds, 50 °C for 5 seconds, and 60 °C for 4 minutes.  A 
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sequencing plate clean up was performed the same day.  Sequencing products were first 
diluted in ethylenediaminetetraacetic acid (EDTA; 125 mM, pH 8.0, 1 l) and a mixture of 
sodium acetate (3 M, pH 5.2, 1 l) and cold ethanol (100%, 25 l), followed by 
centrifugation (Eppendorf centrifuge 5810R, Merck, Germany) at 3,000  g for 20 minutes.  
To dry products, the plate was inverted on paper towel and centrifuged at 150  g for 1 
minute.  Pellets were immediately resuspended in cold ethanol (70%, 35 l) and then 
centrifuged at 3,000  g for 5 minutes.  Following inversion and centrifugation at 150  g for 
1 minute, products were dried in a thermocycler at 50 C for 5 minutes and then stored at      
-20 C until analysis.  Immediately prior to analysis of sequences on the ABI 3130xl Genetic 
Analyzer (Applied Biosystems), products were resuspended in 10 l formamide, vortexed 
and denatured in a thermocycler at 95 C for 3 minutes and then cooled at 4 C for 3 
minutes.  Sequences were visualized and edited in Sequencher 4.8 (Gene Codes, Corp., Ann 
Arbor, USA).  Sequence data were aligned to HIV-1 subtype B reference strain HXB2 
(Genbank accession number K03455) using a modified NAP algorithm [256] and insertions 
with respect to HXB2 were stripped out.  HIV-1 subtype was confirmed using the REGA 
subtyping tool [257]. 
 
These sequences can be located in Genbank under the following accession numbers: 
HM593106-HM593510 and HQ696791- HQ696863. 
  
2.2.2.2 Preparation of the pNL4-3∆gag-protease backbone 
The subtype B pNL4-3∆gag-protease plasmid [225], containing a BstE II restriction enzyme 
site in place of the viral gag-protease coding region, was supplied in E. coli STBL3 cells by 
Toshiyuki Miura (University of Tokyo, Japan; formerly of the Ragon Institute of 
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Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard 
University).  A subtype C pMJ4∆gag-protease vector was initially tested, but due to its low 
infectivity [258] and poor recovery of recombinant stocks, the available subtype B backbone 
was selected for these experiments.  To amplify pNL4-3∆gag-protease stocks, Luria-Bertani 
(LB) broth (Sigma, St Louis, USA) containing 100 μg/ml ampicillin was inoculated with 
17.5 μl STBL3 stock containing pNL4-3∆gag-protease per 100 ml broth and incubated 
overnight at 37 °C in a shaking incubator (Infors HT, Bottmingen, Switzerland).  The 
plasmid was then purified using the Plasmid Maxi kit (Qiagen), quantified using a nanodrop 
spectrophotometer (Thermo Scientific, Delaware, USA) and stored in a -80 °C ultrafreezer 
(Snijders Scientific, Holland) until use.   
 
2.2.2.3 Thawing, culturing, and storing of CEM-GXR25 cells 
A GFP-reporter T cell line, CEM-GXR25 (GXR) [71], was donated by Dr. Mark Brockman 
(Simon Fraser University, Canada; formerly of the Ragon Institute of Massachusetts General 
Hospital, Massachusetts Institute of Technology and Harvard University).  GXR cells 
express the HIV-1 CD4 receptor as well as the co-receptors CXCR4 and CCR5, and encode 
a Tat-inducible HIV-1 LTR-GFP expression cassette [71].  Thus, GXR cells are permissible 
to HIV-1 replication and cells produce GFP upon infection, thereby allowing their detection 
using flow cytometry. 
 
A frozen 1 ml aliquot of GXR cells was transferred immediately from the liquid nitrogen 
freezer (Custom Biogenics Systems, Romeo, USA) into a 37 °C waterbath and gently 
agitated until the last ice crystal melted.  Once thawed, cells were transferred to a T25 flask 
(Corning-Costar, New York, USA) with 4 ml pre-warmed R10 medium and thereafter 
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incubated in a humidified Heraeus incubator (Thermo Scientific) at 37 °C and 5% CO2.  R10 
medium consisted of RPMI-1640 (Sigma) supplemented with 10% foetal bovine serum 
(FBS; Gibco, New York, USA), 2 mM L-glutamine (Sigma), 10 mM N-2-
hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES; Gibco), and 50U/ml penicillin-
streptomycin (Gibco).  The following day, the GXR cells growing in suspension were 
pelleted at 1,500 rpm for 10 minutes (Heraeus multifuge 3SR+, Thermo Scientific) and then 
resuspended in 10 ml fresh R10 medium to remove dimethylsulfoxide (DMSO; Sigma) 
present in the storing medium.  When the phenol red indicator in the medium turned yellow, 
indicating cell growth and a need for medium replacement, GXR cells were transferred to a 
T75 flask (Corning) and a stock culture was maintained in 30-40 ml R10 medium.  Every 2-
3 days, approximately 75-90% of the culture was discarded (if not used for experiments) and 
replaced with fresh R10 medium.  The GXR stock culture was discarded after 2-3 months 
and a new vial of GXR cells thawed.   
 
Prior to initiation of experiments several vials of GXR cells were stored in liquid nitrogen 
for future use.  This required determining the cell concentration of the GXR stock culture.  A 
Neubauer haemocytometer (Assistant, Germany) was used for this purpose.  A 





 ml) and each subdivided into 16 smaller squares for ease of counting.  After 
thorough mixing of the culture, 10 μl cell suspension was pipetted under the coverslip placed 
over the grid area of the slide.  The cells were then counted in 2 large squares of each set of 4 
squares with a phase contrast, bright field microscope (Leica, Germany) and an average 
taken.  The average number of cells in the large squares was multiplied by 10
4 
to determine 
the average number of cells per ml.  The volume of culture to yield the required number of 
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cells for storage was removed and pelleted at 1,500 rpm for 10 minutes.  This volume was 
calculated as follows:  
volume of cell culture required (ml) = number of cells required/cell concentration (cells/ml)                      
Cells were resuspended in R10 medium at a concentration of 5.5˙million cells/ml and 900 μl 
of this suspension was pipetted into each cryovial (Greiner Bio-One, Germany).  DMSO 
(100 μl), a cryo-protectant [259, 260], was added drop-by-drop to each vial, with 
simultaneous gentle swirling, yielding a final concentration of 5 million cells/ml and a final 
volume of 1ml per vial.  To allow sufficient time for DMSO penetration yet minimising 
toxicity, cells were allowed between 10 and 20 minutes exposure to DMSO [261] prior to 
transfer to Mr Frosty (Nalgene, Thermo Scientific) and placement in a -80 °C ultrafreezer 
(Snijders Scientific).  Mr Frosty insulates the cells and achieves a cooling rate of 
approximately 1 °C per minute, which is optimal for most animal cells [259].  The following 
day, cells were stored in the liquid nitrogen freezer.             
 
2.2.2.4  Co-transfection of GXR cells with gag-protease and pNL4-3∆gag-protease 
To allow for production of recombinant viruses, GXR cells were co-transfected with PCR 
amplified patient gag-protease and the pNL4-3∆gag-protease backbone.  Immediately prior 
to the co-transfection, pNL4-3∆gag-protease (10 μg per sample) was digested with BstE II 
enzyme (Promega, Madison, USA) for 2 hours at 60 °C in a waterbath to linearise the 
plasmid at the site of gag-protease deletion and allow for insertion of amplified patient-
derived gag-protease by recombination.  Recombination of gag-protease with pNL4-3∆gag-
protease was made possible by the use of long primers exactly complementary to NL4-3 on 
either side of gag-protease to generate gag-protease PCR product. 
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During the BstE II digestion of pNL4-3∆gag-protease, the GXR stock culture was counted 
and the required number of cells were removed, pelleted, and resuspended in fresh R10 
medium as described in Section 2.2.2.3.  Between 2 and 2.8 million GXR cells, depending 
on availability, in a volume of 800 μl were electroporated (Gene Pulser II, Biorad, Hercules, 
USA) in 4 mm cuvettes (Biorad) at 300 V and 500 μF with 10 μg BstE II-digested pNL4-
3∆gag-protease (≈ 10-15 μl) and ≈ 80-90 μl gag-protease PCR product.  Electroporation 
experiments were performed in batches of approximately 24 different samples.  As a 
negative control, GXR cells were electroporated with pNL4-3∆gag-protease only.  
Electroporation allows for the temporary disruption of cell membranes allowing uptake of 
molecules and is a technique used to transfect cells with DNA [262].    Following a 1-hour 
incubation at room temperature to allow for cell recovery before pipetting, GXR cells were 
gently transferred to T25 flasks containing 4 ml pre-warmed R10 medium each and 
incubated at 37 °C and 5% CO2.    Five days later, 5 ml R10 medium was added to each flask 
followed by further incubation.    
 
It should be noted that at an advanced stage of the present project a more efficient modified 
electroporation protocol was described [246].  Therefore, when the generation of 2 
recombinant viruses encoding Gag-protease from recently infected patients (AS1-0703 and 
AS2-0802) from time points 1 year later than baseline failed using the above methods, the 
new modified protocol was employed.  Briefly, 4 million cells, in a volume of 300 µl, were 
electroporated with the linearised plasmid and PCR product at 250 V and 950 µF.  The cells 
were rested for 5 minutes before being transferred to a T25 flask with 10 ml medium and 1 
million non-electroporated cells.  Five days later, 5 ml R10 medium was added to each flask.     
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2.2.2.5 Monitoring of virus production by flow cytometry 
Electroporated GXR cells were incubated for 12 days before virus production was monitored 
to allow time for recombination of gag-protease amplicons with the NL4-3∆gag-protease 
plasmid, followed by viral transcription, translation, particle production, and spread in the 
culture.  The percentage infected cells was monitored by flow cytometry on a FACSCalibur 
(BD Biosciences, San Jose, USA) since GXR cells produce GFP when HIV-1 infected 
(Section 2.2.2.3).  Flow cytometry is the measurement of cell characteristics such as size and 
granularity (through capture of light scatter) and fluorescence (through fluorescence capture) 
as single cells pass through a fluid stream [263].   
 
In preparation for flow cytometry, 1 ml culture was removed from each flask following 
thorough mixing and pipetted into 96-well matrix cluster tubes (Corning Costar).  The box 
containing these tubes was centrifuged at 1,100 rpm for 10 minutes.  Following removal of 
supernatant, cells were resuspended in residual supernatant by vortexing.  Cells were then 
mixed with 200 μl of 2% paraformaldehyde (PFA) fixative and incubated for 10-15 minutes 
prior to flow cytometry.  The fixative was prepared by dissolving PFA (Merck) in phosphate 
buffered saline (Gibco) at 55 °C for 30 minutes and thereafter adjusting the pH to 7.0 to 
complete dissolution.  PFA fixative was stored at -20 °C and thawed aliquots stored at 4 °C 
were discarded after a week. 
 
Matrix cluster tubes containing fixed cells were placed in re-usable FACS tubes (BD 
Biosciences) that were then placed in the FACSCalibur to allow entry of sample into the 
flow cell chamber.  Flow cytometry instrument settings used were:  forward scatter = E-1, 
side scatter = 440, FL1 = 280, FL2 = 493, and FL3 = 722.   The negative control (uninfected 
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GXR cells) was used to distinguish (i) intact cells from debris, and (ii) GFP positive cells 
from GFP negative cells, as shown in Figure 2.1.  These settings were saved as a template 
file that was minimally adjusted at the start of each flow cytometry run using the relevant 
experiment negative control.  Fluorescence information was captured for 15,000 intact cells 
per sample.  Results were saved and gates were finely adjusted using FlowJo [264] to 
accurately determine the percentage of intact cells in each culture that were infected with 
HIV-1.                
 
2.2.2.6. Harvesting virus stocks 
When approximately 25-30% of the GXR cells were infected, virus concentration in the 
culture supernatant was deemed to be sufficiently high to harvest virus stocks.  The culture 
was centrifuged at 1,700 rpm for 5 minutes and the supernatant was stored in 10 aliquots of 1 
ml each at -80 °C for use in subsequent titration and replication assays.   
 
2.2.2.7 Validation of virus stocks 
To test whether the Gag-protease contained within each recombinant virus pool was 
representative of the original plasma quasispecies, the gag-protease region was amplified 
and sequenced (Section 2.2.2.1) from 42 randomly-selected recombinant viruses and 
compared with the original plasma HIV RNA sequences.   
 
The generation of Gag-protease NL4-3 recombinant viruses is summarised in Figure 2.1.   
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Figure 2.1 Generation of Gag-protease NL4-3 recombinant virus stocks 
Diagram showing the incorporation of patient-derived HIV-1 gag-protease PCR product into 
an NL4-3 gag-protease-deleted viral backbone (pNL4-3∆gag-protease) to generate 
recombinant viruses.  HIV-1 RNA was extracted from patient plasma followed by nested 
PCR amplification (RT-PCR and PCR2) of gag-protease and sequencing of the PCR 
product.  In the second round of PCR, 100-mer primers exactly complementary to the pNL4-
3 backbone were used to allow for recombination of PCR product and backbone.  Prior to 
co-transfection of cells by electroporation with patient-derived gag-protease PCR product 
and pNL4-3∆gag-protease, the backbone was digested with BstE II enzyme to open the 
plasmid at the site of gag-protease deletion and allow for recombination.  Cells were 
cultured for 12 days before monitoring viral spread in the culture.  Viral spread was 
monitored every second day by flow cytometry since the GXR cells express green 
fluorescent protein when infected with HIV-1.  The scattering of light, as the cells pass 
through the capillary of the flow cytometer, allowed distinction of cell populations (GXR 
cells) by cell size and density (A) and the emission of fluorescence allowed calculation of 
percentage HIV-1 infected GXR cells (B and C).  Samples (C) were gated according to the 
negative control (A and B).  At approximately 30 percent infection, the virus-containing 
supernatant was collected from the infected culture, aliquotted and stored at -80 °C until use 
in titration and replication assays.                
Gag – group specific antigen; HIV-1 – human immunodeficiency virus type 1; RNA – ribonucleic acid; RT-PCR – reverse 
transcriptase polymerase chain reaction; PCR – polymerase chain reaction; pNL4-3∆gag-protease – gag-protease-deleted 
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2.2.3 Titration and replication capacity measurement of virus stocks 
Titration of virus stocks and measurement of the replication capacities of these viruses was 
based on methods previously described [71, 225]. 
 
2.2.3.1 Titration 
The aim of the replication capacity assay was to measure the exponential spread of each 
virus in GXR cell cultures over a short period of time.  Therefore, the initial percentage of 
infected cells was required to be sufficiently low to observe subsequent exponential increase 
in infected cells, yet sufficiently high for this to occur over the course of a few days.  
Furthermore, the initial level of infection for the different recombinant viruses had to be 
within a similar range for the replication capacity measurements to be comparable.  In 
preliminary tests, it was determined that an initial level of infection, or multiplicity of 
infection (MOI), of 0.3% was suitable.  The infectious titre of each virus stock determines 
the volume required to obtain the necessary MOI.  This can be precisely measured by 
infecting GXR cells with a known volume of virus stock in the presence of the HIV-1 
protease inhibitor Indinavir, which allows infection of cells but prevents further spread of 
viral infection in the culture, and measuring the percentage of infected cells 2-3 days post-
infection by flow cytometry [71].  However, since it was previously demonstrated that 
similar results could be obtained on day 2 post-infection in the absence of Indinavir [71], this 
simplified approach was used to determine the titre of each recombinant virus in the present 
study.  Specifically, 0.4 ml virus stock was thawed (or 0.4 ml R10 medium for the negative 
control) and incubated with 1 million GXR cells in a final volume of 0.5 ml R10 medium in 
a 24-well culture plate (Corning Costar) for 24 hours at 37 C and 5% CO2.   This was 
followed by addition of 1 ml fresh R10 and incubation for a further 24 hours.  Cultures were 
mixed by pipetting and 0.5 ml was then removed from each well and prepared for flow 
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cytometry as described in Section 2.2.2.5.  The volume of virus stock to use to obtain a MOI 
of 0.3% in the replication assay was calculated as follows: 
volume of virus stock (ml) = (0.3%/% cells infected)*0.4 ml   
 
2.2.3.2 Replication capacity assay 
A previously unthawed aliquot of virus stock was thawed and the calculated volume of virus 
stock (from the titration experiment, Section 2.2.3.1) was diluted to a final volume of 0.4 ml 
with R10 medium.  GXR cells were counted, pelleted, and resuspended at a concentration of 
10,000 cells/μl (Section 2.2.2.3).  Next, 100 μl of cell suspension (1 million GXR cells) was 
pipetted into each well of a 24-well plate and 0.4 ml virus stock was added.  Following 24 
hours of incubation at 37 C with 5% CO2, 1 ml R10 medium was added to each well.   A 
negative (R10 medium) and positive (wild-type NL4-3 virus) control, generated by 
electroporation of GXR cells with 10 μg NL4-3 plasmid (Section 2.4), was included in every 
assay.  The percentage infected cells was measured by flow cytometry (Section 2.2.2.5) from 
days 2-6 post-infection by removal of 0.5 ml culture from each well (and replacement with 
fresh R10 medium).    
 
Viral replication capacity was measured as the slope of exponential increase in percentage 
infected cells from days 3-6 post-infection, calculated using the semi-log method in 
Microsoft Excel, and expressed relative to the wild-type NL4-3 control, as follows: 
Replication capacity = Natural log (Logest[day 3 % infection : day 6 % infection]) 
Normalised replication capacity = replication capacitysample/replication capacityNL4-3  
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The logest function in Excel calculates a log10 exponential curve that best fits the data and 
returns the slope of the curve.  Logest values were converted to natural log, which is more 
typically used for descriptions of exponential growth and decay in biology. 
 
To ensure appropriate calculation of slope during only the exponential phase of viral spread, 
if the percentage infected cells exceeded a cut-off of 11% on day 5 post-infection, the slope 
was calculated from days 3-5 post-infection,.  Replication assays were performed at least in 
duplicate independently and results were averaged.   
 
The methods used to titrate and measure the replication capacity of virus stocks are depicted 
in Figure 2.2. 
 
2.2.4 Variability in measuring Gag-protease-mediated replication capacity 
To assess the total method variability (the sum of variability introduced at each step of the 
methods), RNA was extracted 5 times each from 7 different plasma samples and used to 
generate 5 independent Gag-protease recombinant stocks per individual.  These viruses were 
then assayed to determine replication capacity.    
 
2.2.5 Data Analysis 
Method validation and variability 
To test whether the Gag-proteases encoded by recombinant viruses were representative of 
the original plasma quasispecies, nucleotide differences between the plasma and  
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Figure 2.2 Titration and measurement of replication capacities of Gag-protease NL4-3 
recombinant viruses 
In this figure, the titration of virus stocks to determine the volume of viruses to yield a 
similar and appropriate starting percentage infection (0.3%) for the replication capacity assay 
is shown.  This volume was determined by incubating a set volume of virus stock with GXR 
cells that express green fluorescent protein when infected in a 24-well plate and measuring 
the percentage infected cells by flow cytometry after 2 days.  The replication capacities of 
recombinant viruses were determined by calculating the slope of exponential increase in 
percentage infected cells, as measured by flow cytometry, from days 3-6 following infection 
at a multiplicity of infection of 0.3%.  These slope values were divided by the slope of 
growth of the wild-type NL4-3 positive control included in each assay in order to control for 
assay-to-assay variation. 
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recombinant viral sequences were quantified using the Highlighter tool at Los Alamos [265]. 
In addition, to visually assess the similarity between plasma and recombinant virus 
sequences, a neighbour-joining tree was constructed from nucleotide sequences using Paup 
4.0 and edited in Figtree [266].   
 
To test whether variability in the percentage infection on day 3 (the first reading used in the 
calculation of slope of spread) of the replication assay influenced the replication capacity 
calculated, these 2 parameters were correlated by Pearson’s correlation.  The reproducibility 
of replication capacity measurements taken in duplicate was also tested by Pearson’s 
correlation.   
 
The replication capacities between different recombinant viruses generated 5 times each ( i.e. 
each step of the methods was performed 5 times for each sample) were compared to assess 
whether differences were consistent.  Analysis of variance (ANOVA) was used to determine 
whether there were overall significant differences between the replication capacities of 
viruses generated from the different samples and the Tukey post-hoc tests were used to 
identify which specific samples differed significantly from each other. 
 
Replication capacities versus HLA class I alleles 
Viral replication capacities were grouped according to the HLA class I alleles expressed by 
the host for chronically infected patients.  ANOVA was used to assess whether significant 
differences in replication capacities were observed within expressed HLA-A, -B, and -C 
alleles. Then, for each individual allele (n≥5), the Student’s T test (or the Mann-Whitney U-
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test in cases where the assumptions of the Student’s T test were not met) was used to 
compare replication capacities of viruses generated from persons expressing versus not 
expressing the allele in question.  Recombinant viruses were also categorised according to 
the 10th and 90th percentiles of the replication capacity data into a low- and high-
replication-capacity group, respectively.  The proportion of protective alleles in each group 
was compared with Fisher’s exact test.  For recently infected patients, replication capacities 
were compared between individuals expressing protective and non-protective alleles by the 
Student’s T test. 
 
Replication capacities versus cross-sectional and longitudinal viral loads and CD4+ T cell 
counts 
For chronically infected patients, the relationships between replication capacity and log viral 
load, CD4+ T cell count, and rate of CD4+ T cell decline were assessed using Pearson’s 
correlation (for normally-distributed variables) or Spearman’s rank correlation (for non-
normally distributed variables).  For recently infected patients, the relationships between 
replication capacity and viral set point as well as rate of CD4+ T cell decline were similarly 
assessed. In addition, replication capacities were also compared above and below the median 
viral set point and median rate of CD4+ T cell decline by the Student’s T test or Mann-
Whitney U test if assumptions of the Student’s T test were violated. 
 
Replication capacities versus Gag-protease sequences 
To investigate the relationship between the number of polymorphisms in Gag or protease 
and replication capacity, the percent amino acid similarities of Gag and protease to the 2004 
consensus subtype C sequence [267] were calculated using the sequence identity matrix 
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function in BioEdit 7.0 [268] and correlated (Pearson’s or Spearman’s correlation) with 
replication capacity.  
 
Next, HLA-associated polymorphisms (amino acids that are significantly more likely to 
occur in the presence of a particular HLA allele) in HIV-1 subtype C Gag-protease were 
identified using the large chronically infected cohort data by Dr. David Heckerman and 
Jonathan Carlson (eScience Group, Microsoft Research, Washington).  This was done using 
published methods that take into account the phylogenetic relatedness of sequences, amino 
acid co-variation, and HLA linkage disequilibrium effects [269].  Briefly, a maximum 
likelihood phylogenetic tree was constructed for each gene.  For each observed amino acid at 
each codon and every HLA allele, the likelihood that the observed amino acid was generated 
by the phylogenetic tree alone or alternatively HLA-mediated pressure was tested and p 
values were generated with the likelihood ratio test.  These tests were binary – the presence 
versus absence of each amino acid variant at a codon was related to the presence versus 
absence of each HLA allele.  The HLA allele most significantly associated with the variant 
was removed and the analysis repeated iteratively until no HLA alleles were significantly 
associated with the variant, thereby taking into account overlap of HLA associations.  
Multiple tests were addressed using q values, which are an estimate of the expected 
proportion of false positive associations for each p value threshold [270].  Only associations 
with q≤0.2 (a false-positive proportion of 20% among identified associations) were 
considered.  
 
The relationships between number or proportion of HLA-associated polymorphisms and 
replication capacities were then assessed using Pearson’s correlation (for normally-
distributed variables) or Spearman’s rank correlation (for non-normally distributed 
variables).  For recently infected patients, Pearson’s or Spearman’s correlation was also used 
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to assess the relationship between the number of HLA-associated polymorphisms in Gag and 
viral set point.  Where the HLA-associated polymorphism variable was binary (i.e. 1 
polymorphism or none) the Student’s T test or Mann-Whitney U test was used for analysis.   
 
In an exploratory analysis, the Mann-Whitney U test was used to identify single, specific 
codons in Gag-protease at which amino acid variants (occurring at a frequency of n≥5) were 
associated with increased or decreased replication capacity.  In addition, in the larger 
chronically infected cohort, linear regression with a forward selection process (a multivariate 
method) was used to identify single amino acids associated with changes in replication 
capacity.  Q values were computed to account for multiple comparisons.  To increase power, 
these analyses were also repeated limited to HLA-associated positions only.   
 
Replication capacity versus HIV-1 subtype 
Replication capacities of subtype B and C Gag-protease recombinant viruses were compared 
with the Student’s T test. 
 
Longitudinal replication capacity measurements 
For 13 of the recently infected Durban subjects for whom replication capacity was measured 
at 2 time points approximately 1 year apart, a paired T test was used to test for overall 
significant change in replication capacities over this time.  The longitudinal replication 
capacity measurements were also related to patient viral loads, CD4+ T cell counts and 




The significance cut off for all analyses unless otherwise indicated was p<0.05. 
 
2.3 Measurement of replication capacities of intact viral isolates  
2.3.1 Isolation of HIV-1 and measurement of replication capacity 
HIV-1 subtype C isolates were generated from PBMC samples obtained from 15 chronically 
infected patients (and from plasma for 1 patient [242]) from the Sinikithemba cohort in 
Durban, as shown in Figure 2.3.  Uninfected PBMCs obtained from 2 anonymous HIV-
negative healthy donors were thawed at 37 °C in a water bath, washed twice with 10 ml 
medium (RPMI-1640 containing L-glutamine and HEPES [Sigma] supplemented with 10% 
FBS [Gibco] and 50 U/ml penicillin-streptomycin [Gibco]) at 1,200 rpm for 10 minutes, and 
then combined.  The uninfected PBMCs were stimulated for 72 hours at 37 °C and 5% CO2 
with 5 μg/ml phytohaemagglutinin (PHA; Sigma) and 20 U/ml interleukin-2 (IL-2; Roche 
Applied Science, Mannheim, Germany) in medium at a concentration of 2 million cells/ml.  
After 48 hours of stimulation, infected PBMCs (approximately 5-10 million) were similarly 
thawed, washed and then incubated with 10 million uninfected stimulated cells in a final 
volume of 5 ml for a further 24 hours.  Thereafter cells were washed to remove PHA and 
maintained in R10 with 20 U/ml IL-2.  Every 3-4 days, 2.5 ml supernatant was removed, 
stored in 500 μl aliquots at -80 °C, and replaced with fresh medium.  The p24 concentration 
in stored supernatants was determined by an ELISA using the Vironostika HIV-1 Antigen 
Microelisa system (Biomérieux, Boxtel, The Netherlands) according to manufacturer’s 
instructions as depicted in Figure 2.3.  Supernatants corresponding to peak virus 
concentrations were further cultured in GXR cells to generate virus stocks.  Virus growth 
was monitored by flow cytometry and supernatants were harvested when cultures were  
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Figure 2.3 Isolation of HIV-1 from infected PBMCs and generation of concentrated 
virus stocks  
To isolate HIV-1 from infected PBMCs, uninfected PBMCs were first stimulated for 48 
hours with R10 medium containing PHA and IL-2 before adding infected PBMCs, followed 
by stimulation for a further 24 hours.  To remove PHA, PBMCs were washed by 
centrifugation followed by resuspension in R10 medium without PHA.  To monitor virus 
concentration, at three to four day intervals supernatant was removed, stored in aliquots at    
-80 °C until HIV-1 p24 concentration was measured by ELISA, and replaced with fresh R10 
medium.  The ELISA procedure comprising the following steps is illustrated: (1) disruption 
of HIV-1 in supernatant, (2) binding of p24 to murine p24 antibody bound to plate surface, 
(3) binding of human p24 antibody with attached HRP to the p24 antigen, (4) HRP-mediated 
cleavage of added TMB substrate to form coloured product, (5) stopping of the reaction with 
H2SO4, and (6) quantification of the coloured product by spectrophotometry followed by 
calculation of p24 concentration using a curve generated from kit standards.    Supernatants 
corresponding to peak virus concentrations (approximately 10-80 ng/ml) were cultured in 
GXR cells to generate concentrated virus stocks.  Virus growth was monitored by flow 
cytometry since GXR cells express green fluorescent protein when HIV-1-infected and 
supernatants were harvested when cultures were approximately 30% infected.  Supernatants 
were stored at -80 °C until assayed to determine replication capacities of HIV-1 isolates.       
HIV-1 – human immunodeficiency virus type 1; PBMCs – peripheral blood mononuclear cells; PHA – 
phytohaemagglutinin; IL-2 – interleukin-2; ELISA - enzyme-linked immunosorbent assay; p24 – protein of 24 kDa; HRP - 
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approximately 30% infected (Sections 2.2.2.5-2.2.2.6).  Virus stocks were stored at -80 °C 
until assayed in the GXR cells to determine viral titres and viral replication capacities as 
described in Sections 2.2.3.1-2.2.3.2.                     
 
2.3.2 Data analysis 
Pearson’s correlation was used to test for a significant association between replication 
capacities of viral isolates and recombinant viruses encoding corresponding Gag-protease 
from isolates.  The level of significance was p<0.05. 
 
2.4 Measurement of replication capacities of mutant viruses 
2.4.1 Construction of mutant plasmids 
To confirm suspected fitness cost or compensation of Gag-protease mutations identified 
from the analysis in Section 2.2, these mutations were introduced singly and in combination 
into a plasmid containing HIV-1 gag-protease and the ampicillin-resistance gene by site-
directed mutagenesis.  To investigate fitness differences between HIV-1 subtype B and C, 
the same procedure was used to test the fitness effects of subtype B- or C-specific residues at 
codons that were statistically associated with alterations in viral replication capacity [251] 
(Section 2.2).   
 
2.4.1.1 The site-directed mutagenesis process 
Briefly, the process of site-directed mutagenesis involves PCR amplification of a plasmid 
using primers encoding the desired mutation [271, 272].  The PCR product is the modified 
plasmid containing the mutation.  The original plasmid (isolated from E. coli) is removed by 
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digestion with DpnI enzyme since this enzyme is specific for methylated DNA, and DNA 
isolated from bacterial cells is methylated while that amplified by PCR is not.  To achieve 
plasmid nick repair, the modified plasmid is transformed by heat-shock into bacterial cells 
followed by plating onto LB-ampicillin agar plates for propagation of cells transformed by 
the ampicillin-resistant plasmid only.  Colonies containing the plasmid may be checked for 
the presence of the desired mutation by sequencing.  Stocks of modified plasmid may then 
be generated through propagation of the selected colony in LB broth followed by plasmid 
purification.  The process of site-directed mutagenesis as conducted in the present study is 
illustrated in Figure 2.4.  
 
2.4.1.2 Preparation of plasmid vectors 
Mutations were first introduced into the HIV-1 gag-protease gene isolated from patient SK-
254 (Genbank accession number HM593258) since this sequence was most similar to 
consensus subtype C Gag-protease from all patient-derived sequences generated (Section 
2.2).  SK-254 gag-protease PCR product was first purified (PCR purification kit from 
Qiagen) and then cloned into a TOPO vector plasmid (pCR2.1-TOPO) using the TOPO TA 
cloning kit (Invitrogen) and One Shot TOP10 Chemically Competent E. coli (Invitrogen) as 
per manufacturer’s instructions (Figure 2.4).  Briefly, TA cloning is the insertion of a Taq-
amplified PCR product with single 3’ deoxyadenosine nucleotide (A) overhangs (added by 
the Taq enzyme) into a linearised plasmid vector with single 3’ deoxythymidine nucleotide 
(T) overhangs.  The ligation of the overhangs is mediated by topoisomerase I which is 
covalently bound to the TOPO vector.  Following the cloning procedure, transformed 
colonies were analysed by PCR, followed by gel electrophoresis, for the gag-protease insert.  
The final volume of the PCR reaction was 10 μl, comprised of 6.6 μl DEPC water, 1μl 10X 
Ex Taq buffer, 0.8 μl dNTP, 0.25 μl 100-mer forward primer (10 μM), 0.25 μl 100-mer  
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Figure 2.4 Site-directed mutagenesis procedure 
Diagram showing the introduction of mutations into NL4-3 and SK-254 gag-protease/TOPO 
vector plasmids by site-directed mutagenesis, as well as the preparation of the SK-254 gag-
protease/TOPO vector plasmid.  SK-254 gag-protease was inserted into the TOPO vector 
with a TOPO cloning kit.  The TOPO vector has T overhangs and an attached topoisomerase 
enzyme (Topo E) which mediates the ligation of the vector with PCR product containing A 
overhangs (introduced by Taq polymerase during PCR).  Mutations were introduced into the 
plasmids by PCR with primers containing the mutation.  The original plasmid was removed 
by digestion with DpnI which selectively recognises the original plasmid as it contains 
methylated sites due to its prior propagation in bacterial cells.  The modified plasmid was 
then transformed into E. coli by heat shock and plated on ampicillin-containing agar plates.  
Due to the presence of an ampicillin resistance gene in the plasmids, only transformed cells 
grow on the ampicillin-containing agar.  A colony was picked, touched to another agar plate 
to keep a record, and checked for the presence of the plasmid with the introduced mutation 
by sequencing.  Following confirmation of the introduced mutation, the selected colony was 
propagated in LB broth and a concentrated stock of purified modified plasmid was isolated 
using a maxiprep kit. 
pNL4-3 – NL4-3 plasmid; gag – group specific antigen; PCR – polymerase chain reaction; Topo E - topoisomerase 
enzyme; T – deoxythymidine nucleotide; A – deoxyadenosine nucleotide; DNA – deoxyribonucleic acid; LB - Luria-
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reverse primer (10 μM), 0.08 μl Ex Taq, and 1 μl of a boiled colony suspension (1 colony in 
10 μl DEPC water).  Details of 100-mer primers and thermocycler conditions used are 
described in Section 2.2.2.1.  A colony containing the SK-254 gag-protease insert was 
grown in 3 ml LB broth overnight and then transferred to 100 ml LB broth and grown 
overnight.  Purified plasmid stocks were generated using the Plasmid Maxi kit (Qiagen).    
 
The same mutations were also introduced into a NL4-3 (HIV-1 subtype B) plasmid (pNL4-
3) containing the full HIV-1 genome.  The NL4-3 plasmid was supplied in E. coli STBL3 
cells by Dr. Mark Brockman (Simon Fraser University, Canada; formerly of the Ragon 
Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and 
Harvard University).  Stocks were amplified as described in Section 2.2.2.2. 
 
2.4.1.3 Introduction of mutations into plasmid vectors  
The following positions in SK-254 and NL4-3 Gag were then mutated using the QuikChange 
II XL Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA) and the relevant mutagenesis 
primers (high-performance liquid chromatography purified, 25-45 base pairs, melting 
temperature >75 °C) according to kit specifications:  Q182S, T186S,  T190A, T190I, 
Q182S/T186S, T186S/T190A, and T186S/T190I.  Subtype C-specific Gag residues that 
were associated with altered replication capacity (67A, 473A, 483-/484-) were introduced 
into pNL4-3 and the corresponding clade B-specific residues (67S, 473P, 483L/484Y) were 
introduced into SK-254 gag-protease in the TOPO vector.  Following colony PCR (Section 
2.4.1.2) and sequencing (Section 2.2.2.1) to confirm the presence of introduced mutations, 
the selected colony was propagated and mutant plasmid stocks were purified (Section 
2.4.1.2).  The forward mutagenesis primers used to generate the various mutants are shown 
in Table 2.4.  The reverse mutagenesis primers comprised the reverse complement of these.   
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Table 2.4 Forward primers used to introduce specific Gag mutations into SK-254 HIV-
1 Gag-protease and pNL4-3  
Template Mutant Primer 
SK-254 186S 5’CCACAAGATTTAAACTCCATGTTAAATACAGTGGGGGG3’ 
SK-254 182S 5’CAGAAGGAGCCACCCCATCAGATTTAAACACCATGTTAAATAC3’  
SK-254 190A 5’CCACAAGATTTAAACACCATGTTAAATGCAGTGGGGGGAC3’ 
SK-254 190I 5’CCACAAGATTTAAACACCATGTTAAATATAGTGGGGGGAC3’ 
SK-254 186S 186S/182S 5’CAGAAGGAGCCACCCCATCAGATTTAAACTCCATGTTAAATAC3’ 
SK-254 186S 186S/190A 5’CCACAAGATTTAAACTCCATGTTAAATGCAGTGGGGGGAC3’ 
SK-254 186S 186S/190I 5’CCACAAGATTTAAACTCCATGTTAAATATAGTGGGGGGAC3’ 
SK-254 67S 5’CAGCTACAACCATCCCTTCAGACAGGAACAGAGGAAC3’ 
SK-254 473P 5’GAGGAGACAACCCCCCCTCCGAAGCAGGAG3’ 
SK-254 483L/484Y 5’GAAAGACAGGGAACTGTATCCCTTAACTTCCCTC3’ 
NL4-3 186S 5’CCACAAGATTTAAATTCCATGCTAAACACAGTGGGGGG3’ 
NL4-3 182S 5’CAGAAGGAGCCACCCCATCAGATTTAAATACCATGCTAAACAC3’ 
NL4-3 190A 5’CCACAAGATTTAAATACCATGCTAAACGCAGTGGGGGGAC3’ 
NL4-3 190I 5’CCACAAGATTTAAATACCATGCTAAACATAGTGGGGGGAC3’ 
NL4-3 186S 186S/182S 5’CAGAAGGAGCCACCCCATCAGATTTAAATTCCATGCTAAACAC3’  
NL4-3 186S 186S/190A 5’CCACAAGATTTAAATTCCATGCTAAACGCAGTGGGGGGAC3’ 
NL4-3 186S 186S/190I 5’CCACAAGATTTAAATTCCATGCTAAACATAGTGGGGGGAC3’ 
NL4-3 67A 5’CTGGGACAGCTACAACCAGCTCTTCAGACAGGATCAG3’ 
NL4-3 473A 5’GAGACAACAACTCCCGCTCAGAGGCAGGAGCCG3’ 
NL4-3 483-/484- 5’GGAGCCGATAGACAAGGAA- - - - - - CCTTTAGCTTCCCTC3’  
 
Mutated Gag codons (HXB2 numbered) are shown in red. 
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2.4.2 Generation of mutant viruses and measurement of replication capacity 
Mutated SK-254 gag-protease was amplified using 100-mer primers complementary to 
NL4-3 on either side of gag-protease, followed by electroporation of GXR cells with PCR 
product and pNL4-3∆gag-protease to generate mutant viruses (Sections 2.2.2.1-2.2.2.4).  
Similarly, mutated NL4-3 plasmid was electroporated into GXR cells.  However, the 
modified electroporation protocol (Section 2.2.2.4) was used to generate the mutant 
186S/190I in the NL4-3 backbone (due to difficulty generating concentrated stocks of this 
mutant with the original protocol).  Virus growth was monitored by flow cytometry and 
supernatants were harvested when cultures were approximately 30% infected (Sections 
2.2.2.5-2.2.2.6).  Virus stocks were stored at -80 °C until assayed in the GXR cells to 
determine viral titres and viral replication capacities as described in Sections 2.2.3.1-2.2.3.2.  
Replication capacities of the same mutant viruses generated by both electroporation 
protocols were compared to rule out the possibility of variability introduced by the use of the 
modified protocol.                     
    
2.4.3 Data analysis 
ANOVA with Tukey post-hoc tests was used to test for significant differences in replication 
capacities between wild-type viruses and viruses encoding mutations.  The level of 





















CHAPTER 3 - RESULTS 
3.1 Quality control 
3.1.1 Validation of generated Gag-protease NL4-3 recombinant viruses  
To test whether generated recombinant viruses were representative of the original plasma 
quasispecies, gag-protease was first re-sequenced from 40 randomly-selected recombinant 
viruses generated from HIV-1 subtype C chronically infected patients and compared with the 
original plasma HIV-1 RNA sequences.  The median number of total nucleotide differences 
between recombinant virus and original plasma HIV-1 RNA sequence (when mixtures were 
not included as differences) was 0 (IQR: 0-1.5), resulting in an average nucleotide similarity 
of 99˙% between pairs.  The average number of nucleotide mixtures in recombinant virus 
sequences was 21 (standard deviation [SD] =17), indicating somewhat reduced diversity 
(Student’s T test; p=0.0002) when compared to the original plasma sequences (mean=35, 
SD=36).  Since these data indicated that Gag-protease recombinant viruses were 
representative of the original plasma quasispecies, only 2 randomly selected recombinant 
viruses generated from HIV-1 subtype C recently infected patients were re-sequenced, and 
were found to be identical to the plasma nucleotide sequences.  A phylogenetic tree 
incorporating these 42 sequence pairs shows that the gag sequences from recombinant 
viruses clustered closely with respective gag sequences from plasma (Figure 3.1).  Since 
Gag-protease recombinant viruses were representative of the original plasma quasispecies, 






Figure 3.1 Neighbour-joining tree (Paup 4.0) of HIV-1 gag sequences 
Gag-protease NL4-3 recombinant viruses were generated by co-transfection of a CEM-
derived T cell line with patient-derived gag-protease amplicons and gag-protease-deleted 
NL4-3 plasmid.  Forty-two randomly-selected recombinant viruses were re-sequenced and 
compared with the original plasma HIV-1 RNA sequences.  Gag recombinant virus 
nucleotide sequences (pink) closely clustered with respective plasma gag nucleotide 
sequences (blue) in a tree.     





























3.1.2 Validation of replication capacity assay 
The replication capacities of Gag-protease NL4-3 recombinant viruses were assayed in 
duplicate independently.  Duplicate measurements were highly concordant (Pearson’s 
correlation; r=0.88, p<0.0001) (Figure 3.2i).   
 
Accuracy of recombinant viral titres was achieved: on day 3 of the assay the median % GFP-
expressing cells was 0.66% (IQR: 0.46-0.82%).  Importantly, the observed variability in day 
3 readings did not significantly influence viral replication capacity, as calculated from the 
slope of growth from days 3-6 post-infection (Spearman’s correlation; r=0.05, p=0.23) 
(Figure 3.2ii). 
 
3.1.3 Overall method variability: recombinant virus generation and replication 
capacity assay 
Firstly, 5 samples were randomly selected and methods were repeated 5 times independently 
on each.  There was a significant difference overall between the groups of measurements 
(ANOVA; p=0.0002), indicating that the method variability was not great enough to negate 
differences in replication capacity between samples (Figure 3.3i).  However, these 5 
randomly selected samples were similar in replication capacity and thus overlapped.  To test 
for reproducible differences between samples, 2 samples with low and high replication 
capacities, respectively, were selected for repeated measurements.  The measurements 
between these 2 samples were distinctly different (Student’s T test; p<0.0001) (Figure 3.3ii), 
and each replicate of 1 sample was significantly different from each replicate of the other 
sample (Tukey post hoc tests; p<0.05) (Figure 3.3iii), indicating reproducible differences. 
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Figure 3.2 Replication capacity assay quality control analyses 
(i) Duplicate replication capacity results displayed good concordance (Pearson’s correlation). 
(ii) The range in starting percentage infection on day 3 of the assay did not influence the 
calculation of replication capacity measured by the slope of exponential growth from days 3-


























































































Figure 3.3 Overall method variability: recombinant virus generation and replication 
capacity assay 
(i) Generation of recombinant viruses encoding plasma-derived HIV-1 Gag-protease 
followed by replication capacity measurement was repeated 5 times independently for 5 
randomly selected plasma samples from the SK cohort of patients chronically infected with 
HIV-1 subtype C.  Lines represent the mean and bars represent standard deviation.  A 
significant difference between the groups of measurements for different patients is shown 
(ANOVA). 
(ii) A reproducible difference in the replication capacities of independently repeated 
experiments from one low (SK-68) and one high (SK-276) replication capacity sample is 
shown (Student’s T test).  Lines represent the mean. 
(iii) Graph showing significantly lower replication capacities of each SK-68 replicate 
compared to each SK-276 replicate (ANOVA, Tukey post-hoc tests).  Lines represent the 
mean. 








































































































































































3.2 HIV-1 subtype C chronic infection 
3.2.1 Distribution of replication capacities 
The NL4-3-normalised replication capacities of the recombinant viruses generated from the 
406 HIV-1 subtype C chronically infected patients approximated a normal distribution 
(mean=0.62, SD=0.1) (Figure 3.4).   
 
3.2.2 Replication capacities versus HLA class I alleles 
Replication capacities of recombinant viruses were grouped according to HLA alleles 
expressed by the host (Figure 3.5i-iii).  Overall, replication capacities varied significantly 
between the different HLA-B alleles (ANOVA, p=0.01) but not between HLA-A or HLA-C 
alleles, suggesting that HLA-B alleles have the greatest impact on Gag-protease-mediated 
replication capacity.  Relationships between specific HLA alleles and replication capacity 
were also observed, the strongest of which was the association of HLA-B*81 with lower 
replication capacities (Student’s T test; p<0.0001).  It should be noted that p values 
presented are uncorrected for multiple comparisons.  Only the association of HLA-B*81 
with lower replication capacities would remain statistically significant following Bonferroni 
adjustment for multiple comparisons.  It should also be noted that due to the limitation of 
sample size, the interactions between different HLA alleles expressed within a patient were 
not controlled for statistically, however linkage disequilibrium between HLA alleles was 
taken into account in order to partially control for this.   
 
Besides HLA-B*81, other alleles that were associated with low-replication-capacity 
recombinant viruses were HLA-B*5801, HLA-A*0205 (Mann-Whitney U-test; p=0.05 and 
p=0.04, respectively), HLA-A*3009, and HLA-A*3001 (Student’s T test; p=0.02 and  
99 
Figure 3.4 Replication capacities of Gag-protease NL4-3 recombinant viruses encoding 
Gag-protease from HIV-1 subtype C chronically infected patients 
Histogram showing an approximately normal distribution of replication capacities 
(normalised to the growth of wild-type NL4-3) with a mean of 0.62 and standard deviation 
of 0.1.   
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Figure 3.5 Associations between HLA alleles and replication capacities of recombinant 
viruses encoding Gag-protease from HIV-1 subtype C chronically infected patients   
(i-iii) Graphs show the mean (dot), median (vertical line), inter-quartile range (edges of 
boxes), and most extreme values (edges of whiskers) of replication capacities for each 
different HLA allele for which n 5.  Individual significant (p<0.05) associations (Student’s 
T test) are indicated with *.  Associations that survive Bonferroni correction for multiple 
comparisons are indicated with **.  Overall p values (ANOVA) indicate significance of 
differences in replication capacity between alleles of each group, A, B and C. 
(iv) Graph showing a significantly greater proportion (Fisher’s exact test) of individuals with 
protective HLA alleles (D= HLA-B*57, HLA-B*5801, and HLA-B*81) in the group with 
the least fit viruses (replication capacity ≤ 0.5) compared to those with the fittest viruses 
(replication capacity ≥ 0.74).          
HLA – human leukocyte antigen; Gag – group specific antigen; HIV-1 – human immunodeficiency virus type 1; ANOVA – 















































































































































p=0.05, respectively).  Due to tight linkage between HLA-B*5801 and HLA-A*0205 
(linkage disequilibrium [D’]=0.56 in [175]), the allele driving the effect could not be 
identified.  Out of 5 individuals with HLA-B*3009, 4 possessed HLA-B*81, which likely 
explains the association of HLA-B*3009 with lower replication capacities.   
 
Alleles associated with higher replication capacities were HLA-C*0702 (Student’s T test; 
p=0.05) and HLA-C*0501 (Mann-Whitney U-test; p=0.001).  Only 6 individuals in this 
study possessed HLA-C*0501 and all were linked to replication capacities above the 80th 
percentile of the dataset (>0.7).  HLA-C*0501 is in linkage disequilibrium with HLA-
B*1801 – 5 out of 6 individuals with HLA-C*0501 also carried HLA-B*1801 - and could 
therefore partly contribute to the disadvantage associated with HLA-B*1801 in subtype C 
infection [170].   
 
In an additional analysis, the HLA types of the individuals corresponding to the fittest 
recombinant viruses (≥90th percentile of the dataset, i.e. ≥0.74, n=41) were compared to the 
HLA types of individuals with the least fit recombinant viruses (10th percentile of the 
dataset, i.e. ≤0.5, n=41).  Protective alleles were defined as those that were most strongly 
associated with lower viral loads  in HIV-1 subtype C-infected individuals, namely HLA-
B*57, HLA-B*5801, and HLA-B*81 [170] (Section1.6.4.1), which were also later found to 
be the most strongly associated with lower viral loads or higher CD4+ T cell counts in a 
cohort of over 1,000 HIV-1 subtype C-infected individuals [273].  The proportion of 
individuals possessing a protective allele was significantly greater in the low-replication-
capacity group when compared with the high-replication-capacity group (Fisher’s exact test; 
p=0.003) (Figure 3.5iv).   
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3.2.3 Replication capacities versus viral loads and CD4+ T cell counts 
Replication capacities of recombinant viruses correlated positively with baseline log viral 
loads (Spearman’s correlation; r=0.24, p<0.0001) and negatively with baseline CD4+ T cell 
counts (Spearman’s correlation; r=-0.17, p=0.0004) (Figure 3.6i-ii).  These effects remained 
after removal of protective alleles HLA-B*57, HLA-B*5801, and HLA-B*81 from analysis 
(Spearman’s correlation; r=0.18 p=0.001 and r=-0.14 p=0.01, respectively).  Of interest, 
analysis of the relationship between viral load/CD4+ T cell count and replication capacity 
among individuals expressing these protective alleles also revealed a significant positive 
correlation (Pearson’s correlation; r=0.33 p=0.001 and r=-0.33 p=0.001, respectively).  
 
3.2.4 Replication capacities versus rates of CD4+ T cell decline 
Rate of CD4+ T cell decline following baseline was calculated for 339 HIV-1 subtype C 
chronically infected patients.   There was no statistically significant relationship between 
replication capacity and CD4+ T cell decline overall (Spearman’s correlation; r=-0.01, 
p=0.79).  Since baseline CD4+ T cell count is a determinant of rate of CD4+ T cell decline 
and individuals with lower baseline CD4+ T cell counts have a subsequently slower rate of 
CD4+ T cell decline [274], the analysis was repeated following stratification by baseline 
CD4+ T cell count in increments of 50 cells/mm
3
.  These stratifications failed to reveal any 
significant correlations between replication capacity and rate of CD4+ T cell decline (data 
not shown).  Figure 3.6iii shows a lack of correlation between CD4+ T cell decline and Gag-
protease-mediated replication capacity at baseline CD4+ T cell count ≥200 (Spearman’s 





Figure 3.6 Relationships between replication capacities of recombinant viruses 
encoding patient Gag-protease and markers of disease progression in HIV-1 subtype C 
chronically infected patients   
Graphs show correlations between replication capacity and baseline log viral load (i), 
baseline CD4+ T cell count (ii), and rate of CD4+ T cell decline (iii) (Spearman’s 
correlation).  
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3.2.5 Replication capacities versus Gag-protease sequences 
3.2.5.1 Gag-protease polymorphisms 
To investigate whether an increasing number of polymorphisms in Gag or protease would 
tend to reduce replication capacity, the percentage similarities of both Gag and protease 
sequences to the consensus C sequence were calculated.  Unexpectedly, the calculated Gag 
percentage similarity correlated negatively, although weakly, with replication capacity 
(Pearson’s correlation; r=-0.18, p=0.0004), i.e. the fittest viruses were generally least like the 
consensus sequence (Figure 3.7i).  This analysis was repeated separately for each region of 
Gag, namely p17, p24, p7, and p6, to see whether this relationship differed between regions.  
There remained an inverse relationship between percentage similarity to consensus and 
replication capacity in every region of Gag except p24, although this was only statistically 
significant for p17 and p7 (Figure 3.7ii).  There was no correlation between percentage 
similarity to Gag p24 consensus C and replication capacity.  In contrast, the majority of non-
consensus residues in p17/p7 increased replication capacity.  It should be noted that 
divergence from the consensus C Gag sequence did not represent convergence to the 
consensus B Gag sequence, which would have indicated that divergence from consensus C 
resulted in a better compatibility with the subtype B NL4-3 backbone, and therefore fitter 
viruses.  The calculated protease percentage similarity to consensus did not correlate with 
replication capacity (Spearman’s correlation; r=-0.006, p=0.91) (Figure 3.7iii).   
 
3.2.5.2 HLA-associated polymorphisms 
HLA-associated amino acids in Gag and protease were identified (p<0.05, q≤0.2).  There 
were 131 amino acids either positively or negatively associated with an HLA allele at 66 
different codons in Gag and only 3 amino acids at 2 different codons in protease (Appendix, 
Table A1).  Thus, HLA-associated polymorphism analyses were focussed on Gag. 
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Figure 3.7 Associations between Gag-protease polymorphisms and replication 
capacities of recombinant viruses encoding Gag-protease from HIV-1 subtype C 
chronically infected patients   
(i) A significant negative correlation between percentage similarity of Gag sequences to the 
consensus C Gag sequence and replication capacity (Pearson’s correlation).   
(ii) Gag p17, p24, p7, and p6 percentage similarity to consensus C sequence versus 
replication capacity (Spearman’s correlation).   
(iii) No relationship between the percentage similarity of protease sequences to the 
consensus C sequence (Spearman’s correlation). 
Gag – group specific antigen; HIV-1 – human immunodeficiency virus type 1; p17 – protein of 17 kDa; p24 – protein of 24 








































































































































The number of HLA-associated polymorphisms specific to the host HLA alleles was 
computed for each sequence.  To further analyse the influence of HLA alleles on Gag-
protease replication capacity the computed polymorphisms were then correlated with 
replication capacity.  The total number of HLA-associated polymorphisms in each sequence 
did not correlate significantly with replication capacity overall (Spearman’s correlation;      
r=-0.07, p=0.13) (Figure 3.8i).  Similarly, the proportion or number of polymorphisms 
stratified by HLA-A, -B, or –C alleles did not correlate significantly with replication 
capacity.  Likewise, when the relationship between the number of HLA-associated 
polymorphisms and replication capacity was investigated irrespective of patient HLA class I 
profile, i.e. also taking into account inherited polymorphisms, no significant associations 
were found.  Therefore, the sum of HLA-selected polymorphisms irrespective of location in 
Gag was not associated with replication capacity in these chronically infected patients.   
 
There was, however, irrespective of host HLA profile, a weak trend (Spearman’s correlation; 
r=-0.09, p=0.08) towards lower replication capacities with increasing number of HLA-
associated polymorphisms (88% HLA-B-associated) in optimal epitopes or within 5 amino 
acids adjacent to epitopes restricted by the HLA allele associated with the relevant 
polymorphism.  (The A-list of optimal epitopes from the Los Alamos HIV database [275] 
was used [Appendix, Table A2].)  These polymorphisms are more likely to represent escape 
mutations and not secondarily arising compensatory mutations [207].  Similarly, the number 
of HLA-B-associated polymorphisms in or within 5 amino acids of Gag epitopes was also 
negatively correlated with fitness (Spearman’s correlation; r=-0.11, p=0.03) (Figure 3.8ii).    
Therefore, there was a relatively weak relationship between the number of HLA-associated 
polymorphisms (irrespective of host HLA profile) in or immediately adjacent to Gag 
epitopes and replication capacity in the present chronic infection cohort.  
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Figure 3.8 Associations between HLA-associated polymorphisms and replication 
capacities of recombinant viruses encoding Gag-protease from HIV-1 subtype C 
chronically infected patients   
(i) No correlation between the total number of HLA-associated polymorphisms in Gag and 
replication capacity (Spearman’s correlation).   
(ii) A weak negative correlation between the number of HLA-B-associated polymorphisms 
in or within 5 amino acids of Gag epitopes and replication capacity (Spearman’s correlation).  
(iii) A significant positive correlation between entropy of HLA-associated sites in or within 
5 amino acids of Gag epitopes and the average replication capacity of viruses with HLA-
associated polymorphisms at these sites (Pearson’s correlation).   
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Since there is some evidence that HLA-associated escape mutations occurring in conserved 
sites of HIV carry a greater fitness cost than those occurring in regions of high variability  
[104] (Section 1.6.5.1), we compared the average replication capacity of viruses possessing 
each HLA-associated polymorphism with the corresponding entropy (degree of variability) 
at those positions.  A trend towards significant correlation between these parameters was 
found (Pearson’s correlation; r=0.24, p=0.06).  When the analysis was restricted to those 
polymorphisms in epitopes or within 5 amino acids adjacent to epitopes restricted by the 
associated HLA allele, the correlation was much stronger (Pearson’s correlation; r=0.64, 
p=0.02) (Figure 3.8iii).  Thus, HLA-associated polymorphisms (likely to be escape 
mutations) at more conserved sites in Gag were associated with greater fitness costs.     
 
3.2.5.3 Amino acid variants 
Specific codons at which amino acid variants (occurring at a frequency of n≥5) associated 
with significantly increased or decreased replication capacity were identified by univariate 
analysis (Appendix, Table A3).  Although none of the comparisons yielded q≤0.2, at p<0.05, 
68 amino acid variants (including consensus amino acids) at 51 codons were identified in 
Gag and 12 amino acid variants at 9 codons were identified in protease.  Of the 51 codons in 
Gag, 20 occurred in p17, 11 in p24, 3 in p2, 7 in p7, and 10 in p6.   
 
Considering amino acids in Gag associated with alterations in viral replication capacity, at 
most of codons in p24 the absence of the consensus amino acid was associated with lower 
replication capacity (10/11), while in p17 the absence of the consensus amino acid was 
associated with decreased replication capacity in only 8 out of 20 cases.  This difference was 
statistically significant (Fisher’s exact test; p=0.008) (Figure 3.9).  Nineteen out of 51  
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Figure 3.9 Association between Gag-protease amino acid variants and altered 
replication capacities of recombinant viruses encoding Gag-protease from HIV-1 
subtype C chronically infected patients   
Graph showing a significant difference in the proportion of non-consensus amino acids 
associated with decreased replication capacity in p24 versus p17 (Fisher’s exact test).     
Gag – group specific antigen; HIV-1 – human immunodeficiency virus type 1; No. – number; RC – replication capacity; 






































































codons in Gag corresponded to an HLA-association at that position and 22 of the 51 Gag 
codons occurred in optimal epitopes.  In combination, 29 out of the 51 Gag codons were 
either HLA-associated or in optimal epitopes.   
 
Multivariate analysis (linear regression with forward selection) was also undertaken.  
Seventeen out of 51 codons in Gag and 4 out of 9 codons in protease identified by univariate 
analysis were also p<0.05 (although q>0.2) in the multivariate model and the strongest of 
these associations was the consensus T at position 186 with increased replication capacity 
(Appendix, Table A3).  The associations with p<0.001 and q<0.25 are shown in Table 3.1.     
 
To increase statistical power, the univariate analysis was repeated limited to HLA-associated 
positions only.  Seven HLA-associated amino acid variants at 6 codons in Gag only were 
identified at p<0.05 and q≤0.2.  One variant was associated with decreased replication 
capacity: 186S.  Six amino acids were associated with increased replication capacity: 28Q, 
186T (consensus), 309A (consensus), 312D (consensus), 381G, and 467E (consensus).      
 
3.2.5.4 HLA-B*81-associated 186S  
Since the consensus 186T was strongly associated with increased replication capacity, 
changes away from consensus at this position were compared between the least fit and fittest 
viruses.  In the least fit group, 9 sequences had an S and 1 had an A at position 186 while 
only 1 had an S at this position in the fittest group (Fisher’s exact test; p=0.01) (Figure 
3.10i).  In the entire cohort, with the exception of 1 sequence with 186A and another 
sequence which had a mixture of T and S at this position, the non-consensus amino acid at 
codon 186 was S.  Overall, 186S was associated with a decrease in replication capacity when   
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Table 3.1. Amino acids in HIV-1 subtype C Gag-protease from chronically infected 
subjects associated with altered replication capacities by multivariate analysis 
(p<0.001, q<0.25) 




p24 186 T Yes + 0.0001 0.225 TL9 – B*0702, B*3910, 




p17 118 V  - 0.0002 0.225   




p7 389 M  + 0.0003 0.225   
p17 61 I Yes + 0.0003 0.225   
p17 28 Q  + 0.0004 0.225 RK9/RLY10 – A*0301, GK9 











pro 64 M  + 0.0007 0.236 RI10 – B*13  
p24 323 V Yes - 0.0008 0.236   
p7 411 K Yes + 0.0008 0.236 
CC9 – B*14 A*0301
a 
 
HIV-1 – human immunodeficiency virus type 1; Gag – group specific antigen; p24 – protein of 24 kDa; p17 – protein of 17 
kDa; p7 – protein of 7 kDa; pro – protease; AA – amino acid; Con. – consensus; RC – replication capacity; HLA – human 
leukocyte antigen. 













Figure 3.10 Single HLA-B*81-associated Gag amino acid associations with altered 
replication capacities of recombinant viruses encoding Gag-protease from HIV-1 
subtype C chronically infected patients   
(i) A greater proportion of 186S/A in the least fit viruses (replication capacity ≤ 0.5) 
compared to the fittest viruses (replication capacity ≥ 0.74) (Fisher’s exact test).   
(ii) Lower replication capacities of viruses with 186S compared to those with consensus 
186T (Student’s T-test).  Lines represent the mean.   
(iii) Significantly higher replication capacities of viruses with 186T and 186S with co-
varying mutations 190X and 182S compared to viruses with 186S alone (Student’s T-test).  
Lines represent the mean.   
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compared with consensus 186T (Student’s T test; p=0.006) (Figure 3.10ii).  This 
polymorphism is associated with HLA-B*81 and occurs in the HLA-B*81-restricted epitope, 
TL9.  However, when only HLA-B*81 positive individuals were considered, the replication 
capacities of viruses with 186S and 186T were both below average and were not 
significantly different from one another (Student’s T test; p=0.82), suggesting that other 
mutations may also be responsible for the lower fitness of viruses from these individuals 
and/or that the fitness cost of 186S was compensated for in some cases.   
 
3.2.5.5 Residues co-varying with 186S 
Amino acid co-variation lists were generated from the current dataset when testing for HLA-
associated amino acids [269] (Section 2.2.5).  Amino acids positively associated with 186S 
and/or negatively associated with 186T include 177D, 182S, 190A, 190I, 256I, and 343I 
(p<0.05, q≤0.2).  Amino acids negatively associated with 186S and/or positively associated 
with 186T include 65Q, 177E, 190T, 256V, and 343L (p<0.05, q<0.2).  Replication 
capacities of viruses with 186S and various numbers of associated residues (Q65X, E177X, 
Q182S, T190X, V256X, and L343X) were compared to assess whether these might be 
functioning as compensatory mutations.  The number of co-varying residues present 
correlated positively but not significantly with replication capacity (Pearson’s correlation; 
r=0.26, p=0.19).  However, on closer examination of sequences with 186S, a greater 
occurrence of mutations at positions 182 and 190 (but not at other co-varying positions) was 
noted in the fitter viruses (Figure 3.10iii).  This was statistically significant (Student’s T test; 
p=0.006), suggesting that 190X and 182S, which occur parallel to and on either side of 
residue 186 in a helix structure [276, 277], might be compensatory mutations.  Results of 
experiments testing the fitness effects of these mutations are presented in Section 3.6.      
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3.3 HIV-1 subtype C recent infection 
3.3.1 Distribution of replication capacities 
To assess the impact of HIV-1 Gag-protease function on disease progression, recombinant 
viruses encoding Gag-protease from patients in early HIV-1 subtype C infection were 
constructed and the replication capacities of these were measured.  Replication capacities of 
recombinant viruses encoding Gag-protease from patients in early infection were normally 
distributed (Figure 3.11).  The mean replication capacity expressed relative to wild-type 
NL4-3 was 0.63 (SD=0.12), which is comparable to replication capacities of recombinant 
viruses encoding Gag-protease from chronically infected patients (Section 3.2.1).  
 
3.3.2 Replication capacities versus markers of disease progression 
Viral set point and rate of CD4+ T cell decline were used as markers of HIV-1 disease 
progression in the present study (Section 1.6.1).  The average viral load between 3 and 12 
months post-infection was the measure of viral set point used in this study, and could be 
calculated for 56 of 60 (93%) study subjects.  No significant correlation between the viral set 
points and replication capacities of the Gag-protease NL4-3 recombinant viruses was 
observed (Pearson’s correlation; r=0.12 and p=0.37) (Figure 3.12i).  Next, the replication 
capacities of recombinant viruses encoding Gag-protease from subjects with below median 
versus above median viral set points were next compared.  Patients with below median viral 
set points tended to have viruses with an attenuated Gag-protease function and this was 





Figure 3.11 Replication capacities of Gag-protease NL4-3 recombinant viruses 
encoding Gag-protease from HIV-1 subtype C recently infected patients 
Histogram showing an approximately normal distribution of replication capacities 
(normalised to the growth of wild-type NL4-3) with a mean of 0.63 and standard deviation 
of 0.12.   




































    














    














    
   













    
   













    
   













    
   
























Figure 3.12 Relationships between replication capacities of recombinant viruses 
encoding patient Gag-protease and markers of disease progression in HIV-1 subtype C 
recently infected patients   
(i) A positive non-significant correlation between replication capacity and viral set point 
(Pearson’s correlation).   
(ii) Significantly lower replication capacities of viruses encoding Gag-protease from patients 
with below median viral set points versus above median viral load set points (Student’s T 
test).  Lines represent the mean.   
(iii) A negative non-significant correlation between replication capacity and rate of CD4+ T 




(iv) Lower replication capacities of viruses encoding Gag-protease from patients with above 
median (slower) rates of CD4+ T cell decline versus below median (faster) rates of CD4+ T 
cell decline for subjects with baseline CD4+ T cell counts >300 cells/mm
3
 (Student’s T test).  
Lines represent the mean.    








































































































































































A rate of CD4+ T cell decline was then calculated for each subject by linear regression.  
Since baseline CD4+ T cell count influences rate of decline, when analysing the relationship 
between rate of CD4+ T cell decline and Gag-protease-mediated replication capacity, 
subjects with a reasonably moderate to high CD4+ T cell count (>300 cells/mm
3
, n=45) at 
baseline were considered separately from those with already substantially low CD4+ T cell 
counts at baseline (<300 cells/mm
3
, n=15).  At higher CD4+ T cell counts there was a weak 
negative trend of association between rates of CD4+ T cell decline and replication 
capacities, i.e. at higher replication capacities the rate of CD4+ T cell decline was 
increasingly negative or faster, however this trend was not statistically significant 
(Spearman’s correlation; r=-0.25 and p=0.09) (Figure 3.12iii).  The same trend was not 
shown for subjects with low baseline CD4+ T cell counts which could be due to limited 
sample size (n=15) in this stratum (Pearson’s correlation; r=-0.18 and p=0.53).  When 
replication capacities were grouped according to the median rate of CD4+ T cell decline for 
subjects with baseline CD4+ T cell count >300 cells/mm
3
, although the mean replication 
capacity was lower for subjects with slower rates of decline this was not statistically 
significant (Student’s T test; p=0.27) (Figure 3.12iv). 
 
3.3.3 Replication capacities versus protective HLA alleles 
Previous studies have reported few sequence changes in Gag in at least the first 6 months of 
infection [187, 207].  However, for HLA-B*57 positive individuals, associated escape in 
Gag has been reported as early as 45 days following screening in acute infection [106], 
although the median reported time in another study is 13 months [187].  Although it is 
expected that the Gag-protease recombinant viruses were largely representative of 
transmitted viruses, the possibility of some early selection, particularly by protective alleles, 
could not be excluded.  Therefore replication capacities were compared between protective 
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and non-protective HLA alleles expressed by the host.  There was a trend towards lower 
replication capacities of recombinant viruses encoding Gag-protease from patients with 
protective HLA alleles (Student’s T test; p=0.08) (Figure 3.13), suggestive of some early 
selection pressure.   
 
It should be noted that for the patients analysed here, viral set points did not differ 
significantly between individuals with and without protective HLA alleles (4.4 versus 4.61  
log10 copies/ml, Student’s T test; p=0.46).  Here a study limitation should also be noted: 12 
patients were excluded from this study due to gag-protease amplification failure (likely as a 
consequence of limited available plasma); of these 7 had protective HLA alleles and the 
median viral set point of excluded patients was significantly lower than those patients 
included in the study (3 versus 4.69 log10 copies/ml; Student’s T test; p<0.0001).    
 
3.3.4 Replication capacities/viral set points versus Gag-protease sequences 
3.3.4.1 Amino acid variants 
Although statistical power was limited by the number of patients, in an exploratory analysis, 
the Mann-Whitney U test was used to identify specific codons in Gag-protease at which 
amino acid variants (occurring at a frequency of n≥5) were associated with increased or 
decreased replication capacity in early infection.  Eighteen codons in Gag (24 associations) 
and 2 codons in protease (3 associations) with p<0.05 were identified, however, calculated q 
values were >0.2 in all cases (Table 3.2).  The number of patients was not sufficient to 
perform a multivariate analysis. 
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Figure 3.13 Relationship between protective HLA alleles and replication capacities of 
recombinant viruses encoding Gag-protease from HIV-1 subtype C recently infected 
patients   
Lower replication capacities of viruses encoding Gag-protease from patients with protective 
HLA alleles versus non-protective HLA alleles (Student’s T test).  Lines represent the mean.   
















































































Table 3.2. Amino acids in HIV-1 subtype C Gag-protease from recently infected patients associated with alterations in replication capacity (p<0.05)   




capacity p q Optimal epitopes with HLA restriction HLA association 
-AA +AA - AA +AA 
p17 15 K Yes 31 29 0.58 0.67 0.012 0.80 GI9 – B*4002  
p17 15 T  49 11 0.63 0.56 0.043 0.80 GI9 – B*4002  







p17 82 V Yes 6 54 0.53 0.63 0.009 0.80 
EV9 – B*0801, RY11 – A*3002, B*58, B*63,  SL9 – A*0201, A*0202, 
A*0205, LL8 – C*14, LY9 – A*2902, B*4403 
 
p17 82 I  53 7 0.63 0.56 0.010 0.80 
EV9 – B*0801, RY11 – A*3002, B*58, B*63,  SL9 – A*0201, A*0202, 
A*0205, LL8 – C*14, LY9 – A*2902, B*4403 
 
p17 90 K  50 10 0.64 0.54 0.035 0.80 TK8 – A*1101 A34
b 
p17 95 R Yes 14 46 0.57 0.64 0.023 0.80 IL10- B*4001  
p17 109 K  53 7 0.62 0.75 0.017 0.80   
p17 110 K  5 55 0.74 0.62 0.017 0.80   
p17 115 T  10 50 0.72 0.62 0.005 0.79   
p17 122 - Yes 9 51 0.70 0.62 0.035 0.80   
p24 163 G  52 8 0.63 0.54 0.038 0.80 





p24 223 I Yes 41 19 0.67 0.57 0.011 0.80 HA9 – B*07 A*2911
b 










p24 248 T  53 7 0.62 0.75 0.044 0.80 TW10 – B*5701, B*5801  
p24 256 V  42 18 0.64 0.58 0.050 0.80 PY9 – B*3501 C18
a
 
p24 256 I Yes 18 42 0.58 0.64 0.050 0.80 PY9 – B*3501 C18
a
 
p24 323 V Yes 6 54 0.76 0.62 0.038 0.80   
p2 374 T Yes 43 17 0.63 0.56 0.031 0.80  B*1503
a 
p2 377 L  50 10 0.64 0.53 0.001 0.42  B*5802
b 
p2 377 M Yes 9 51 0.53 0.64 0.001 0.42  B*5802
b 
p7 389 I Yes 25 35 0.67 0.59 0.019 0.80   
p7 389 T  47 13 0.62 0.71 0.038 0.80   
Pro 15 I  51 9 0.64 0.54 0.005 0.28   
Pro 15 V Yes 8 52 0.55 0.64 0.011 0.28   
Pro 19 T  49 11 0.64 0.55 0.015 0.28   
Gag – group specific antigen; p17/24/7/6 – protein of 17/24/7/6 kDa; Pro – protease; AA – amino acid; con. – consensus; No. – number.  HLA – human leukocyte antigen; 
a 
HLA allele is negatively associated with the 
consensus amino acid or positively associated with a polymorphism at that codon.  
b 







Eight of the associations identified (all in Gag) corresponded to HLA-associated codons 
(28H, 90K, 163G, 223I, 242N, 256V, 374T, and 377L) and a further 4, although not HLA-
associated, were situated in Gag epitopes (15T, 82I, 95R, and 248T) (Table 3.2).  Limiting 
the analysis to HLA-associated positions only, one association achieved statistical 
significance at q<0.2, namely 377L was significantly associated with lower replication 
capacities (Mann-Whitney U Test; p=0.001 and q=0.07).  This polymorphism was 
negatively associated with HLA-B*5802 in the subtype C chronically infected cohort - it did 
not occur in any of the 68 HLA-B*5802 positive individuals but was present in 32 out of 316 
HLA-B*5802 negative individuals.  The selection or maintenance of the consensus 377M by 
HLA-B*5802 which is associated with higher replication capacities could possibly be one of 
the contributing factors to the detrimental effect of this HLA allele in HIV-1-infected 
individuals [170, 176].   
 
Two polymorphisms associated with protective HLA alleles, namely 242N (HLA-B*5801/ 
B*57) and 163G (HLA-B*57), were associated with lower replication capacities in the 
present study, which is consistent with previous reports [33, 187, 211] (Section 1.6.5.1).  
Interestingly, only 2 of the 18 individuals that had a virus with 242X (17=242N and 1=242S) 
were HLA-B*5801 positive and none of the 8 with 163G were HLA-B*57 positive, 
indicating that these mutations were transmitted to, rather than selected in, the study subjects 
in nearly all cases.  Consistent with previous reports [251], 242X-expressing viruses 
harbouring 2 or more 242X-associated compensatory mutations – 219Q, 223V, 228I, and 
248T [33]  - displayed higher replication capacities (0.67, n=3) than those with 1 or 0 (0.55, 
n=15; Mann-Whitney U test; p=0.04) and 248T was individually associated with higher 
replication capacities (Table 3.2).    
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3.3.4.2 Number of HLA-associated polymorphisms in Gag  
3.3.4.2.1 Replication capacity 
Next the relationship between the number of HLA-associated polymorphisms in Gag and 
replication capacity was investigated.  Each sequence was analysed firstly in the context of 
the patient’s HLA alleles (the absolute number as well as the proportion of polymorphisms 
associated with host alleles were computed) and secondly irrespective of the host HLA 
profile.  The overall number of HLA-associated polymorphisms in Gag did not correlate 
with replication capacity.  However, when limited to HLA-associated polymorphisms 
occurring in or within 5 amino acids of optimal epitopes (likely representing escape), there 
was a significant inverse correlation between the total proportion of host-specific HLA-A, B 
and C polymorphisms and replication capacity (Spearman’s correlation; r=-0.32 and p=0.04) 
(Figure 3.14i), which appeared to be driven mainly by HLA-B-associated polymorphisms.  
Similarly, when all polymorphisms were included irrespective of host HLA profile, there 
was also a trend towards lower replication capacities with an increasing absolute number of 
HLA-B-associated Gag polymorphisms in or adjacent to epitopes (Spearman’s correlation; 
r=-0.25 and p=0.06, one extreme outlier removed).  In summary, overall there was a negative 










Figure 3.14 Associations between HLA-associated Gag polymorphisms, replication 
capacities of recombinant viruses encoding patient Gag-protease, and viral set points in 
HIV-1 subtype C recently infected patients   
(i) A significant negative correlation between the proportion of host-specific HLA-associated 
polymorphisms in or adjacent to Gag epitopes and the replication capacities of recombinant 
viruses encoding Gag-protease.   
(ii) A significant positive correlation between the proportion of host-specific HLA-B-
associated polymorphisms present in Gag and viral set point. 
(iii) Significantly higher viral set points in patients with protective HLA alleles that have a 
polymorphism associated with those alleles in Gag versus those that do not (Mann-Whitney 
U test).  Lines represent the mean. 
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3.3.4.2.2 Viral set point 
Next sequences were analysed for a correlation between Gag polymorphisms and viral set 
point, as has been previously described [207].  Unexpectedly, the proportion of total host-
specific HLA-B-associated polymorphisms and presence of host-specific protective HLA-
associated polymorphisms were both positively associated with viral set point (Spearman’s 
correlation; r=0.33 and p=0.01; and Mann-Whitney U test; p=0.03) (Figure 3.14ii,iii).  
Similar results were calculated for absolute numbers of host-specific HLA-B-associated 
polymorphisms.   Thus, the presence of Gag polymorphisms that could be selected by host 
alleles was generally associated with higher viral set points.   
 
Since Goepfert et al. (2008) showed that the negative association between the number of 
HLA-B-associated polymorphisms in transmitted viruses and viral set point in recipients was 
stronger when host-specific HLA-associated polymorphisms were excluded (i.e. there was 
benefit associated with inheriting polymorphisms that were not associated with HLA alleles 
of the recipient) [207], the analysis was repeated the same way here using the same 
published list of polymorphisms.  This analysis showed no significant relationship between 
transmitted HLA-B-associated polymorphisms and viral set points (Pearson’s correlation; 
r=-0.1 and p=0.43) in contrast to positive significant relationships observed in earlier 
analyses.  Also of interest, 5 of 12 subjects for whom gag-protease amplification failed here 
and who had very low viral set points overall, had viruses that harboured protective HLA-
associated polymorphisms that they could not have selected based on their HLA profiles; 
and only 1 of the 7 with protective HLA alleles had an associated polymorphism.  (Note that 
extraction and sequencing was performed on these subjects previously [278].)  These data 
are not inconsistent with a benefit to inheriting Gag polymorphisms that could not be 
selected by host HLA alleles.                    
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3.3.5 Longitudinal analyses of replication capacities, CD8+ T cell responses and clinical 
parameters  
For 13 recently infected subjects, Gag-protease NL4-3 recombinant viruses were 
additionally generated and assayed from time points approximately 1 year later than the first 
available time points following screening.  Overall, paired replication capacity 
measurements were not found to be significantly different from one another (paired T test; 
p=0.77).  In some samples where the replication capacity changed more than 0.1, sequence 
changes in the Gag protein could partly explain the alteration.  For example, in patient AS2-
0945 (HLA-B*5703 positive) fitness-reducing mutations 242X (mixture of T, S, and N at 
this residue) and 146P were selected by 1 year later with a substantial decrease in replication 
capacity.   Also, in patient AS2-0802 a CD8+ T cell response to the B*08-restricted epitope 
EV9 was present at the early time point and the mutation 75I had developed in this epitope 1 
year later.  The mutation 75I was significantly associated with higher replication capacities 
in the subtype C chronically infected cohort (Appendix, Table A3) and accordingly viral 
replication capacity increased for this patient.   
 
Viral replication capacities and CD8+ T cell responses to Gag epitopes were next related to 
clinical information.  Of interest, in patient AS2-0341, replication capacity remained low but 
viral set point and viral load at the later time point were high (4.89 log10 copies/ml and 5.44 
log10 copies/ml respectively).  This patient made no detectable CD8+ T cell responses to Gag 
epitopes.  In contrast, replication capacity remained low in AS2-0174 but this patient 
mounted CD8+ T cell responses to 9 Gag epitopes and viral load remained below 3.15 log10 
copies/ml from 8 months post-infection onwards (i.e. patient AS2-0174 was a controller).  In 
patient AS2-0945, in whom viral set point was low (3.46 log10 copies/ml), a detectable 
CD8+ T cell response was made to a key epitope in Gag (TW10) and mutations were 
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selected that decreased replication capacity.  However, it should be noted that there was a 
rise in viremia in this patient coinciding with selection of these mutations.  In patients AS2-
0358 and AS2-1037, although CD8+ T cell responses were made to Gag epitopes, viremia 
was not well-controlled and Gag-protease-mediated replication capacities were also high in 
these patients.   
 
The viral replication capacities, together with CD8+ T cell responses to Gag epitopes, 
clinical parameters and patient HLA types, are presented in Table 3.3.            
 
3.4 Contribution of Gag-protease to overall replication capacity 
To test whether HIV-1 Gag-protease function significantly contributes to viral replication 
capacity, HIV-1 was isolated from patients and recombinant viruses encoding Gag-protease 
from these patients were also generated.  The replication capacities of the isolates and the 
Gag-protease recombinant viruses were then compared.  A moderate statistically significant 
correlation was found between the replication capacities of the isolates and their 
corresponding recombinant viruses (Pearson’s correlation; r=0.51 and p=0.04) (Figure 3.15).  




Table 3.3.  Longitudinal measurements of Gag-protease-mediated viral replication capacities, Gag CD8+ T cell responses, and clinical 
measures from patients recently infected with HIV-1 subtype C (including patient HLA profiles) 
ID 
RC VL CD4 
HLA type 
CD8+ T cell responses 
A B A B A B Early Median of 6 weeks later 
AS1-0703 0.6 0.58 5.15 3.88 625 549 
A*2601  A*3004  B*4403  
B*5802  C*0210  C*0602 
AW11 – B*44 AW11 – B*44, QW9 – B*57 
AS1-0919 0.75 0.71 4.65 4.43 665 383 
A*2902  A*7400  B*3501  
B*4201  C*0401  C*1700 
TL9 – B*42  
AS2-0016 0.61 0.7 4.55 3.96 528 537 
A*2601  A*3002  B*1518  
B*4201  C*1700  C*1800 
RLY10 – A*30 RLY10 – A*30, EL9 – A*26, TL9 – B*42 
AS2-0174 0.57 0.58 5.47 2.01 361 416 
A*2301  A*3002  B*0801  
B*1402  C*0304  C*0802 
 
RLY10 – A*30, RY11 – A*30, AF8 – A*30, 
DI8 – B*08, EL8 – B*08, DA9 – B*14, CC9 – 
B*14, YL9 – C*03, TL9 – C*08 
AS2-0341 0.5 0.43 5.86 5.44 553 346 
A*3402  A*6801  B*1503  
B*5802  C*0210  C*0602 
  
AS2-0358 0.97 0.82 5.18 5.34 331 553 
A*2402  A*3001  B*4202  
B*5301  C*0404  C*1700 
HW9 – A*23 HW9 – A*23, SW11 – A*30, QW9 – B*53 
AS2-0483 0.7 0.54 5.54 4.65 359 440 
A*3001  A*3402  B*1503  
B*4201  C*0210  C*1700 
 RY11 – A*30, TL9 – B*42 
AS2-0802 0.32 0.65 5.11 4.27 316 338 
A*3002  A*4301  B*0801  
B*5802  C*0602  C*0701 
RY11 – A*30, EV9 – B*08, 
KF11 – B*57 
RY11 – A*30, DI8 – B*08, EL8 – B*08 
AS2-0945 0.62 0.46 3.66 4.51 686 648 
A*2301  A*7400  B*1510  
B*5703  C*0701  C*1601 
TW10 – B*57 QW9 – B*57, GI9 – B*1510 
AS2-1037 0.71 0.73 5.93 4.82 403 219 
A*03      A*3402  B*1503  
B*1510  C*0210  C*0304 
VL10 – B*1510, YL9 – 
C*03 
YL9 – C*03 
AS3-0268 0.54 0.56 5.88 5.64 483 419 
A*2902  A*8001  B*1503  
B*1801  C*0202  C*0210 
RY11 – A*29, LY9 – A*29, 
VF9 – B*1503 
LY9 – A*29, VF9 – B*1503 
AS3-0369 0.59 0.63 4.55 4.4 485 436 
A*6602  A*6802  B*1510  
B*4403  C*0304  C*0701 
RL11 – B*44, AW11 – 
B*44, YL9 – C*03 
YL9 – C*03, VL10 – B*1510 
AS3-0458 0.43 0.69 4.27 4.21 488 455 
A*2902  A*3402  B*4403  
B*5802  C*0401  C*0602 
AW11 – B*44 AW11 – B*44, RY11 – A*29 
 
Gag – group specific antigen; CD8 – cluster of differentiation 8; HIV-1 – human immunodeficiency virus type 1; ID – patient code; A – early time point; B – time point a median of 1 year later than 







Figure 3.15 Contribution of Gag-protease to overall HIV-1 fitness 
A significant positive correlation between replication capacities of HIV-1 subtype C isolated 
from patients and corresponding NL4-3 recombinant viruses encoding Gag-protease derived 
from the same patients (Pearson’s correlation).  



































































3.5 HIV-1 subtype B versus subtype C 
3.5.1 Gag-protease NL4-3 recombinant viruses 
The replication capacities of the 25 recombinant viruses encoding Gag-protease from 
patients chronically infected with HIV-1 subtype B were normally distributed, with a mean 
of 0.95 (SD=0.14) (Figure 3.16i).  The replication capacities of the 25 subtype B 
recombinants were significantly greater than that of the 406 subtype C recombinant viruses 
constructed from chronically infected patients (Student’s T test; p<0.0001) (Figure 3.16ii).  
Consistent with this difference, the median time to generate high titre virus stocks of subtype 
B recombinant viruses was 12 days (IQR: 12-13 days) compared with a median of 27 days 
(IQR: 23-32 days) to generate subtype C recombinant viruses.                    
 
Since viral replication capacity may be related to stage of disease [247, 251], a subset (n=25) 
of HIV-1 subtype C-infected patients were matched with subtype B-infected patients in 
terms of CD4+ T cell counts and viral loads and the analysis repeated.  The replication 
capacities of this subset (average replication capacity=0.65; SD=0.08) were still significantly 
lower than the replication capacities of the subtype B viruses (Mann-Whitney U-test; 
p<0.0001) (Figure 3.16iii).                              
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Figure 3.16 Comparison of replication capacities of recombinant viruses encoding 
subtype B and C Gag-protease from patients chronically infected with HIV-1 
(i) Histogram showing an approximately normal distribution of subtype B Gag-protease 
recombinant virus replication capacities (normalised to the growth of wild-type NL4-3) with 
a mean of 0.95 and standard deviation of 0.14.   
(ii) Significant difference between HIV-1 subtype B and C Gag-protease-mediated 
replication capacity (Student’s T test).  Lines represent the mean.   
(iii) Significant difference in HIV-1 Gag-Protease-mediated replication capacity between 
subtype B and subtype C samples matched for viral load and CD4+ T cell count (Student’s T 
test).  Lines represent the mean.    
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3.5.2 Subtype-specific Gag mutations 
Specific single amino acids in subtype B [251] and C (Appendix, Table A3) Gag-protease 
significantly associated with viral fitness differences have been identified.  Residues 67A, 
473P and 483L in subtype B Gag were strongly and significantly associated with altered 
replication capacities (p<0.0001 and q<0.0001) [251].  Similarly, 473P in subtype C Gag 
was significantly associated with increased replication capacity (Appendix, Table A3).  The 
consensus amino acids at these codons differ between subtype B and C, which therefore 
might partly explain the observed Gag-protease-mediated fitness difference between the 
subtypes.  In HIV-1 subtype C, 67A, which is strongly associated with decreased fitness in 
subtype B viruses, is the consensus amino acid while in subtype B viruses 67S is the 
consensus.  In subtype B viruses, 483L, which is strongly associated with increased fitness, 
is the consensus amino acid, while there is a deletion at positions 483 and 484 in subtype C 
viruses.  In both subtype B and C viruses, 473P is associated with increased fitness however 
the frequency of this amino acid at position 473 is 1.7% in the subtype C chronically 
infected cohort of the present study and 39% in a subtype B-infected cohort [251].   
 
The fitness effects of these amino acid differences between subtypes B and C were evaluated 
by site-directed mutagenesis.  The insertion of amino acids L and Y at positions 483 and 484 
in subtype C Gag-protease resulted in significantly increased fitness when compared to the 
wild-type or 67S and 473P mutants (ANOVA, Tukey post-hoc tests; p<0.01) (Figure 3.17i).  
Accordingly, the deletion of these amino acids in the subtype B virus NL4-3 resulted in 
decreased replication capacity compared with other mutants and the wild-type (ANOVA, 
Tukey post-hoc tests; p<0.05) (Figure 3.17ii).  However, alterations at residues 67 and 473 
did not appreciably alter fitness in either backbone (Figure 3.17i,ii).             
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Figure 3.17 Replication capacities of HIV-1 encoding subtype-specific mutations in Gag     
Differences in the replication capacities of:  
(i) NL4-3 recombinant viruses encoding wild-type HIV-1 subtype C Gag-protease derived 
from patient SK-254 and SK-254 Gag-protease with introduced mutations 67S, 473P, and 
483L/484Y; and  
(ii) NL4-3 wild-type virus and NL4-3 viruses encoding Gag mutations 67S, 473A, and 483-
/484-.   
ANOVA with Tukey post-hoc tests was used to test for significant differences in replication 
capacities between wild-type and mutant viruses.  Asterisks above mutant groups indicate 
significantly altered replication capacity when compared with the wild-type group, while 
asterisks with a bar indicate significant differences between various mutant groups.  The 
number of asterisks denotes the level of significance, namely, p<0.05 (*), p<0.01 (**) and 
p<0.001 (***).         

































































































































3.6 HLA-B*81-associated mutations  
Since recombinant viruses encoding HIV-1 subtype C Gag-protease from individuals with 
the protective allele HLA-B*81 had significantly reduced fitness (Section 3.2.2), and the 
B*81-associated mutation T186S in the TL9 epitope was strongly associated with reduced 
replication capacity (Section 3.2.5.4), mutagenesis was performed to confirm the fitness cost 
of T186S.    In addition, since viruses with T186S and either Q182S or T190X (also HLA-
B*81-associated mutations) were significantly fitter than those with T186S alone (Section 
3.2.5.5), suggesting that they might function as compensatory mutations, these mutations 
were introduced alone and in combination into a subtype C Gag-protease (SK-254).  The 
location of these residues in the Gag capsid is shown in Figure 3.18.  The generation of the 
following mutants failed:  186S, 186S/182S, and 186S/190A.  The remaining mutants – 
182S, 190A, 190I, and 186S/190I – were successfully generated and their replication 
capacities were lower than that of the wild-type virus, although only the 182S and 186S/190I 
mutants were significantly less fit than the wild-type virus (ANOVA, Tukey post-hoc tests; 
p<0.01) (Figure 3.19i).   
 
The failure to generate mutant viruses containing 186S, with the exception of 186S/190I, 
was not inconsistent with the hypothesised fitness cost of 186S.  However, to further clarify 
the role of these mutations in viral fitness, they were introduced into wild-type NL4-3 since 
NL4-3 is a highly fit laboratory strain of HIV-1, thereby presumably increasing the chances 
of successful generation of all mutant viruses.  All mutants were successfully generated, 
however, the mutant 186S/190I virus was obtained by a modified electroporation protocol 
(Section 2.2.2.4).  All mutants, except 182S, were significantly less fit than wild-type NL4-3 
and the mutant 182S was significantly fitter than mutants 186S, 190I, 186S/182S, and 
186S/190I (ANOVA, Tukey post-hoc tests; p<0.05) (Figure 3.19ii).  In contrast, the 182S    
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Figure 3.18 Structure of the HIV-1 Gag p24 capsid 
Gag residues 182, 186, and 190 are highlighted in yellow.  Helices are represented by 
cylinders in green, strands are represented by arrows in brown and coils are shown in blue.  
Modified from structure 1GWP (Tang (2002) [276]) viewed in Cn3D 
(http://www.ncbi.nlm.nih.gov/Structure/CN3D [277]).  
































Figure 3.19 Replication capacities of HIV-1 encoding HLA-B*81-associated mutations 
in Gag     
Differences in the replication capacities of:  
(i) NL4-3 recombinant viruses encoding wild-type HIV-1 subtype C Gag-protease derived 
from patient SK-254 and SK-254 Gag-protease with introduced mutations 190A, 190I, 182S, 
and 186S/190I; and 
(ii) NL4-3 wild-type virus and NL4-3 viruses encoding Gag mutations 186S, 182S, 190A, 
190I, 186S/182S, 186S/190A, and 186S/190I. 
ANOVA with Tukey post-hoc tests was used to test for significant differences in replication 
capacities between wild-type and mutant viruses.  Asterisks above mutant groups indicate 
significantly altered replication capacity when compared with the wild-type group, while 
asterisks with a bar indicate significant differences between various mutant groups.  The 
number of asterisks denotes the level of significance, namely, p<0.05 (*), p<0.01 (**) and 
p<0.001 (***).         
HIV-1 – human immunodeficiency virus type 1; HLA – human leukocyte antigen; Gag – group specific antigen; SK – 













































































































































• • • 










mutation in SK-254 Gag-protease significantly decreased fitness (Figure 3.19i).  NL4-3 
mutants 186S and 186S/182S were less fit than mutants 190I, 190A, 186S/190A, and 
186S/190I, although this was only statistically significant when comparing mutants 
186S/190A and 186S/182S (ANOVA, Tukey post-hoc tests; p<0.05) (Figure 3.19ii).  This 
supports a fitness cost associated with 186S and suggests that 190A rather than 182S may 
partially, although weakly, compensate for the fitness cost of 186S.  Overall, none of the 
mutations, co-varying with 186S, that were tested here significantly or strongly compensated 
for the fitness cost of 186S.   
 
Since a modified electroporation protocol was used to make a small minority (3) of the 
mutants/recombinant viruses in the latter stages of the present project, the fitness of 186S 
mutants that were made by both the original and modified protocols were compared, and 
found to be the same (Student’s T test; p=0.81) (Figure 3.20).  This indicates that the use of 










Figure 3.20 Replication capacities of 186S mutants generated by the original and 
modified electroporation protocols 
Graph showing no significant difference between the replication capacities of 186S mutant 












































































































CHAPTER 4 – DISCUSSION 
4.1 Impact of HLA on HIV-1 replication capacity 
HLA class I profile is the strongest genetic correlate of differential rates of disease 
progression in HIV-1-infected individuals; however the mechanisms underlying HIV-1 
control by protective HLA alleles are not fully understood.  These mechanisms could involve 
the targeting of functionally important epitopes in HIV-1 Gag, resulting in selection of 
escape mutations that significantly attenuate HIV-1 and slow disease progression.  
Therefore, the impact at the population level of HLA-mediated immune pressure in Gag on 
HIV-1 replication capacity and pathogenesis was investigated in the present study.  
 
4.1.1 Protective HLA alleles: HLA-B*81 
The results showed an association between protective HLA alleles (HLA-B*57, HLA-
B*5801, and HLA-B*81), especially HLA-B*81, and lower Gag-protease-mediated 
replication capacities in HIV-1 subtype C chronic infection. Since, (i) protective HLA alleles 
were associated with lower viral loads, and (ii) Gag-protease-mediated replication capacity 
correlated with viral loads even on removal of protective HLA alleles from the analysis and 
within individuals with protective alleles, the possibility that HLA alleles and replication 
capacity were indirectly related to each other through association with viral load cannot be 
excluded.  Arguing against this possibility, HLA-B*81 was by far the most strongly 
associated with lower replication capacity even though HLA-B*5703 positive individuals 
had a lower average viral load than HLA-B*81 positive individuals.  Furthermore, several 
observations from the present study as well as previous studies [33, 187, 211-213, 229, 251] 
are consistent with a direct influence of HLA alleles on viral replication capacity.  First, in 
the present study, Gag-protease-mediated replication capacity varied significantly between 
the different HLA-B but not HLA-A or HLA-C alleles, supporting a direct effect of HLA-
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driven sequence variability on replication capacity since HLA-B alleles have been shown to 
exert the greatest selection pressure on HIV-1 [170].  Second, increasing numbers of HLA-
associated mutations, particularly those associated with HLA-B alleles, in or flanking Gag 
epitopes (likely HLA-selected escape mutations) generally correlated with decreased HIV-1 
replication capacities in the present project (in both recent and chronic infection), and similar 
correlations were observed in an independent study [251].  Third, specific mutations in Gag 
epitopes that are selected by protective alleles have been demonstrated to significantly 
decrease HIV-1 replication capacity [33, 187, 211-213].  Two of these mutations, namely 
242N (associated with HLA-B*57/B*5801) and 163G (associated with HLA-B*57), were 
associated with lower replication capacities in the early HIV-1 infection cohort of the present 
study.  In addition, in the chronic infection cohort studied here, the 186S mutation present in 
the HLA-B*81-restricted epitope TL9 (residues 180-188; previously described as one of the 
key Gag epitopes under strong selection pressure by protective HLA alleles with variance 
mainly at residues 182 and 186 [174]), was identified as most strongly associated with lower 
replication capacities, thereby providing a possible mechanism for HLA-B*81 influence on 
HIV-1 replication capacity.  These findings, namely the association of HLA-B*81 and the 
186S mutation with lower Gag-protease-mediated fitness, were recently (in 2011) 
reproduced in a cohort of HIV-1 subtype C infected patients from Bloemfontein, South 
Africa [246].  Interestingly, in the present study, one common HLA allele (HLA-A*3001), 
not typically associated with HIV-1 control, was associated with lower Gag-protease-
mediated replication capacities. Taking the results together, it seems likely that HLA alleles, 
to a greater extent protective HLA alleles and in particular HLA-B*81, may influence Gag-
protease-mediated replication capacity through HLA-restricted CD8+ T cell-mediated 
selection pressure.     
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4.1.2 HLA-B*81 associated mutations: 186S 
Since the HLA-B*81-associated 186S mutation in the TL9 epitope was strongly associated 
with reduced viral replication capacity, this mutation was introduced by site-directed 
mutagenesis into a laboratory-adapted strain of HIV-1 to directly test the consequences of 
this mutation for HIV-1 replication.  A significant deleterious effect of 186S on HIV-1 
replication was confirmed.  Consistent with this data, residue 186 in HIV-1 Gag has 
previously been classified as a reverting mutation site, at which mutations revert on 
transmission to a host lacking the HLA allele that selected them, presumably due to a fitness 
cost [209].  Furthermore, introduction of 186A, a rare naturally occurring variant at this 
codon (observed at a frequency of 0.5% in the SK cohort), into HIV-1 previously resulted in 
defective virus replication [70, 279].   
 
The mechanisms involved in decreased replication capacity of the 186S mutant are 
unknown. There are however previous detailed reports of defective virus replication 
following introduction of 186A (or capsid residue 54A) into HIV-1 [70, 279] and similar 
mechanisms may apply to 186S.  Although residue 186 occurs outside the CypA binding 
loop, the defective phenotype (186A) is dependent on the presence of CypA and replication 
of the mutant is significantly enhanced by addition of the CypA inhibitor, cyclosporin A 
(CsA) [279].  It has been proposed that CypA protects HIV-1 from an unknown host 
restriction factor in human cells, possibly through modulating capsid structure following 
binding [34, 279] (Section 1.3.3).  Thus these studies may suggest that the 186A mutant is 
inhibited by an unknown host restriction factor in a CypA-dependent manner through 
alteration of the CypA-capsid interaction [279].  However, since CsA did not fully restore 
replication capacity of the mutant to wild-type levels, there may be other mechanisms 
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involved.   Consistent with this, 186A reduced the efficiency of capsid formation [70], 
resulted in unstable capsids, and also modestly reduced reverse transcription [279].  
   
In the present study, it was observed that viruses harbouring 186S in the presence of other 
HLA-B*81-associated mutations, 182S and 190X, replicated better than those with 186S 
alone (although 182X was also individually associated with lower viral replication 
capacities), suggesting that 182S and 190X may partially compensate for the fitness cost of 
186S.  However, site-directed mutagenesis experiments in a laboratory-adapted HIV-1 strain 
revealed that 182S did not increase fitness in the presence of 186S, and while mutations at 
position 190 tended to increase the fitness of 186S mutants, this was not statistically 
significant.  In support of a compensatory role (albeit very weak) for 190X and not 182S, in 
the cohort analysed here, mutations at codon 190 occurred in conjunction with 186S in 13 
out of 18 cases (72%) and only in 2 cases (out of 25 cases) without 186S in HLA-B*81 
positive individuals, while 182S only occurred in conjunction with 186S in 7 out of 21 cases 
(33%) and mutations at residue 182 in the absence of 186S were common  in HLA-B*81 
positive individuals (occurring in 52% of sequences).  The close proximity of residues 186 
and 190, which occur parallel to one another in a helix structure (Figure 3.18), may explain 
the slight replication advantage observed when both positions, rather than position 186 
alone, were mutated.   
 
Overall, no evidence was found that mutations co-varying with 186S significantly and 
substantially compensate for the fitness cost of this mutation. Although, since there were a 
few instances in which Gag-protease recombinant viruses harbouring 186S in the natural 
Gag-protease background had average to high replication capacities, the possibility that 
mutations at other residues not identified as co-varying specifically with 186S might be an 
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important part of the interaction with HLA-B*81-associated mutations cannot be excluded.  
However, consistent with the hypothesis that the 186S mutation is difficult to compensate, 
Huang et al. (2011) showed an association of 186S with higher CD4+ T cell counts and 
evidence for its reversion (probably concurrent with immune relaxation) at extremely low 
CD4+ T cell counts (<100 cells/mm
3
) in individuals with advanced disease [246].  In 
contrast, that study showed preservation of the HLA-B*57/*5801-associated fitness-
reducing 242N mutation, likely due to the development of compensatory mutations that 
resulted in increased Gag-protease-mediated replication capacity at extremely low CD4+ T 
cell counts.   
 
The apparent lack of effective compensation for HLA-B*81-associated 186S mutation and 
efficient eventual compensation for HLA-B*57/B*5801-associated 242N mutation may also 
explain the particularly strong association between HLA-B*81 and lower replication 
capacity, relative to HLA-B*57/B*5801, in HIV-1 subtype C chronic infection.  A parallel, 
companion study on individuals recently and chronically infected with HIV-1 subtype B 
[251] lends support to this idea.  That study showed an association between protective HLA 
alleles (namely HLA-B*13, HLA-B*27, HLA-B*57, and HLA-B*5801), as well as 
increasing numbers of host HLA-associated polymorphisms, and lower Gag-protease-
mediated replication capacities in early infection but not in the very late chronic stage of 
infection.  This suggests that the development of compensatory mutations over the course of 
infection diminished associations between HLA-mediated immune pressure and replication 
capacity.  The lack of such significant associations in the chronic infection cohort of that 
study while the presence of such associations in the present study may be at least partly 
explained by the notably earlier stage of chronic infection of the present study cohort, as 
evidenced by considerably higher average CD4+ T cell counts.           
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Interestingly, in a recent study, the number of public T cell clonotypes specific for SIV Gag 
CM9 (residues 181-189), which occurs in the same region as HLA-B*81-restricted TL9 
(residues 180-188) and is restricted by the protective allele Mamu-A*01, correlated strongly 
and negatively (r
2
= -0.71) with viral set point in rhesus macaques [280].  This suggests that 
the CD8+ T cell targeting of CM9 may result in slower SIV disease progression, which 
might be partly explained by fitness constraints since an escape mutation in CM9 was 
previously shown to significantly reduce SIV fitness [281].  It should be noted though that 
the 186S mutation in the HIV-1 TL9 epitope was not associated with lower viral loads in the 
present study of HIV-1 chronic infection (data not shown).  In fact, in HLA-B*81 positive 
individuals only, there was a trend towards higher viral loads in individuals harbouring the 
186S mutation.  It should also be noted that, although 186S was strongly associated with 
reduced replication capacity, there was no difference in the replication capacities of viruses  
with or without 186S in HLA-B*81 positive individuals, and since there was no strong 
evidence for compensation of the 186S mutation, this may suggest that other mutations 
selected by HLA-B*81 are also responsible for the lower fitness associated with this allele.  
In fact, mutations at the HLA-B*81-associated codon 182 were also significantly linked to 
lower replication capacity, although this was not as pronounced as for 186S.  It may be that, 
while decreased viral fitness due to HLA-driven mutations could be beneficial in HLA-B*81 
positive individuals, the development of the 186S mutation may decrease the effectiveness 
of CD8+ T cell responses to TL9 that may be important in maintaining low viral loads, and 
that a balance between fitness costs and effective CD8+ T cell responses is important in 
determining clinical outcome (discussed in Section 4.2).     Huang et al. (2011) suggest that 
viral fitness influences HIV-1 disease progression:   they found  that reversion of 186S, 
compensation of fitness-reducing mutations, and generally increased viral fitness were 
associated with advanced disease, and suggest that increased viral fitness is a mechanism of 
progression to AIDS [246].  The relationship between HIV-1 Gag-protease-mediated fitness, 
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in particular HLA-driven fitness costs in Gag, and HIV-1 disease progression is considered 
next. 
 
4.2 Impact of HIV-1 replication capacity on disease progression 
4.2.1 Chronic infection: cross-sectional and longitudinal analyses 
The cross-sectional correlation of lower Gag-protease-mediated replication capacities with 
lower baseline viral loads and higher CD4+ T cell counts in the chronically infected cohort 
of the present study is in accordance with Huang and co-workers’ (2011) recent 
demonstration of increased Gag-protease fitness at extremely low CD4+ T cell counts, also 
in cross-section [246].  A parallel study on individuals chronically infected with HIV-1 
subtype B yielded similar findings [251].  These results suggest that Gag-protease-mediated 
replication capacity increases with HIV-1 disease progression.  This finding is also 
consistent with a previous study that showed increasing fitness of HIV-1 isolates with 
disease progression [247]. 
 
Since the correlation between markers of disease progression and replication capacity in the 
chronically infected cohort was cross-sectional, it could not be determined from this result 
whether increasing HIV-1 fitness results in further disease progression or if it is merely a 
consequence of disease progression.  Therefore, the relationship between replication capacity 
at baseline and subsequent rate of CD4+ T cell decline was analysed.  No correlation 
between these two parameters was observed.  A potential explanation for the lack of 
correlation may be that replication capacity is not static and the development of 
compensatory mutations at a time point later than that measured may influence the 
subsequent rate of CD4+ T cell decline.  Data from previous studies suggest that mutations 
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with a fitness cost are readily compensated [33, 212, 213, 251].  The lack of correlation 
between replication capacity and rate of CD4+ T cell decline could therefore indicate that 
Gag-protease-mediated replication capacity measured in chronic infection does not have an 
enduring impact on the rate of disease progression.  An alternative explanation for the lack 
of correlation could be that replication capacity significantly influences disease progression 
but that a balance between replication capacity and Gag CD8+ T cell responses influences 
clinical outcome i.e. the relationship is not unidirectional.  Accumulation of escape 
mutations in HIV-1 carries a fitness cost to the virus, but at a certain level of accumulation, 
the disadvantage to the virus is offset by the advantage of escaping effective CD8+ T cell 
responses that were holding replication in check, resulting in increased viral loads and 
accelerated disease progression despite a replication-deficient virus [187, 228].  It should 
also be noted that rate of CD4+ T cell decline was previously described to explain only 3% 
of the variability in time to AIDS, probably due to the large variance in the CD4+ T cell 
count slopes [282] (Section 1.6.1).  Therefore, factors influencing disease progression may 
not correlate as strongly with this measurement as with viral set point, for example, which is 
a strong correlate of time to AIDS [283] (Section 1.6.1). 
  
4.2.2 Recent infection: longitudinal analyses 
To better assess the impact of Gag-protease-mediated replication capacity on the rate of 
disease progression, the replication capacity of the early virus in recent infection was related 
to the subsequent viral set point as well as rate of CD4+ T cell decline.  A weak but 
significant association between reduced Gag-protease-mediated replication capacities in 
early infection and lower viral set points, as well as a trend of correlation between lower 
replication capacities and slower rates of CD4+ T cell decline, was found.  A recent study (in 
2010), comparing controllers and non-controllers infected with HIV-1 subtype B, 
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demonstrated considerably stronger correlations between Gag-protease-mediated replication 
capacity in early infection and disease outcome than were found in the present study [226].  
This difference could possibly be partly explained by the lack of extreme phenotypes at the 
lower end of the clinical spectrum in the present study.  The observation of a trend of 
association between Gag-protease-mediated replication capacity and rate of CD4+ T cell 
decline in early infection in the present study, while the absence of such an association in 
chronic infection, might suggest that replication capacity in early infection has more far-
reaching effects than that measured in chronic infection.   
 
To analyse the impact of HLA-driven fitness costs in Gag on disease progression, the 
number of HLA-associated Gag polymorphisms was related to replication capacity and viral 
set point in recently infected patients.  The number of HLA-associated polymorphisms 
(mainly attributed to HLA-B) in or adjacent to Gag epitopes was inversely associated with 
replication capacity, however, unexpectedly the presence of host-specific HLA-B-associated 
polymorphisms was positively associated with viral set point.  One contributing factor could 
be the presence of compensatory mutations since no significant relationship with viral set 
point was observed when the analysis was limited to polymorphisms in or adjacent to 
epitopes.  Further, although the host expressed the required HLA alleles to select these 
polymorphisms, it is unlikely that many were selected by the host at such an early stage of 
infection and they were thus presumably largely inherited.  Usually, in the Gag protein, the 
fastest selection occurs in epitopes restricted by the protective HLA-B*57/B*5801 within 
about six months of infection [106, 284] (but on average at 13 months post-infection in 
another study [187]) and reversion events rather than selection of new mutations in Gag 
predominate in early infection [187, 285].  Further, Schaefer et al. (2009) show that in linked 
transmission pairs most of the HLA-associated polymorphisms present at one year after 
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infection were transmitted and not selected by the host [286], and it is estimated that 
approximately 18% of the possible mutations in Gag are present in transmitted viruses on 
average [287].  Therefore, these results indicate a host disadvantage to inheriting 
polymorphisms which the host could have newly selected, likely due to diminished early 
CD8+T cell responses to the mutated epitopes, as suggested in previous studies [187, 207].   
 
Analysis of Gag sequences derived from individuals with protective HLA alleles in recent 
infection yielded similar conclusions.  Gag-protease recombinant viruses derived from 
individuals with protective HLA alleles in early infection tended to have reduced replication 
capacities, but viral set points were not significantly lower; therefore, a benefit to reduced 
Gag-protease function in these particular individuals was not overall evident.  In fact, in 
individuals with protective HLA alleles, viral set points were overall significantly higher in 
those who had viruses with associated Gag mutations than in those who did not.  Conversely, 
in six of the seven subjects with protective HLA alleles for whom Gag-protease 
amplification failed here (but were sequenced previously [278]), there were no Gag 
mutations associated with the hosts’ protective HLA alleles and the viral set points were 
considerably low.   
 
One possible explanation is that some early selection of fitness-reducing mutations occurred 
in individuals with protective alleles and was disadvantageous due to subsequent reduction 
in CD8+ T cell responses.  The possibility of some early selection of fitness-reducing Gag 
mutations in individuals with protective alleles does exist, and has been reported as early as 
45 days post-screening, but the average reported time of selection in another study was 13 
months [187], suggesting that in the present study sequences were likely to be representative 
of the transmitted virus in most cases.  Although a parallel study on individuals recently 
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infected with HIV-1 subtype B showed significantly reduced Gag-protease-mediated 
replication capacities in individuals with protective HLA alleles, the least fit viruses with 
associated fitness-reducing mutations were sampled from a later date post-infection than the 
fitter viruses [251].  Furthermore, although there was a trend towards lower replication 
capacities from individuals with protective HLA alleles in the present study, which may 
suggest some early selection pressure, there was an amplification bias.  The viruses from 
individuals with protective HLA alleles who had higher viral set points were preferentially 
amplified, and this could suggest that there was preferential amplification of viruses with 
inherited polymorphisms that reduced fitness but precluded effective CD8+ T cell responses, 
leading to a trend of association between fitness and protective HLA alleles in early infection 
in the present study.        
 
It is likely that in most cases here, the protective HLA-associated polymorphisms were 
inherited rather than selected by the hosts’ protective alleles thereby resulting in weakened 
early CD8+ T cell responses to key epitopes and a disadvantage to the host.  Supporting this 
hypothesis, 23 out of 50 individuals with non-protective HLA alleles harboured mutations 
associated exclusively with protective HLA alleles indicating high level transmission of 
these polymorphisms in sub-Saharan Africa.  A notable example is the case of 242N which 
was present in 17 viruses out of which 15 were derived from individuals without the 
associated protective HLA-B*57/B*5801.  Further, in one patient with HLA-B*5801 and a 
high viral set point (5.46 log10 copies/ml), at 26 days post-infection two associated mutations 
were present (146L and 242N) at which point none of the viruses in other studies had shown 
evidence of adaptation in Gag [106, 251].  It is also notable that in a patient with HLA-B*81 
and a high viral set point (4.92 log10 copies/ml), the 186S mutation in the TL9 epitope was 
present, however, there was no detectable initial CD8+ T cell response to this epitope (data 
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not shown) suggesting it may have been inherited rather than selected.  Yet in another patient 
(AS2-0945) with HLA-B*5703 and a low viral set point (3.46 log10 copies/ml), all HLA-
B*57-restricted epitopes were initially wild-type and one year later mutations 146P and 
242N had been selected with a concomitant decrease in fitness, although there was also a 
coincident rise in viremia.  A similar rise in viremia following selection of 242N was 
recently reported in a single patient [278], however decreased viremia following early 
selection of the HLA-B*57-associated mutations 242N and 147L has been reported in 
several patients [187].   Taken together, these data imply that the benefit in an individual 
with a protective allele is derived from an initial effective CD8+ T cell response and that the 
subsequent selection of fitness-reducing Gag mutations is likely to, but may not necessarily, 
contribute to clinical benefit.  Furthermore, results suggest that CD8+ T cell-driven benefit 
appears diminished or even lost when protective HLA-associated polymorphisms in Gag are 
inherited by individuals with the relevant protective alleles, despite reduced viral replication 
capacity.                  
 
The high transmission prevalence of protective HLA-associated polymorphisms in the 
populations studied supports recent evidence that mutations selected by protective alleles 
may be accumulating over time [288].  This may be particularly evident in the present cohort 
since HIV infection is most prevalent in sub-Saharan Africa [10] (Section 1.1).  In KwaZulu-
Natal there is an explosive rate of infections in young adults probably fuelled by the high 
viral loads in acute infection [289] and consequently transmission may often occur early in 
infection before such mutations revert.  The median reversion time reported for HLA-B*57-
associated Gag mutations in HLA-mismatched recipients was 23 months [187] and for 242N 
mostly between six and 24 months [208].  The consequence of this is firstly, that HIV-1 is 
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being attenuated over time and secondly, that the association of current protective alleles 
with slower disease progression may eventually diminish [288].  
 
Longitudinal measurements of replication capacities and CD8+ T cell responses to Gag 
epitopes in 13 recently infected patients also support the importance of both CD8+ T cell 
responses and viral replication capacity in influencing disease progression.  For example, in 
one patient viral replication capacity was low but there was a lack of CD8+ T cell Gag 
responses and uncontrolled viremia.  In others, CD8+ T cell Gag responses were present but 
viral replication capacities were high and viremia was uncontrolled.  Two patients who had 
low viral set points showed low replication capacities and either CD8+ T cell responses to 
key epitopes (such as TW10) or a very broad Gag response, which has previously been 
suggested to be beneficial [195].  It should be noted that likely explanations for viral set 
point based on CD8+ T cell responses or viral replication capacity could not be made for all 
patients.  Other HIV-1 regions, such as Env [222] and protease-reverse transcriptase [224], 
significantly contribute to overall viral replication capacity and may help to explain 
differences in viral control [290].  Indeed, Env ranks among the most important determinants 
of viral fitness [222, 240] and several studies provide evidence for overall HIV-1 fitness as a 
significant determinant of disease progression [218, 224] (Section 1.6.5.2.1).            
 
Overall, results suggest that Gag-protease-mediated fitness has an impact on HIV-1 disease 
progression, but that a balance between viral fitness and effective CD8+ T cell responses 
together influence disease.  Viral fitness in early infection may have a greater influence than 
that measured in chronic infection, and HIV-1 fitness tends to increase with disease 
progression (which may partly contribute to progression to AIDS).  Since protective HLA 
alleles are associated with lower Gag-protease-mediated replication capacities, and viral 
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fitness influences disease progression, viral attenuation may be a mechanism by which 
protective HLA alleles slow disease progression.  These results support the idea of a vaccine 
strategy in which immune responses are directed towards Gag with the aim to attenuate HIV-
1 and slow disease progression (discussed further in Section 4.6).  
  
4.3 Identification of mutations with impact on HIV-1 replication capacity 
In such a vaccine strategy it would be desirable to identify Gag mutations that have 
significant impact on HIV-1 replication capacity, and more specifically, regions of Gag that 
would have the greatest fitness impact if mutated.  In the present study, several Gag 
mutations associated with significant changes in replication capacity were identified. Site-
directed mutagenesis experiments may constitute future work to confirm these associations 
with viral replication capacity. 
 
Notably, several of the Gag mutations significantly associated with alterations in replication 
capacity were HLA-associated.  As discussed earlier (Section 4.1), the 186S mutation linked 
to the protective HLA-B*81 allele was the most strongly associated with lower replication 
capacity.  As shown previously [33, 187, 211, 212], Gag p24 mutations 163G and 242N, 
selected by the protective alleles HLA-B*5801 and/or HLA-B*57, were significantly 
associated with lower replication capacity and there was evidence for increased replication 
capacity with accumulation of previously described [33, 251] compensatory mutations, 
especially 248T.  Previous reports suggest that the mechanism of replication defects induced 
by 186S and 242N may be related to altered interaction with the host factor CypA [33] 
(Sections 1.6.5.1 and 4.1.2), which plays an important role in the HIV-1 replication cycle 
[34] (Section 1.3.3).  Two of the other HLA-associated codons linked to altered replication 
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capacities, codons 223 and 256, occur in and within 6 residues, respectively, of loops in Gag 
p24 that were previously described to interact with host cellular factors that determine HIV-1 
host tropism [291].  A recent study included 223V and 256V in a group of eight 
polymorphisms suggested to be compensatory since they co-vary with polymorphisms in 
Gag p24 that were shown or inferred to carry fitness costs [292].  Accordingly, in the early 
infection cohort of the present study, V instead of the consensus amino acid I [267] was the 
most frequent residue at codon 223, and 223I was associated with decreased replication 
capacity.  However, the 256V polymorphism correlated negatively with replication capacity.  
It is notable that several of the HLA-associated codons linked to replication capacity 
differences were associated with common HLA alleles or those not typically associated with 
HIV-1 control.  A recent study has also reported attenuating mutations in Gag (specifically 
Gag p24) associated with the common allele HLA-C*03, which is not associated with viral 
control [293]. 
      
Several of the Gag codons identified in the present study as significantly associated with 
altered replication capacities in either chronic or recent infection (or both) have previously 
been implicated in specific roles in the HIV-1 replication cycle (discussed in Section 1.3).  
Codons 28, 30, 31, 110, 111, and 114 are part of NLSs in Gag p17 [41].  Some of these 
mutations could therefore disrupt the NLS and adversely affect replication capacity; 
however, only mutations at codons 31, 110, and 114 were associated with decreased 
replication capacity in the present study.  Codons 15, 20, 28, 30, and 31 also form part of the 
basic domain involved in membrane binding, although codons 30 and 31 specifically are not 
basic residues [58].  Accordingly, mutation of the basic residues at positions 15 (K) and 20 
(R) were associated with decreased replication capacity, while mutation of the basic residue 
H to another basic residue R at position 28 increased replication capacity.  Mutation of the 
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consensus amino acid at codon 31 was associated with decreased replication capacity 
perhaps since this position is involved in Env glycoprotein incorporation [48]; however 
mutation of codon 35, also involved in Env glycoprotein incorporation [48], was associated 
with increased replication capacity.  Mutations at codon 224 and an uncommon mutation at 
codon 223, both in the CypA binding loop (which plays an important role in the life cycle 
[34] [Section1.3.3]), were linked to decreased fitness.  Codons 374, 377, 381, and 382 are in 
the p2/p7 cleavage site which controls the rate and order of Gag cleavage [249], and this 
may explain why these codons were significantly associated with changes in replication 
capacity.  In addition, a mutation at residue 453 in the p1/p6 cleavage site was linked to 
lower replication capacity.  Mutation of two of the basic residues (397 and 411) in Gag p7 
required for budding [65] and partly responsible for RNA binding (as part of the 
hydrophobic plateau [53]), were associated with lower viral fitness.  Codon 466 is one of the 
codons mediating incorporation of Vpr into virions [64] and a mutation at this residue was 
linked to decreased fitness.  Mutation of residue 485 in the Alix binding L-domain, which 
mediates budding [67], was however associated with increased fitness.  Thus, the disruption 
of specific functions mediated by codons listed above may explain some, although not all, of 
the mutation-fitness associations identified in the present study.                    
     
In general, the results from the present study support the hypothesis that mutations occurring  
at conserved residues/regions are more likely to result in a fitness cost or have the greatest 
fitness impact:  HLA-associated escape mutations at conserved sites were associated with 
lower replication capacities, and most of the mutations significantly associated with altered 
replication capacities in conserved Gag p24 decreased replication capacity while most in the 
less conserved Gag p17 increased replication capacity.  In agreement with these data, in an 
independent South African cohort, beneficial HLA alleles were associated with strong 
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selection at key epitopes which occurred mostly in Gag p24 [174] and there is evidence that 
HLA-B*57 mediates its protective effect mainly through attenuating mutations in Gag p24 
[227].  Further, the breadth of Gag p24 but not p17 or p15 CD8+ T cell responses in HLA-
B*13 positive individuals was significantly associated with decreasing viral load [188].  The 
direct relationship between HIV-1 replication capacity and the entropy of HLA-associated 
mutated sites in the present study is also supported by the recent finding that escape 
mutations in conserved Gag p24 carry significant fitness costs while most of the escape 
mutations in the highly variable Env protein are fitness neutral or increase fitness [104]. 
 
Another interesting result in the present study may be consistent with the finding that 
mutations in more conserved regions carry greater fitness costs than those in variable 
regions.  Gag p17 and p7 were significantly more divergent from consensus than the p24 
region, i.e. significantly more mutations occurred in variable p17 and p7 regions than in the 
conserved p24 region, and percentage similarity to consensus in both p17 and p7 was overall 
negatively correlated with fitness, while there was no correlation for p24.  This resulted in an 
overall negative correlation between the number of amino acid differences from consensus C 
Gag and viral fitness, i.e. a greater number of changes from consensus was associated with 
increasing viral fitness.  In summary, the majority of mutations in HIV-1 arise in variable 
regions and are likely to have no/little fitness cost or actually increase fitness. 
 
4.3 Impact of Gag-protease on overall HIV-1 replication capacity 
An important finding of the present study was the moderately strong and significant 
correlation between the fitness of 16 HIV-1 isolates and the fitness of recombinant viruses 
encoding only the Gag-protease of these isolates.  This suggests that, in addition to Env 
[222] and protease-reverse transcriptase [224], variations in HIV-1 Gag-protease sequence 
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significantly impact overall viral fitness.  This is consistent with the important role that Gag 
plays in all stages of the HIV-1 replication cycle (reviewed in Section 1.3).  Since Gag-
protease recombinant viruses generated from individuals with protective HLA alleles had 
significantly lower replicative capacities, this result further supports overall virus attenuation 
through targeting of Gag by protective HLA alleles as a mechanism of slower disease 
progression.  These data are also consistent with the idea that, in a vaccine strategy to reduce 
viral fitness, targeting the Gag gene should effectively impact overall viral fitness following 
the selection of attenuating mutations. 
 
4.4 Impact of Gag-protease on HIV-1 replication capacity in different subtypes  
Given the importance of Gag in HIV-1 replication and as a target of effective immune 
responses, the contribution of Gag-protease function to the dramatically lower fitness of 
subtype C isolates when compared with subtype B isolates [221] was investigated in the 
present study.  Gag-protease NL4-3 recombinant viruses encoding subtype C Gag-proteases 
were significantly less fit than those encoding subtype B Gag-proteases.  These results 
suggest that the considerable fitness difference observed between subtype B and C isolates 
may not only be explained by Env differences, as suggested by a previous study comparing 
Env gp120 recombinant viruses derived from a single subtype C isolate and subtype B 
isolate [222], and similarly reverse transcriptase differences [294], but also by differences in 
the Gag-protease region.  Since a recent study did not observe differences in protease 
activity between HIV-1 subtype B and C [294], and subtype C protease was previously 
reported to have a higher catalytic efficiency than subtype B protease [295], the Gag protein 
is likely to largely contribute to the results here.  The finding that Gag-protease significantly 
contributes to overall HIV-1 fitness is also consistent with the explanation that Gag-protease 
variability partly explains lower fitness of subtype C viruses when compared to subtype B 
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viruses.  However, an alternative explanation for this result could be that insertion of Gag-
protease into the backbone of another subtype is disadvantageous, which would point to an 
important interaction between Gag-protease and another region of the HIV genome, for 
example Env gp41 [296].  In favour of the former rather than the latter explanation, greater 
similarity of subtype C Gag sequences to the consensus subtype B sequence was not 
associated with fitter subtype C Gag-protease NL4-3 recombinant viruses.  However, further 
fitness studies using a replicating subtype C backbone may be required to exclude the latter 
possibility.   
 
To further investigate the difference between subtype B and C Gag-protease-mediated 
fitness, residues at which amino acids differed between the subtypes and were also linked to 
altered replication capacities in the present study and/or previous studies [251], were 
introduced into a laboratory-adapted strain of HIV-1.  A significant finding was that the 
deletion of Gag residues 483 and 484 from HIV-1 subtype B (since these residues are not 
present in consensus subtype C) substantially decreased replication capacity of HIV-1 
subtype B, and correspondingly, insertion of the subtype B amino acids at these codons into 
HIV-1 subtype C Gag-protease (placed in a subtype B NL4-3 backbone) significantly 
increased replication capacity.  Residues 483 and 484, in a L-domain at Gag residues 483-
492, are essential for binding the Alix host protein [64], which acts in concert with the 
primary budding factor Tsg101, recruited by the L-domain at Gag residues 455-458, to 
mediate viral budding [68] (Section 1.3.8).  It is notable that an unusual mutant with deletion 
at residues 482 and 483, shown to disrupt Alix binding [67], was previously associated with 
non-progressive HIV-1 infection [297].  Fujii and co-workers (2009) recently demonstrated 
significantly reduced particle production and infectivity of Alix-binding domain mutants 
(including a virus mutated at codon 484) with disrupted Alix binding, and this was 
particularly severe in the presence of Tsg101-binding domain mutations, demonstrating an 
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important role for Alix in HIV-1 replication [68].  Although Alix-binding mutations slowed 
viral replication in several cell types including PBMCs, Alix-binding was not essential for 
virus replication in PBMCs, and passaging of mutants increased replication capacity 
concomitant with the development of secondary site mutations in gp120 and gp41 [68].  The 
putative compensatory role of these secondary site mutations is yet to be confirmed by the 
investigators of that study.  Overall, these results may suggest that the subtype-specific 
difference in the consensus amino acids at Gag codons 483 and 484 largely contributes to the 
fitness difference between HIV-1 subtypes B and C, and that this is mediated by altered 
budding efficiency.  But a possibility exists that disrupted Alix binding is compensated for 
by secondary site mutations in other HIV-1 subtype C proteins, and that observed effects 
were due to incompatibility of subtype C and B components.  Future experiments to test this 
possibility may include mutation of these residues in a replicating subtype C backbone. 
       
4.5 Study limitations 
As mentioned, a limitation of the present study was the insertion of subtype C gag-protease 
into a subtype B NL4-3 backbone to test the fitness effects of the introduction of subtype B-
specific mutations into subtype C Gag-protease.  Recombinant viruses constructed using 
clinically-derived HIV-1 subtype C Gag-protease sequences were also a mixture of HIV-1 
subtype B and C genetic components.  It is therefore possible that the fitness of the 
recombinant viruses encoding patient-derived Gag-protease could be a reflection of the 
compatibility of the subtype C Gag-protease with the subtype B backbone and that some 
Gag-protease mutations associated with altered replication capacities might represent those 
that interact with other components of the backbone.  However, the degree of similarity of 
subtype C Gag to subtype B did not associate with the fitness of these subtype C/B 
recombinant viruses.  Furthermore, the fitness of subtype C/B recombinants correlated with 
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viral loads, CD4+ T cell counts, as well as specific HLA alleles in the present study, as did 
subtype B/B recombinants in a parallel, companion study [251], indicating that, despite the 
mixing of subtypes, the assay was biologically and clinically relevant.   
 
The introduction of HLA-B*81-associated Gag mutations (182S, 186S, and 190X), 
identified in clinically-derived subtype C Gag sequences, firstly into a subtype C/B 
recombinant virus and then into a fitter subtype B laboratory strain (due to failure in 
generating some mutants using the subtype C/B recombinant) is also a study limitation.  
Introduction of mutations out of context of the natural sequence background is a general 
limitation of site-directed mutagenesis experiments [236] (Section 1.7.1.1).  However, 
particularly since variability at Gag residues 182, 186, and 190 is rare in HIV-1 subtype B 
viruses (likely because the HLA-B*81 allele is uncommon in Caucasian individuals in 
whom this subtype is most commonly found [298]), a subtype C background would more 
likely reflect the fitness effect of mutations at these residues as they occur naturally.  The 
discrepant results obtained for the 182S mutation in the different backbones used (182S in 
the subtype C/B recombinant significantly reduced fitness with respect to wild-type while 
182S in NL4-3 did not), further increase the desirability of confirmatory experiments in a 
purely subtype C background.  Future experiments may involve identification of a subtype C 
backbone that will replicate adequately in the GXR cell line and may be used to repeat site-
directed mutagenesis of the HLA-B*81-associated Gag mutations. 
 
As discussed in Section 1.7.2, the possibility that viral replication capacity measurements 
might differ if primary cells were used cannot be excluded.  In support of the relevance of 
results obtained in the current assay system, viral replication capacity measurements 
correlated with clinical outcomes and mutations previously shown to have a fitness cost, 
162 
such as 242N and 163G [33, 187, 211, 212], were also associated with lower fitness in the 
present study. Further, although primary cells are not used in the current assay system, it has 
the advantages of using a homogenous population of cells and of being high-throughput [71] 
(Section 1.7.4).   
 
It should also be noted that parameters other than those measured in the present study, such 
as T cell activation, are important markers of disease progression [137] (Section 1.6.1) and it 
remains to be determined whether these additional important parameters that influence HIV-
1 pathogenesis might also correlate with viral fitness.                 
 
4.6 Implications for HIV-1 vaccine design 
The present study strengthens evidence that HLA alleles may drive biologically and 
clinically relevant fitness costs in HIV-1 through selection of immune escape mutations in 
Gag.  This knowledge could be used to design an HIV-1 vaccine to stimulate specific CD8+ 
T cell responses that could result in HIV-1 attenuation, reduce viral set point, slow disease 
course, and reduce transmission at the population level, which may be a more 
realistic/feasible goal than a sterilising vaccine approach [94, 121].  Such a vaccine should 
stimulate CD8+ T cell responses to multiple epitopes in which immune escape mutations 
result in significant fitness costs and avoid including epitopes in which mutations result in no 
fitness cost or increased viral fitness [121, 299, 300].  The identification of Gag amino acid 
variants, many of which were at HLA-associated codons and/or located in CD8+ T cell 
epitopes, that significantly impact viral replication capacity in the present study should aid in 
rational design of a fitness-reducing vaccine.  The fact that some of these variants were 
associated with common HLA alleles, supports the relevance of such a vaccine for the 
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general population.  The data from the present study further indicate that conserved Gag 
epitopes should be targeted in such a vaccine, since mutations in conserved rather than 
variable regions more often resulted in significant fitness costs.  The targeting of multiple 
conserved epitopes should constrain immune escape and only allow partial immune evasion 
(thereby allowing continued immune responses) which would then result in significant 
fitness costs [299, 300].  A vaccine targeting conserved elements has the added advantage of 
overcoming the problem of HIV-1 diversity [299].  Further in support of a conserved 
elements vaccine to maintain immune responses and/or reduce viral fitness, previous studies 
show that HIV-1-infected individuals who target conserved epitopes across the HIV-1 
proteome, including those with common non-protective HLA alleles, have low viral loads 
[191, 192].             
 
Recent work by Dahirel et al. (2011), using methods from quantum physics, has identified 
groups of amino acids in HIV-1 that co-evolve, termed “sectors”, and supports the concept 
of a fitness-reducing HIV-1 vaccine targeting structurally constrained regions [301].   This 
study revealed that there is a particularly vulnerable sector in Gag in which multiple 
mutations are likely to result in low viral fitness.  The authors of that study recommend an 
HIV-1 vaccine including protein segments which cover epitopes (including those targeted 
sub-dominantly by common HLA alleles to achieve broad population coverage) containing 
sites in this sector.  Interestingly, two suitable immunogens with broad population coverage 
suggested are Gag residues 160-188 and 240-277.  These two immunogens are in the 
conserved Gag p24 region (in which mutations were more likely to result in fitness costs in 
the present study) and include residues which were identified, in the present study and/or 
previous studies [33, 187, 211, 212], to carry significant fitness costs when mutated, namely 
163G, 186S, and 242N.  Future work to confirm the findings of Dahirel et al. (2011) [301] 
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could involve testing whether an increasing number of mutations in the vulnerable Gag 
sector correlates with decreased viral fitness measured in vitro.   
 
In addition, the fitness consequences of mutations not occurring naturally in combination 
could be considered for a vaccine strategy aiming to constrain immune escape and reduce 
viral fitness.  A recent study identified 18 pairs of non-covarying (mutually exclusive) 
escape mutations in Gag p24 which resulted in severe fitness defects in combination, and 
could therefore be considered for simultaneous targeting by a HIV-1 vaccine [302].  Such an 
antagonistic pair of HLA-associated escape mutations in a conserved region of Nef also 
reduced replication capacity in combination as well as impairing the pathogenic activities of 
Nef [303].  This highlights that regions in the HIV-1 proteome other than Gag also be 
considered in a fitness-based vaccine strategy. 
       
A potential consequence of a fitness-reducing vaccine strategy is the accumulation of 
immune-driven escape variants at the population level [300].  This may result in the loss of 
immunogenic CD8+ T cell epitopes and diminished vaccine-induced CD8+ T cell immune 
responses, and is a potential drawback of this vaccine strategy [300].  There is already 
evidence, from previous studies [288] and the present study (Section 4.2.2), that fitness-
neutral immune escape mutations selected by common HLA alleles, or fitness-reducing 
escape mutations selected by protective alleles and transmitted prior to reversion or 
stabilised by compensatory mutations, are accumulating at the population level, and vaccines 
may have to be designed accordingly [288].  Another potential challenge of the fitness-
reducing strategy is the development of compensatory mutations that may eventually restore 
or partially restore viral fitness, although the extent of this would probably be dependent on 
the level of viral control achieved [300].  A more thorough understanding of immune-driven 
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fitness costs and compensation and the consequences of this at the individual and population 
levels, is required for the development of an effective fitness-reducing vaccine [300].   
 
The consequences of immune-driven fitness costs in HIV-1 for pathogenesis and the 
implications of this for HIV-1 vaccine design are outlined in Figure 4.1.   
 
4.7 Summary and conclusions 
In summary, the findings of the present study support the hypothesis that HLA alleles, in 
particular the protective allele HLA-B*81, may impact HIV-1 replication capacity through 
driving the selection of attenuating mutations in Gag, and that viral attenuation may result in 
clinical benefit.  The data support that this may be a mechanism of slower disease 
progression in individuals with protective HLA alleles, but also highlight that a balance 
between HLA-associated viral fitness costs and effective CD8+ T cell responses is important 
in determining clinical outcome.  Results also indicate that conserved regions of Gag, 
particularly in Gag p24, be included in a vaccine designed to constrain immune escape and 
reduce viral fitness in the event of escape.  Results suggesting the significant contribution of 
Gag to overall HIV-1 fitness and as a determinant of fitness differences between subtype B 
and C isolates, further support that a vaccine targeting immune responses to specific Gag 
regions could successfully attenuate HIV-1.  In conclusion, the present study showed 
evidence for biologically and clinically relevant fitness costs of naturally occurring HLA-
driven sequence variability in Gag, particularly for protective HLA alleles, and this 
knowledge could possibly be exploited in the design of a fitness-based HIV-1 vaccine.  
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Figure 4.1 Impact of immune escape with fitness costs on HIV-1 pathogenesis and 
implications for HIV-1 vaccine design 
The potential consequences of CD8+ T cell-mediated attenuation of HIV-1 for clinical 
outcome and HIV-1 transmission (in green) and the implications of this for HIV-1 vaccine 
design (in blue) are shown in this figure.  A balance between fitness costs (due to escape) 
and effective CD8+ T cell responses in influencing HIV-1 pathogenesis is highlighted.  The 
dotted lines indicate binding between the CD8 receptor and the HLA class I molecule, and 
between the TCR and epitope complexed with the HLA molecule on the surface of the 
infected cell, leading to cytotoxic and non-cytotoxic antiviral activity.  
HIV-1 – human immunodeficiency virus type 1; CD – cluster of differentiation; HLA – human leukocyte antigen; TCR – T 
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Table A1. HLA-associated amino acids in HIV-1 subtype C Gag-protease 




Consensus p value q value 
Gag Negative B*1503 7 I I <0.0005 0.106 
Gag Positive B*1503 7 V I <0.0005 0.106 
Gag Positive B*1503 11 G G 0.001 0.176 
Gag Negative A*74 12 K K <0.0005 <0.0005 
Gag Positive A*74 12 N K <0.0005 <0.0005 
Gag Negative B*5802 14 D D 0.001 0.176 
Gag Positive B*5802 14 E D 0.001 0.176 
Gag Negative A*74 20 R R 0.001 0.165 
Gag Negative C*06 20 R R <0.0005 0.106 
Gag Positive C*06 20 K R <0.0005 0.001 
Gag Positive A*6801 20 R R <0.0005 0.095 
Gag Positive A*74 20 K R <0.0005 0.042 
Gag Negative C*17 28 H H <0.0005 0.026 
Gag Positive B*13 28 K H <0.0005 <0.0005 
Gag Positive B*42 28 Q H <0.0005 <0.0005 
Gag Positive C*17 28 S H <0.0005 0.056 
Gag Negative C*17 30 M M <0.0005 <0.0005 
Gag Positive B*42 30 K M <0.0005 0.022 
Gag Negative C*0701 31 L L 0.001 0.120 
Gag Negative B*1503 49 G G <0.0005 0.043 
Gag Positive A*3001 54 A S 0.001 0.186 
Gag Positive A*6802 54 T S 0.001 0.116 
Gag Positive B*1402 62 N K <0.0005 0.106 
Gag Positive C*16 67 S A 0.001 0.160 
Gag Positive C*1601 67 S A <0.0005 0.082 
Gag Negative A*01 73 E E <0.0005 0.096 
Gag Negative A*29 79 F Y <0.0005 0.003 
Gag Positive A*2902 79 Y Y <0.0005 0.001 
Gag Negative A*34 90 K E <0.0005 0.040 
Gag Negative A*74 91 R K <0.0005 0.037 
Gag Negative C*06 91 R K <0.0005 0.036 
Gag Negative B*4101 93 E E 0.001 0.117 
Gag Positive A*74 93 G E <0.0005 0.110 
Gag Positive B*08 93 K E <0.0005 0.036 
Gag Positive A*3001 103 R K 0.001 0.165 
Gag Positive B*5801 106 K E <0.0005 0.036 
Gag Negative B*44 121 A D <0.0005 0.030 
Gag Positive C*04 128 A V <0.0005 0.115 
Gag Negative A*3009 138 L L <0.0005 0.001 
Gag Negative C*06 146 P A <0.0005 <0.0005 
Gag Negative B*1510 146 A A 0.001 0.176 
Gag Negative B*57 146 A A <0.0005 0.019 
Gag Negative B*4201 146 P A <0.0005 <0.0005 
Gag Positive B*57 146 P A <0.0005 0.096 
Gag Negative A*2911 147 I I <0.0005 0.004 
Gag Negative B*57 147 I I <0.0005 0.002 
Gag Negative B*1503 147 L I 0.001 0.148 
Gag Positive A*2911 147 L I <0.0005 0.020 
Gag Positive B*57 147 L I <0.0005 0.006 
Gag Positive C*15 147 L I <0.0005 0.004 
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Gag Positive B*1503 147 I I <0.0005 0.042 
Gag Negative B*5703 163 A A <0.0005 0.009 
Gag Positive B*5703 163 G A <0.0005 <0.0005 
Gag Positive B*5703 163 N A <0.0005 0.101 
Gag Negative A*0202 165 S S 0.001 0.174 
Gag Positive A*0202 165 N S 0.001 0.174 
Gag Negative B*81 182 Q Q <0.0005 0.022 
Gag Negative C*17 182 Q Q <0.0005 0.045 
Gag Positive B*81 182 S Q <0.0005 0.042 
Gag Negative B*81 186 T T <0.0005 <0.0005 
Gag Positive B*81 186 S T <0.0005 <0.0005 
Gag Negative B*81 190 T T <0.0005 0.004 
Gag Negative C*18 190 T T <0.0005 <0.0005 
Gag Positive C*18 190 A T 0.001 0.129 
Gag Positive A*43 215 M L 0.001 0.176 
Gag Positive C*07 215 I L <0.0005 0.058 
Gag Positive B*5801 219 P H <0.0005 0.082 
Gag Positive A*2911 223 I I 0.001 0.119 
Gag Negative B*57 242 T T <0.0005 <0.0005 
Gag Negative B*5801 242 T T <0.0005 <0.0005 
Gag Positive B*57 242 N T <0.0005 <0.0005 
Gag Positive B*5801 242 N T <0.0005 <0.0005 
Gag Positive B*4201 252 A N 0.001 0.136 
Gag Negative C*18 256 I I <0.0005 0.106 
Gag Negative B*35 260 D D <0.0005 0.006 
Gag Positive B*35 260 E D <0.0005 0.001 
Gag Negative B*14 302 K K <0.0005 <0.0005 
Gag Positive B*14 302 R K <0.0005 <0.0005 
Gag Negative C*0304 303 T T <0.0005 <0.0005 
Gag Positive C*0304 303 A T <0.0005 0.003 
Gag Negative B*53 309 A A <0.0005 0.027 
Gag Negative B*44 312 D D <0.0005 <0.0005 
Gag Positive B*44 312 E D <0.0005 <0.0005 
Gag Negative B*39 332 T T <0.0005 0.030 
Gag Negative C*08 335 K R <0.0005 0.027 
Gag Positive C*08 335 R R <0.0005 0.027 
Gag Negative C*0804 336 A A <0.0005 0.001 
Gag Positive C*0804 336 G A <0.0005 0.001 
Gag Negative C*08 339 P P <0.0005 0.028 
Gag Negative C*0804 339 P P 0.001 0.120 
Gag Positive B*15 339 A P <0.0005 0.028 
Gag Negative B*1510 340 G G <0.0005 0.001 
Gag Positive C*0304 340 A G <0.0005 0.004 
Gag Negative B*07 357 S S <0.0005 <0.0005 
Gag Positive B*07 357 G S <0.0005 <0.0005 
Gag Negative C*04 370 A A <0.0005 0.068 
Gag Positive B*1401 370 A A 0.001 0.134 
Gag Positive A*3002 371 N N <0.0005 0.054 
Gag Negative B*1503 374 T T 0.001 0.176 
Gag Negative B*5802 377 L M <0.0005 0.083 
Gag Positive B*5802 377 M M <0.0005 0.083 
Gag Negative B*3501 378 M M <0.0005 0.020 
Gag Negative A*43 381 G S 0.001 0.176 
Gag Negative C*18 382 N N <0.0005 0.002 
Gag Positive A*01 382 K N <0.0005 0.026 
Gag Negative B*42 386 P P <0.0005 0.001 
Gag Positive B*4201 386 S P <0.0005 0.001 
Gag Negative A*03 403 K R <0.0005 <0.0005 
Gag Negative A*3001 403 K R 0.001 0.197 
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Gag Negative A*74 403 R R <0.0005 <0.0005 
Gag Positive A*74 403 K R <0.0005 0.088 
Gag Positive A*03 403 R R <0.0005 <0.0005 
Gag Positive A*3001 403 R R <0.0005 <0.0005 
Gag Positive A*0301 411 R K 0.001 0.176 
Gag Negative A*0205 427 T T <0.0005 0.080 
Gag Negative B*13 437 I I 0.001 0.168 
Gag Positive B*13 437 L I <0.0005 0.008 
Gag Negative A*74 441 H H <0.0005 <0.0005 
Gag Positive A*74 441 N H <0.0005 <0.0005 
Gag Negative A*6801 464 R R 0.001 0.119 
Gag Negative A*6801 467 E E 0.001 0.168 
Gag Negative C*0304 467 E E <0.0005 0.106 
Gag Positive C*0304 467 G E <0.0005 0.058 
Gag Positive C*18 474 P P 0.001 0.168 
Gag Positive A*6802 477 D E 0.001 0.139 
Gag Negative C*17 478 Q P <0.0005 0.063 
Gag Positive C*04 478 M P 0.001 0.188 
Gag Negative C*17 487 T T <0.0005 0.019 
Gag Positive C*17 487 I T <0.0005 0.052 
Gag Negative B*4201 488 S S <0.0005 0.101 
Gag Positive B*4201 488 A S <0.0005 0.103 
Protease Negative B*44 35 E E <0.0005 0.004 
Protease Positive B*44 35 D E <0.0005 0.004 













Table A2. Best-defined (A-list) optimal Gag epitopes from the Los Alamos HIV 




Subtype HLA restriction 
GELDRWEKI p17 11-19  B*4002 
KIRLRPGGK p17 18-26  A*0301 
IRLRPGGKK p17 19-27 B B*2705 
RLRPGGKKK p17 20-28  A*0301 
RLRPGGKKKY p17 20-29 B A*0301 
GGKKKYKLK p17 24-32 B B*0801 
KYKLKHIVW p17 28-36 B A*2402 
HLVWASREL p17 33-41  C*0804 
LVWASRELERF p17 34-44  A30 
WASRELERF p17 36-44 B B*3501 
ELRSLYNTV p17 74-82  B*0801 
RSLYNTVATLY p17 76-86 B A*3002, B58, B63 
SLYNTVATL p17 77-85 B A*0201, A*0202, A*0205 
LYNTVATL p17 78-85  C14 
LYNTVATLY p17 78-86  A*2902, B*4403 
TLYCVHQK p17 84-91  A*1101 
IEIKDTKEAL p17 92-101  B*4001 
NSSKVSQNY p17 124-132 B B*3501 
VQNLQGQMV p24 135-143  B13 
HQAISPRTL p24 144-152  B*1510 
QAISPRTLNAW p24 145-155 B A*2501 
ISPRTLNAW p24 147-155  B*5701, B63 
SPRTLNAWV p24 148-156  B*0702 
VKVIEEKAF p24 156-164  B*1503 
EEKAFSPEV p24 160-168  B*4415 
KAFSPEVI p24 162-169 B B*5703 
KAFSPEVIPMF p24 162-172 B B*5701, B*5703, B63 
FSPEVIPMF p24 164-172  B57 
EVIPMFSAL p24 167-175 B A*2601 
VIPMFSAL p24 168-175 B C*0102 
SEGATPQDL p24 176-184  B*4001 
TPQDLNTML p24 180-188 B 
B*0702, B*3910, B*4201, B*8101, 
C*0802 
GHQAAMQML p24 193-201 B B*1510, B*3901 
KETINEEAA p24 202-210  B*4002 
ETINEEAAEW p24 203-212  A*2501 
AEWDRVHPV p24 210-218  B*4002 
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HPVHAGPIA p24 216-224  B07 
GQMREPRGSDI p24 226-236  B13 
TSTLQEQIGW p24 240-249 B B*5701, B*5801 
PPIPVGDIY p24 254-262 B B*3501 
EIYKRWII p24 260-267 B B*0801 
RRWIQLGLQK p24 263-272  B*2703 
KRWIILGLNK p24 263-272 B B*2705 
GLNKIVRMY p24 269-277 B B*1501 
VRMYSPVSI p24 274-282  C18 
RMYSPTSI p24 275-282  B*5201 
FRDYVDRFF p24 293-301  C18 
FRDYVDRFYK p24 293-302 B, D B*1801 
RDYVDRFFKTL p24 294-304 A A*2402 
RDYVDRFYKTL p24 294-304 B B*4402 
YVDRFYKTL p24 296-304  A*0207 
YVDRFFKTL p24 296-304  B*1503, C*0303, C*0304 
DRFYKTLRA p24 298-306 B B*1402 
AEQASQDVKNW p24 306-316 B B*4402 
AEQASQEVKNWM p24 306-317  C05 
QASQEVKNW p24 308-316 B B*5301, B*5701 
DCKTILKAL p24 329-337 B B*0801 
ACQGVGGPGHK p24 349-359  A*1101 
GPGHKARVL p24 355-363 B B*0702 
AEAMSQVTNS p2p7p1p6 364-373  B*4501 
CRAPRKKGC p2p7p1p6 405-413  B14 
TERQANFL p2p7p1p6 427-434  B*4002 
RQANFLGKI p2p7p1p6 429-437  B13 
FLGKIWPSYK p2p7p1p6 433-442  A*0201 
KELYPLTSL p2p7p1p6 481-489  B*4001 
 
HIV-1 – human immunodeficiency virus type 1; HLA – human leukocyte antigen; p17 – protein of 17 kDa; p24 – protein of 
24 kDa; p2 – protein of 2 kDa; p7 – protein of 7 kDa; p1 – protein of 1 kDa; p6 – protein of 6 kDa. 
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Table A3. Amino acids in Gag-protease from HIV-1 subtype C chronically infected subjects associated with altered replication capacities 








analysis Optimal epitopes with HLA restriction HLA association 
-AA +AA -AA +AA p q p q 
p17 20 R Yes 42 363 0.58 0.62 0.021 0.57 - - KK9/RK9/RLY10 - A*0301, IK9 - B*2705 C*06a, A*74a, A*6801b 
p17 28 Q  324 81 0.61 0.64 0.002 0.34 <0.0005 0.23 
RK9/RLY10 – A*0301, GK9 – B*0801, 
KW9 – A*2402 
B*13a, B*42a,  C*17a 
p17 28 R  314 91 0.62 0.64 0.040 0.6 - - 
RK9/RLY10 – A*0301, GK9 – B*0801, 
KW9 – A*2402 
B*13a, B*42a,  C*17a 
p17 30 R  340 65 0.61 0.64 0.009 0.47 - - GK9 – B*0801, KW9 – A*2402 B*42a,  C*17a 
p17 31 I  355 50 0.62 0.58 0.003 0.34 0.001 0.27 GK9 – B*0801, KW9 – A*2402 C*0701a 
p17 35 V Yes 44 361 0.66 0.62 0.011 0.47 - - 
KW9 – A*2402, HL9 – C*0804, LF11 – 
A*30 
 
p17 35 I  355 50 0.62 0.65 0.023 0.57 - - 
KW9 – A*2402, HL9 – C*0804, LF11 – 
A*30 
 
p17 49 S  393 12 0.62 0.56 0.036 0.58 - -  B*1503a 
p17 58 Q  400 5 0.62 0.69 0.023 0.57 - -   
p17 61 I Yes 157 248 0.61 0.64 0.004 0.41 <0.0005 0.23   
p17 62 S  373 32 0.62 0.68 <0.0005 0.27 <0.0005 0.23  B*1402 a 
p17 75 L Yes 24 381 0.65 0.62 0.005 0.27 - - EV9 – B*0801  
p17 75 I  366 39 0.61 0.66 0.002 0.47 0.002 0.28 EV9 – B*0801  
p17 76 R Yes 231 174 0.63 0.6 0.021 0.57 - - EV9 – B*0801, RY11 – A*3002, B*58, B*63  
p17 76 K  153 252 0.6 0.63 0.016 0.57 - - EV9 – B*0801, RY11 – A*3002, B*58, B*63  
p17 84 A  397 8 0.62 0.7 0.010 0.47 - - 
RY11 – A*3002, B*58, B*63,  SL9 – 
A*0201, A*0202, A*0205, LL8 – C*14, LY9 
– A*2902, B*4403, TK8 – A*1101 
 
p17 84 I  398 7 0.62 0.68 0.024 0.57 - - 
RY11 – A*3002, B*58, B*63,  SL9 – 
A*0201, A*0202, A*0205, LL8 – C*14, LY9 
– A*2902, B*4403, TK8 – A*1101 
 
p17 109 S  393 12 0.62 0.65 0.047 0.65 0.002 0.28   
p17 111 C  319 86 0.62 0.64 0.038 0.59 - -   
p17 114 E  398 7 0.62 0.57 0.011 0.47 - -   
p17 115 M  397 8 0.62 0.7 0.007 0.47 - -   
p17 118 V  397 8 0.62 0.51 0.025 0.57 <0.0005 0.23   
p17 119 Q  398 7 0.62 0.68 0.025 0.57 - -   
p17 119 T  392 13 0.62 0.65 0.034 0.58 - -   
p17 120 K  394 11 0.62 0.56 0.008 0.47 - -   
p17 123 G Yes 91 314 0.6 0.63 0.020 0.57 - -   





p24 182 Q Yes 54 351 0.59 0.63 0.031 0.57 - - 
SL9 – B*4001, TL9 – B*0702, B*3910, 
B*4201, B*8101, C*0802 
B*81a, C*17 a 
p24 182 G  398 7 0.62 0.54 0.024 0.58 - - 
SL9 – B*4001, TL9 – B*0702, B*3910, 
B*4201, B*8101, C*0802 
B*81a, C*17 a 
p24 186 T Yes 28 377 0.58 0.62 0.006 0.47 <0.0005 0.23 
TL9 – B*0702, B*3910, B84201, B*8101, 
C*0802 
B*81a 
p24 186 S  377 28 0.62 0.59 0.012 0.47 - - 
TL9 – B*0702, B*3910, B84201, B*8101, 
C*0802 
B*81a 
p24 191 V Yes 10 395 0.54 0.62 0.005 0.47 - -   
p24 191 I  392 13 0.62 0.56 0.032 0.58 - -   
p24 200 M Yes 6 399 0.57 0.62 0.029 0.57 - - GL9 – B*1510, B*3901  
p24 200 I  399 6 0.62 0.57 0.029 0.57 - - GL9 – B*1510, B*3901  
p24 223 Y  398 7 0.62 0.55 0.021 0.57 0.003 0.28 HA9 – B*07 A*2911b 
p24 224 A Yes 31 374 0.59 0.62 0.020 0.57 - - HA9 – B*07  
p24 224 P  376 29 0.62 0.59 0.046 0.64 - - HA9 – B*07  
p24 228 M Yes 73 332 0.59 0.62 0.027 0.57 - - GI11 – B*13  
p24 302 K Yes 5 400 0.54 0.62 0.042 0.63 - - 
FK10 – B*1801, RL11 – A*2402, B*4402, 
YL9 – A*0207, B*1503, C*0303, C*0304, 
DA9 – B*1402 
B*14a 
p24 309 A Yes 20 385 0.54 0.62 0.004 0.34 - - 
AW11 – B*4402, AW12 – C*05, QW9 – 
B*5301, B*5701 
B*53a 
p24 309 S  387 18 0.62 0.56 0.010 0.47 - - 
AW11 – B*4402, AW12 – C*05, QW9 – 
B*5301, B*5701 
B*53a 
p24 312 D Yes 112 293 0.6 0.63 0.007 0.47 - - 
AW11 – B*4402, AW12 – C*05, QW9 – 
B*5301, B*5701 
B*44a 
p24 312 E  269 136 0.62 0.6 0.032 0.58 - - 
AW11 – B*4402, AW12 – C*05, QW9 – 
B*5301, B*5701 
B*44a 
p24 323 V Yes 16 389 0.69 0.62 0.011 0.47 0.001 0.24   
p2 369 H  395 10 0.62 0.74 0.007 0.47 - - AS10 – B*4501  
p2 371 S  389 16 0.62 0.57 0.036 0.58 - - AS10 – B*4501 A*3002b 
p2 374 P  397 8 0.62 0.56 0.046 0.64 - -  B*1503a 
p7 381 G  291 114 0.61 0.64 0.005 0.41 - -  A*43b 
p7 382 K  400 5 0.62 0.49 0.015 0.52 - -  A*01a, C*18a 
p7 385 N  400 5 0.62 0.79 0.024 0.57 - -   
p7 389 M  390 15 0.62 0.68 0.001 0.27 <0.0005 0.23   
p7 389 T  319 86 0.61 0.63 0.035 0.58 - -   
p7 397 K Yes 9 396 0.57 0.62 0.015 0.52 0.004 0.28   
p7 411 K Yes 8 397 0.54 0.62 0.004 0.34 0.001 0.24 CC9 – B*14 A*0301a 
p7 425 D Yes 11 394 0.68 0.62 0.029 0.5 - -   
p7 425 E  381 24 0.62 0.65 0.013 0.57 - -   







p6 466 K  400 5 0.62 0.5 0.039 0.59 0.004 0.28   
p6 467 E Yes 34 371 0.68 0.62 0.007 0.47 - -  C*0304a, A*6801a 
p6 471 N  390 15 0.62 0.57 0.008 0.47 0.001 0.24   
p6 473 P  398 7 0.62 0.71 0.010 0.47 - -   
p6 473 D  400 5 0.62 0.54 0.044 0.64 - -   
p6 478 V  399 6 0.62 0.73 0.007 0.47 0.003 0.28  C*17b, C*04a 
p6 479 K Yes 79 326 0.6 0.62 0.028 0.57 0.002 0.28   
p6 481 R Yes 28 377 0.56 0.62 0.008 0.47 - - KL9 – B*4001  
p6 485 H  396 9 0.62 0.68 0.023 0.57 - - KL9 – B*4001  
p6 498 W  394 11 0.62 0.67 0.031 0.58 - -   
Pro 13 V  398 7 0.62 0.55 0.028 0.57 - -   
Pro 16 G Yes 13 392 0.56 0.62 0.001 0.27 0.002 0.28   
Pro 16 E  387 18 0.62 0.57 0.023 0.57 - -   
Pro 20 K Yes 73 332 0.58 0.62 0.007 0.47 - -   
Pro 20 R  318 87 0.62 0.59 0.039 0.59 - -   
Pro 35 E Yes 142 263 0.61 0.62 0.042 0.62 0.003 0.28 EW9 – B*44; DL9 – A*6802 B*44a 
Pro 61 Q Yes 29 376 0.65 0.62 0.018 0.41 0.002 0.28 RI10 – B*13  
Pro 61 E  381 24 0.62 0.67 0.005 0.57 - - RI10 – B*13  
Pro 64 M  400 5 0.62 0.73 0.024 0.57 0.001 0.24 RI10 – B*13  
Pro 70 R  391 14 0.62 0.66 0.029 0.57 - - GL9 – B*1503; KV8 – B*57  
Pro 74 S  361 44 0.62 0.64 0.042 0.63 - - GL9 – B*1503; KV8 – B*57  
Pro 89 L  351 54 0.61 0.65 0.006 0.47 - - TL11 – B*81  
 
HIV-1 – human immunodeficiency virus type 1; p17 – protein of 17 kDa; p24 – protein of 24 kDa; p2 – protein of 2 kDa; p7 – protein of 7 kDa; p6 – protein of 6 kDa; pro – protease; AA – amino 
acid; con. – consensus; HLA – human leukocyte antigen. 
a HLA allele is negatively associated with the consensus amino acid or positively associated with a polymorphism at that codon. 
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